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1.1 Definition of COPD 
 
Chronic Obstructive Pulmonary Disease (COPD) is currently the fifth leading cause of death 
in Europe and is predicted to become the third most common cause of disease worldwide by 
2020 [1]. Today, it is the only major disease with increasing mortality rates [2]. The Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) recently introduced a new definition 
for COPD, which has been accepted among others by the American Thoracic Society, the 
European Respiratory Society, and the British Thoracic Society, which had all published their 
own separate definitions earlier. 
The GOLD definition of COPD is: “Chronic Obstructive Pulmonary Disease is a 
preventable and treatable disease with some significant extra-pulmonary effects that may 
contribute to the severity in individual patients. Its pulmonary component is characterized by 
airway obstruction that is not fully reversible. The airway obstruction is usually progressive 
and associated with an abnormal inflammatory response of the lung to noxious particles or 
gases.” 
  COPD is a heterogeneous disease comprising three related pathological processes: 
chronic (obstructive) bronchitis in the large airways, small airway disease, and emphysema. 
All three components are concomitantly present in most COPD patients, although one may be 
more prominent than the other. 
Chronic bronchitis is defined clinically by the presence of chronic bronchial 
secretions, enough to cause expectoration, occurring on most days for a minimum of 3 months 
of the year for 2 consecutive years. The pathological basis of chronic bronchitis is mucus 
hypersecretion secondary to hypertrophy of the glandular elements of the bronchial mucosa. 
Small airway disease manifests itself as airway obstruction caused by inflammation, 
fibrosis and accumulation of mucus in the lumen of the airways that are smaller than 2 mm in 
diameter.  
Emphysema is a condition characterized by a permanent enlargement of the distal 
airspaces, beyond the terminal bronchioles, caused by destruction of the airway walls, without 
obvious fibrosis. This leads to fewer but larger alveoli, with a decreased surface area and a 
decreased ability to absorb oxygen and exude carbon dioxide by diffusion. The elastic recoil 
force that drives air out of the lungs is decreased and small airways consequently collapse 
during exhalation. 
Individuals with decreased levels of α1-antitrypsin (AAT), a serine protease inhibitor 
protecting the lungs against protease attack, develop emphysema in a higher proportion. 
While this genetic deficiency provides some insight into the pathogenesis of the disease, it 
only accounts for a small proportion of the disease (about 1-3% of patients with diagnosed 




for the development of COPD in the industrialized world, since 90% of patients with COPD 
have smoked or are still smoking [4]. Only a minority of smokers (15-20%) develops the 
disease [4], suggesting that besides smoking there is an underlying individual susceptibility. 
There is a clear distinction between smoking-induced emphysema and AAT deficiency related 
emphysema, with respect to disease pathogenesis and manifestation. Emphysema associated 
with tobacco smoking manifests itself mostly centrilobular (destruction of the respiratory 
bronchioles) and affects to a higher extent the upper lung, whereas AAT deficiency manifests 
itself panlobular (destruction of the entire acinus) [5] and most frequently appears in the lower 
rather than in the upper regions.  
The research presented in this thesis targets only the smoking-induced emphysema. 
 
1.2 Pathogenesis of Emphysema development in COPD 
 
For many years the prevailing concept on the pathology of emphysema development relied on 
lung inflammation caused by cigarette smoke, environmental pollutants, or bacterial products, 
leading to a protease/antiprotease imbalance [6], which ultimately causes alveolar tissue 
destruction. Significant progress in understanding the underlying mechanisms of emphysema 
over the past 6 years points towards novel processes related to senescence and stress response 
involved in the pathogenesis of the disease [7]. Whether the inflammatory cells are directly 
triggered by cigarette smoke, or inflammation is a secondary response to cellular and 
molecular alterations induced by chronic cigarette smoke inhalation, is nowadays a matter of 
debate [7]. However, independent of the recruitment pathway of inflammatory cells, the 
ultimate effect is the same: alveolar tissue degradation. 
In young asymptomatic smokers several inflammatory and structural changes have 
been reported in the peripheral airways [8-10], whereas at a higher age, both peripheral and 
central airways are affected by smoking and present increased numbers of goblet and 
inflammatory cells [11]. Signs of inflammation are also present in sputum and 
bronchoalveolar lavage (BAL) as reflected by increased inflammatory cell numbers 
(macrophages, neutrophils and in some reports lymphocytes and eosinophils), as well as 
higher levels of proinflammatory cytokines (among which tumor necrosis factor-alpha (TNF-
α) and interleukin-6 (IL-6)) and chemokines [12-15]. Macrophages and neutrophils are not 
only important producers of cytokines but also release proteases, such as serine proteases 
(neutrophil elastase), cysteine proteases (cathepsins) and matrix metalloproteases (MMPs), 
which normally are counter-regulated by anti-proteases. The function of anti-proteases 
appears to be impaired in COPD, either by the direct influence of smoking on anti-proteases 
activity or due to oxidants produced by other cells in response to smoking [16]. In addition, 
oxidants can activate proteases [17]. Oxidative stress, which is increased in COPD patients, 
activates the transcription of the nuclear factor kappa B (NF-KB), which orchestrates the 
inflammatory response by inducing the expression of proinflammatory cytokines such as 
TNF-α and IL-8 thereby contributing to an overall increased inflammatory response.  
Remodeling is an important process in the airways of patients with COPD, 
contributing to a large extent to the progressive nature of airflow limitation, which occurs in 
all patients with COPD. When considering remodeling events in relation to the pathogenesis 
of COPD, the main focus has been on the destructive effects (as a consequence of imbalances 
between oxidants and antioxidants and between proteases and antiproteases) [6,18-20]. More 
recently, attention has been given to an aberrant repair process, which also may contribute to 
the development and/or progression of the disease [21]. The MMPs and their inhibitors are the 
main components in the destructive part of the remodeling events, whereas in the tissue 
repair/fibrotic changes, basic fibroblast growth factor (bFGF) and transforming growth factor 
beta (TGF-ß) play major roles [22]. The increase of MMP-9 (gelatinase/collagenase) found in 
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COPD [20], may coincide with the increased presence of TGF-ß, which is up- regulated in 




Fig. 1. Schematic representation of decorin molecule. 
 
Depending on the relative contribution of each component in a specific compartment 
(in either the airways or parenchyma), this could result in either destructive or fibrotic events. 
In a similar way, increased TGF-ß together with possible activation of MMP-12 (elastase) 
[25,26] could have elastolytic as well as fibrotic effects. 
Thus, the pathogenesis of COPD is a complex process. Although the exact 
mechanisms are far from clear, there are several important processes playing major roles in 
the development and pathogenesis of COPD: 1) an imbalance between proteases and anti-
proteases; 2) an imbalance between oxidants and anti-oxidants; 3) inflammation and 4) 
impaired remodeling. 
 
1.3 Decorin in lung extracellular matrix 
 
Lung extracellular matrix (ECM) is a complex protein network composed mainly of 
collagens, elastin, noncollagenous glycoproteins, and proteoglycans (PGs). PGs consist of a 
protein core having covalently attached at least one long polymeric chain of repeating 
disaccharide units, termed glycosaminoglycan (GAG). Depending on the disaccharide 
composition, GAGs can be divided into four main categories: chondroitin sulfate (CS) and 
dermatan sulfate (DS), heparin and heparan sulfate (HS), keratan sulfate (KS), and hyaluronan 
(HA). 
Decorin (DCN) is a ubiquitous extracellular matrix proteoglycan with a variety of 
important biological functions that are mediated by its interactions with extracellular matrix 
proteins, cytokines, and cell surface receptors. DCN is the prototype of the family of small 
leucine-rich repeat proteoglycans and proteins (SLRPs), all having the protein core composed 
of tandem leucine-rich repeats (LRRs), flanked on either side by clusters of conserved 
cysteins. The mature protein core of DCN (without the signal peptide and the pro-peptide) 
consists of 329 [27] or 330 [28] amino acids, comprising 12 LRR domains of 24 amino acid 
residues each. Towards the amino terminus, at Serine 4 [29], the chondroitin/dermatan sulfate 
GAG chain is attached. DCN also has three potential consensus sites for N-glycosylation, 
located within the LRR domain, towards the C-terminus [15,30]. A schematic representation 
of DCN molecule is presented in Fig. 1. Other members of the LRR proteoglycans include 
biglycan, fibromodulin and lumican, decorin sharing the highest degree of structural 
similarities with biglycan. 
The DCN gene is located on the q arm of chromosome 12 in the close proximity of 











Fig. 2. Reduction of decorin in the outer bronchial wall (adventitia) in lungs of patients with severe 
chronic obstructive pulmonary disease (A) as compared with normal subjects (B) (immunoperoxidase 
immunostaining). Reproduced with permission from reference [31]. 
 
Proteoglycans, such as decorin and biglycan, have important functions, not only as 
components of the ECM scaffold, but also as important regulatory molecules through their 
ability to bind several cytokines and growth factors [21,31]. TGF-β stimulates the synthesis of 
DCN in many cell types [32,33], while DCN has the ability to modulate the activity of TGF-
β. DCN binds free TGF-β via the protein core [34] sequestering the growth factor within the 
ECM away from its receptor and decreasing TGF-β response. Reversely, degradation of 
decorin liberates TGF-β, leading to increased TGF-β activity [34]. DCN acts in this way as a 
negative feedback regulator of TGF-β activity [35]. Therefore, the participation of TGF-β into 
tissue repair/fibrosis implies also an important role for decorin into these processes. 
DCN binds via its protein core at the surface of mature type I, III, and VI collagens 
[36-40] and is also involved in collagen fibrillogenesis [41,42]. Deletions or proteolytic 
processing in the regions responsible for collagen binding may cause defects in collagen 
network formation. The GAG chain of DCN controls the size of the interfibrillar space 
between collagen fibrils [43], and therefore, changes in GAG length may perturb collagen 
matrix assembly. Using both protein core and GAG chain, DCN functions as a cross-linking 
molecule between collagen fibrils. In this way the amount of DCN present in the ECM 
determines how tight or loose collagen fibrils are attached together. Consequently, a strong 
increase in decorin would imply stiffening of local collagens, whereas loss of decorin would 
lead to the loosening and perhaps destruction of collagen structure. Significant reduction of 
decorin in the adventitia of small airways was found in lung tissue from patients with severe 
COPD (Fig. 2), when compared with mild COPD and control subjects [31], whereas no 
differences in collagens between patients with mild or severe COPD and normal subjects were 
found. Consequently, this decrease in decorin could be accompanied by loosening of the 
adventitial collagen and, in due time, loss of elastic recoil. Thus, the decreased amount of 
decorin, together with the smoking-related net proteolytic and oxidative effects in COPD, 
would lead to easy destruction of the peribronchial attachments of the parenchyma to the 
adventitia of small airways [44]. 
All LRR proteins adopt a curved solenoid fold. Although it has been widely assumed 
that horseshoe-shaped SLRPs interact with collagen and other ligand molecules through their 
concave surfaces [45-47], recent findings challenge this view [48]. Biophysical analyses have 
demonstrated that decorin is dimeric in solution [49], and the crystal structure of the decorin 
dimer [48] confirms that the concave surfaces mediate dimerization in a highly specific and 
conserved manner and therefore, it is unlikely that they are available for ligand binding. 
Further biochemical studies are needed to explore the molecular basis of the interactions 
between decorin and its many ligands. N-linked oligosaccharides are disposed across one side 
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of the dimer [48] and it is known that homodimerization is promoted in the absence of the N-
glycans [50]. This suggests also that loss of N-glycan chains may promote dimerization, 
making the molecule of DCN unavailable for ligand-binding and perturbing in this way the 
ECM architecture. 
In summary, DCN is a critical component of lung ECM and all its structural 
components (protein core, GAG chain and N-linked oligosaccharides) contribute to the fine 
tuning of DCN biological functions. We can anticipate that variations/structural modifications 
in any of these decorin components can induce changes in the connective tissue formation, 
depending on its ability to bind matrix molecules, cytokines or growth factors. As discussed 
above, some of these changes may lead to emphysema development.  
 
1.4 Aim of the thesis 
 
In the lungs of heavy smokers, cells are continuously exposed to a highly toxic environment 
(free radicals, potent oxidants such as hydrogen peroxide, hydroxyl anions, and organic 
radicals). The oxidative stress created by these molecules, together with the inflammation and 
the imbalance in favour of proteases, induce the vulnerability of ECM constituents to 
structural alterations and/or degradation.  
As mentioned also above, DCN is an important player in maintaining the functionality 
and organization of lung extracellular matrix. Structural alterations (post-translational 
modifications, proteolysis, and/or aberrant glycosylation) would impede or inactivate decorin, 
causing defects in the formation and functionality of lung ECM, which in the long term could 
have as final result emphysema development.  
In several ECM pathological conditions such as lung [31,51], joint [52], 
cardiovascular [53], or renal diseases [54] impeded decorin expression has been found. The 
studies investigating decorin in relation to COPD or other extracellular matrix related diseases 
focus mostly on the expression profiles of DCN. No information with respect to potential 
structural alterations of DCN as a consequence of disease development and progression could 
be extracted from these studies. More information at the structural level, explaining whether 
and in which way decorin is affected during emphysema development and progression, is 
needed. Investigation of potential alterations of decorin in relation with emphysema, involves 
the study of all three components (protein core, GAG, N-linked glycans) of the molecule. 
The purpose of this thesis was to develop and establish the methodology for enabling 
the study of the primary structure of human lung decorin and for performing a comparison 
between decorin molecules from emphysematous and control lung tissues. Our final goal was 
to establish whether there are induced structural alterations in the molecule of decorin as a 
consequence of emphysema development. Each of the chapters 4, 5, and 6 targets a certain 
component of the decorin molecule: the protein core, the N-linked oligosaccharides and the 
glycosaminoglycan chain, respectively. 
In Chapter 2 an extensive review on proteoglycans is given with the purpose of 
offering a background for the research topics addressed by this thesis. The diversity of 
proteoglycans and their complex functions in different tissues is presented. The current 
methods available for tissue proteoglycan purification as well as for their structural 
characterization are discussed. 
Chapter 3 presents the chromatographic method we developed for purifying decorin 
core protein with its attached N-linked oligosaccharides from human lung tissue. The method 
uses a combination of two anion exchange and one reversed phase chromatography steps and 
the enzymatic digestion with chondroitinase ABC. We applied this method for purifying DCN 
from two different locations (upper and lower lobes) of a control lung (smoker without 
emphysema) and from the same two locations of an emphysematous lung. The results of the 
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purifications are presented in Chapter 4, where we also investigated the occupancy of the 
glycosylation sites for all four batches of purified decorin. The study of glycosylation was 
performed using Matrix Assisted Laser Desorption Ionization-Time of Flight Mass 
Spectrometry (MALDI-TOF-MS) in combination with Liquid Chromatography-Mass 
Spectrometry (LC-MS). 
Chapter 5 describes the isolation and partial structural characterization of the N-
linked glycans attached to decorin protein cores purified from all four locations. 
Fragmentation patterns of the glycans, leading to their partial structural characterization were 
obtained using Post Source Decay MALDI-TOF-MS. 
Chapter 6 investigates indirectly the composition of the glycosaminoglycans attached 
to decorin, by studying their derived disaccharides. After digestion with Chondroitinase ABC, 
the pool of disaccharides is directly separated by liquid chromatography on a porous 
graphitized carbon (PGC) column and identified by on-line electrospray mass spectrometry 
under negative ionization conditions. The method is quantitative and allows distinguishing the 
sulfate position. Different types of biological samples (lung tissue, bronchoalveolar lavage 
fluid (BALF), induced sputum, and urine) obtained from patients suffering from chronic lung 
inflammation have been analyzed with this method.  
In Chapter 7 the general discussion is given, together with the future perspectives. 
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Recent developments in proteoglycan purification and analysis 
 
 
A slightly adapted version of this chapter has been published as: Mihaela Didraga, Begona 
Barroso, and Rainer Bischoff, Current Pharmaceutical Analysis 2 (2006) 323. 
 
Proteoglycans are ubiquitous biomolecules in the body located in the extracellular matrix, on 
the cell surface and also within the cells. They contain at least one glycosaminoglycan (GAG) 
chain covalently attached to a core protein and may also present N- or O-linked glycans. The 
high structural diversity and distribution relate to the various biological functions of 
proteoglycans. In recent years, new members have enlarged the proteoglycan family and 
advances in molecular biology and glycobiology contributed to elucidate more of the 
biological functions of proteoglycans. In order to study the structure of a proteoglycan 
molecule and relate it to its function (or dysfunction), its isolation and purification from cell 
culture or tissue extracts is necessary. Next to the widely used anion exchange 
chromatographic methods, techniques based on lectin affinity chromatography have created 
new possibilities to increase the degree of purity. Introduction of electrospray ionization (ESI) 
and matrix–assisted laser desorption-ionization (MALDI) sources, together with tandem mass 
spectrometry (MS/MS or MSn), mark a further important step towards the structural analysis 
of glycosaminoglycans. The aim of this review is to present the most recent advances in 






Proteoglycans are ubiquitous molecules in eukaryotic species carrying as hallmark at least one 
glycosaminoglycan (GAG) side chain covalently attached to a protein core. GAGs are linear 
polymeric structures composed of repeating disaccharide units of one hexosamine (D-
glucosamine or D-galactosamine) alternating with one uronic acid (D-glucuronic acid or L-
iduronic acid) or galactose (keratan sulfate) [1]. Depending on the disaccharide composition, 
GAGs can be divided into four categories: chondroitin sulfate (CS) and dermatan sulfate 
(DS), heparin and heparan sulfate (HS), keratan sulfate (KS) and hyaluronan (HA). 
Hyaluronan, the largest GAG (> 2500 disaccharide units) [2], is the only non-sulfated GAG 
and is not covalently bound to a protein core. It is considered a PG because it associates with 
a wide variety of proteins. HA is synthesized by one of three different transmembrane 
hyaluronan synthases (HAS1, HAS2 and HAS3) with the active sites on the inner face of the 
plasma membrane [3]. During synthesis, the growing HA chain is extruded into the 
extracellular space [4,5], allowing unconstrained polymer growth. All other GAGs are 
synthesized and assembled as PGs in the endoplasmic reticulum and Golgi apparatus and 
secreted in a way similar to other glycoproteins. CS, DS, heparin and HS are built on a 
common tetrasaccharide sequence (-O-Xyl-Gal-Gal-GlcA-), which is O-linked to the protein 
cores via a serine or threonine residue, while KS may be attached to the protein cores via both 
O- and N-linkages [6-8]. The type of GAG present on a given proteoglycan may vary among 
different cells and different GAG types may be present on the same protein core (e.g. 
aggrecan, syndecan) [9]. Therefore, for the classification of proteoglycans it is necessary to 
mention their tissue location (intracellular, on the surface of the cells or in the extracellular 
matrix) in addition to the GAG type.  
The distribution of proteoglycans is variable. They are abundantly expressed by 
fibroblasts and chondrocytes, but also by cell types that do not typically take part in 
extracellular matrix or tissue construction, like those of the immune system or metastasizing 
tumor cells [10]. Articular cartilage, blood vessels, skin, and cornea are a few examples of 
tissues rich in proteoglycans. The structure and size of these molecules may vary enormously, 
particularly with respect to their glycosaminoglycan content. Perlecan is the largest 
characterized proteoglycan, possessing a 4400 amino acid protein core with three GAG 
substitution sites [11]. Aggrecan may bind 100 CS and 30 KS chains to its 2000 amino acid 
protein core [12]. Leucine-reach repeat proteoglycans have relatively short core proteins (300-
400 amino acids), but are still larger than some cell surface proteoglycans (e. g. serglycin) 
possessing less than 200 amino acids [13].  
The structural diversity and distribution of proteoglycans determines their various 
functions. Although it is difficult to discriminate between functions mediated by the GAGs 
themselves or by the protein cores, it seems that GAGs are responsible for targeting of PGs to 
the proper (extra)cellular environment [9], modulation of growth-factor activities [14], 
binding and organization of water molecules, repulsion of negatively charged molecules, 
while the protein cores are mostly mediating protein-protein interactions [15-17]. Through the 
combination of GAG and protein core mediated functions, PGs act as tissue organizers [18], 
influence tissue’s mechanical properties [19], control cell proliferation (e.g. tumor cell growth 
and invasion) [20], regulate collagen fibrillogenesis [21] and skin tensile strength [22], and 
influence corneal transparency [23]. Heparin is well known for its anticoagulant activity [24]. 
The role of DS as anticoagulant has also been proven [25], as well as its activity against 
venous thrombosis [26]. In the neural system sulfated PGs behave as axon guidance 
molecules during brain development [27,28] and are involved in the repair process of injured 
Central Nervous System (CNS) and disrupted Blood Brain Barriers (BBD) [29]. The 
compelling evidence for participation of proteoglycans in a multitude of biological processes 
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as well as the association of hampered proteoglycan functions with disease development or 
progression (e.g. rheumatoid arthritis, atherosclerosis, vascular and pulmonary diseases) call 
for additional, more detailed structural investigations which, in turn, stimulate further 
methodological developments.  
The purpose of this review is to highlight the developments in analytical strategies 
applied to proteoglycans, from their isolation and purification toward their structural analysis, 
revealing especially the composition of the attached glycosaminoglycans. Special attention 
will be accorded to mass spectrometry, which has contributed significantly to the detailed 
analysis of PGs, although we feel that its potential has not been fully exploited. The structural 
analysis of branched N- and O-linked oligosaccharides, while sharing some methodological 
aspects with glycosaminoglycans, is beyond the scope of this review. This topic was covered 
by Mechref and Novotny, who reviewed the methodological advances in the analysis of 
glycoproteins and their glycan structures [30]. 
 
2.2 Proteoglycan purification 
 
Proteoglycans can be purified from tissues, cells or cell culture supernatants using similar 
approaches. In this review we will focus on the purification of PGs from tissue, as this is the 
most complex starting material for proteoglycan purification. The purification of 
proteoglycans from tissue is often complicated by limited availability, their large molecular 
size and the necessity of chaotropes for efficient extraction. 
 
2.2.1 Extraction from tissue 
 
Slicing, grinding, or pulverization is required in order to increase the area of tissue available 
for extraction and to reduce the extraction time. Tissue homogenates are further incubated 
with suitable extraction buffers for 12 to 48 h followed by re-extraction of the pellet resulting 
after centrifugation. The extraction yields are tissue and time dependent. Inactivation of 
proteases is accomplished by including protease inhibitors in the extraction buffers, 
performing the extraction at low temperatures (4°C) and under pH conditions unfavorable for 
protease activity. Occasionally wide-spectrum proteases (proteinase K or papain) can be used 
to solubilize the tissue when the interest lies mainly in GAG characterization.  
Different concentrations of several salts (LiCl, CaCl2, MgCl2) [31] have been 
employed for proteoglycan extraction, promoting solubilization by dissociating 
intermolecular interactions between proteoglycans and other molecules. In 1969, Sajdera and 
Hascall [32] reported the extraction of cartilage proteoglycans with 3-4M guanidine 
hydrochloride (GuHCl) followed by further purification by cesium chloride (CsCl) density 
gradient centrifugation. 4M GuHCl has proven to offer the best extraction yield and has 
become the most widely used extraction agent. Brand et al [33] extracted bovine articular 
cartilage with increasing concentrations of GuHCl and concluded that the ionic strength 
employed for the efficient solubilization of PGs is directly proportional to their size. 
However, for tissues less abundant in proteoglycans, GuHCl extraction results also in a high 
amount of other proteins. Chaotropes and detergents are especially necessary for extraction of 
proteoglycans localized intracellular or in cell membranes preventing formation of large 
aggregates. If for example cell cultures are the target, addition of 0.1% Triton X-100 may 
solubilize cell membranes. Inositol hexaphosphate [34,35] or phosphatidylinositol specific 
phospholipase C [34,36] are needed for releasing membrane associated PGs. EDTA dissolves 
hydroxyapatite mineral and therefore inclusion of EDTA in the extraction buffer permits to 
distinguish between matrix associated PGs (4M GuHCl soluble) and mineral associated PGs 
(4M GuHCl insoluble/4M GuHCl + 0.5M EDTA soluble) in fetal porcine calvarial bone [37]. 
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HSPGs associated with murine erytholeukemia cells were separated into two urea-soluble 
classes (with the molecular weights of 280 kDa and 80 kDa) versus one high molecular 
weight (360 kDa) urea-insoluble [38] class. Extensive denaturation of the protein components 
of proteoglycans occurs in concentrated solutions of these chaotropic reagents. Removal of 
denaturant by dialysis does not always restore the protein conformation to its native state. 
When it is intended to use the protein component for further activity studies it is necessary to 
preserve its native structure to avoid compromising the biological activity. Chaotrope-free 
extraction buffers have been described for soluble PGs [39], preserving their native state, but 




Following their extraction, proteoglycans are isolated and further separated into different 
classes based on their physico-chemical properties. The most important feature of PGs is their 
polyanionic nature conferred by sulfate substituents on carbohydrate residues and by carboxyl 
groups of uronic acid moieties. In addition, some protein cores may contribute also specific 
properties. Membrane PGs (e.g. perlecan, agrin, bamacan) possess a phosphatidylinositol 
moiety, which increases their hydrophobicity [40], freely soluble secreted PGs (biglycan, 
decorin and fibromodulin) show an amphipathic nature [41-43], while aggrecan or versican 
have peptide sequences that confer lectin-like properties [44]. Therefore, using different types 
of chromatography, PGs may be fractionated based on charge density (anion exchange 
chromatography), size and shape (size exclusion chromatography), surface hydrophobicity 
(hydrophobic interaction chromatography), or interaction with affinity ligands recognizing the 
distribution of specific amino acids or carbohydrate residues at their surface (affinity 
chromatography). An example of the work flow used to purify decorin core protein from 




Fig. 1. Schematic representation of the work flow used to purify decorin (DCN) core protein from 
human lung tissue (Reprinted from ref. [65] Copyright © 2006, with permission from Elsevier.) 
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Proteoglycans can be separated as intact molecules or subjected to 
chemical/enzymatic treatment depending on whether the interest lies in the structural 
characterization of the GAG chain(s) or the protein cores. Separation of intact PGs is usually 
achieved by gradient density centrifugation or by chromatographic methods like size 
exclusion or anion exchange chromatography.  
Centrifugation in density gradients of cesium chloride (CsCl) or cesium bromide 
(CsBr) with addition of protein denaturants separates proteoglycans from non-covalently 
associated proteins and constitutes the first step in most preparative methods. One run 
typically takes 2-3 days. By using either non-denaturing (0.5M GuHCl) or denaturing (4M 
GuHCl) buffers, PGs can be isolated as aggregates (with hyaluronan and link protein) or as 
monomers [45].  
Anion-exchange chromatography (AEC) is the method of choice for the 
isolation/purification of PGs extracted from tissues or cells with a relatively low ratio of 
proteoglycan to protein. Separation of PGs by AEC involves binding of PGs to a cationic 
stationary phase via their anionic GAG chains followed by elution with elevated salt 
concentration. The most common resins employed in AEC of PGs contain the weak anion 
exchanger diethylaminoethyl (DEAE) groups immobilized on a hydrophilic support material 
(e.g. DEAE-Sepharose [46], DEAE-Sephacel [47], DEAE-Cellulose [48]). DEAE groups 
possess a net positive charge at neutral to slightly acidic pH. The columns are generally 
equilibrated in urea-containing buffers (e.g. 7M urea, 0.05 M sodium acetate, pH 6-7, 0.5% 
detergent) and eluted with NaCl gradients [49]. Strong anion-exchange chromatographic 
supports containing quaternary ammonium groups have also been used (Mono Q [47], Q-
Sepharose [39,50]). These supports are positively charged independent of pH. These resins 
are usually used to concentrate PGs by bulk volume loading and step elution in high salt 
buffers [39,51] (1 to 2 M NaCl).  
Size exclusion chromatography (SEC) fractionates PGs based on their hydrodynamic 
volume. Large PGs will be excluded from the internal pore volume and exit the column first, 
while smaller PGs will traverse the pores of the stationary phase and hence elute later. SEC 
employing porous gel beads of polymerized dextran (Superdex, Sephadex), agarose 
(Sepharose, Sephacryl, Superose), polyacrylamide (Bio-Gel), or silica (Bio-Sil, TSK-Gel) 
have found applications in proteoglycan purification protocols. Decorin was purified from the 
culture medium of MRC-5 cells using gradient elution from an anion exchange column 
(HiTrap Q HP) followed by two successive steps of gel filtration on Superdex 200 columns 
[52]. Rapid SEC of intact PGs in buffers containing up to 8 M urea was performed with a 
BioSil Sec-400 column, which is compatible with the high urea concentration and has an 
upper back-pressure limit of more than 10 MPa [53]. The addition of poly-L-glutamic acid to 
both sample and mobile phase overcomes the non-specific binding of PGs to the silica matrix 
[53]. Another way to avoid electrostatic interaction between PGs and the resin is to increase 
the ionic strength of the eluent to 0.05 M salt. Two tandem Bio-Gel columns (Bio-Gel TSK-
60 and Bio-Gel TSK-50) were used to resolve intact cartilage proteoglycans from proteolytic 
degradation products present in the extract [54]. SEC can also provide an estimation of the 
weight average (Mr) of proteoglycans, when the column is calibrated with PG standards of 
known molecular weight. Ohno and co-workers used a Sepharose CL-2B column, 
equilibrated in 4M GuHCl, to derive the molecular mass of PGs from chicken chondrocytes 
[55]. Proteoglycans extracted from ovine skeletal muscle were separated into two populations 
by a Sephacryl S-200HR column [56]. Cooper et al [57] employed a Superose 6 HR column 
to purify a keratan sulfate/chondroitin sulfate proteoglycan from the culture medium of 
human embryonal carcinoma stem cells. SEC may also be utilized in place of dialysis to 
remove salts and/or unincorporated radiolabel [51]. Separation based on surface 
hydrophobicity is accomplished by either hydrophobic interaction chromatography (HIC) or 
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reversed-phase chromatography (RPC). In general, HIC resins contain a much lower ligand 
density as compared to RPC resins. In HIC, elution from the stationary phase (short chains of 
octyl or phenyl groups) takes place with descending salt gradients or increasing non-ionic 
detergent gradients [58], while in RPC the bound compounds are eluted with organic solvent. 
Octyl-Sepharose has been efficiently used for separating small leucine-rich PGs (biglycan, 
decorin and fibromodulin) from each other [59,60] and also for isolating membrane 
associated PGs [61-63]. Phenyl-Sepharose has proven successful for fractionation of retinal 
cell-associated PGs [64]. Reversed phase columns have not generally been used for 
proteoglycan purification. However, for the separation of the protein cores of small 
proteoglycans, reversed phase chromatography may be helpful and presents some advantages 
over other types of chromatography. In our own research we used a C4 reversed phase 
column in the last step of a decorin purification protocol [65]. Reversed phase 
chromatography separates decorin from the other proteoglycan protein cores (see Fig. 2) and 
offers the possibility to profile the proteoglycans from the CS/DS class, gaining more insight 




Fig. 2. Separation of decorin core protein (F*) from other CS/DS proteoglycan components from a 
lung extract using a Vydac protein C4 column. (Reprinted from ref. [65] Copyright © 2006, with 
permission from Elsevier.) 
 
Hydroxyapatite (HAP) presents a complex mosaic of charges (contributed by calcium, 
phosphate and hydroxyl groups), which give rise to its amphoteric nature. Electrostatic 
interactions occur between the cationic sites of the mineral (calcium) and the anionic groups 
of the analyte (carboxyl and sulfate). For chromatography, most columns are equilibrated by 
extensive washing with phosphate buffer at pH 6.8 [49], which confers a negative net charge 
to the resin’s surface. Carboxyl groups on the protein core or GAGs are repelled 
electrostatically from the negatively charged phosphate groups of the column and bind by 
complexing to calcium. PGs can thus interact with the resin via both the protein cores and the 























Proteoglycan purification and analysis 
 
17 
only native proteins bind to HAP effectively [66]. Elution of PGs from HAP is performed 
with an increasing gradient of phosphate. A Bio-Gel HTP hydroxyapatite column was 
employed to fractionate human aorta PGs [67], porcine bone PGs [37], or rat microvascular 
endothelial cell PGs [68]. 
Heparan sulfate proteoglycans bind to a large number of proteins and are therefore 
most frequently isolated by affinity chromatography. Different proteins immobilized to 
chromatographic resins were employed to affinity purify this class of PGs, antithrombin III 
[68], TGF-β [69], laminin [70], fibronectin [35] or thrombospondin [71] being only few 
examples. Monoclonal or polyclonal antibodies immobilized on chromatographic resins can 
also be used in immunoaffinity purifications of different proteoglycans [72-74]. Another 
affinity method for the isolation of PGs takes into account the N- or O-linked 
oligosaccharides present on their protein cores in addition to the GAG chains. Different 
lectins, with particular specificity for a certain oligosaccharide sequence, may be directed to 
affinity capture PGs by binding to their specific glycans. Cooper et al. used a peanut lectin 
affinity column [57] as the first step in their protocol to purify a keratan sulfate/chondroitin 
sulfate proteoglycan expressed in pluripotent primate stem cells. Brown et al [39] used 
Concanavalin A as the last step when purifying decorin from bovine cornea.  
 
2.2.3 Specific assays 
 
In any purification procedure it is necessary to have an assay to follow the yield of the 
component of interest at each step of the protocol. Many assays for PG quantification take 
advantage of the attached GAGs. For uronic acid containing PGs (HS, CS, DS) the 
colorimetric carbazole-sulfuric acid assay, as modified by Muir and coworkers [75], can be 
applied. The method involves the hydrolysis of hexuronic acid derivatives with carbazole and 
absorbance measurement at 525 nm. The assay is linear between 4-400 µg of standard (D-
glucurono-6,3-lactone). Neutral glycans give about 10% interference and heparin and HS 
produce an anomalously high absorbance.  
Another way to quantify PGs is through interaction of their GAGs with cationic dyes. 
The method involves precipitation of the dye-GAG complexes followed by dissociation of the 
complexes and resolubilization of the dye. A spectrophotometer is employed to read the 
absorbance at wavelengths characteristic for each dye. Various dyes, like alcian blue, safranin 
O, cuprolinic blue or 1,9-dimethylmethylene blue have been employed in assays for GAG 
quantitation. The same principle can be utilized on a larger scale to selectively precipitate PGs 
from tissue extracts and to separate them from non-proteoglycan components. McBain and 
Muller [76] treated cultured cells with cetylpyridinium chloride (CPC) followed by phenol 
extraction of the pellet (to remove unglycosylated proteins) to yield lipophilic PGs of high 
density. Bjornsson optimized a method to quantify PGs (1-20 µg GAG) after precipitation 
with alcian blue from extracts containing GuHCl. Different GAG classes can be specifically 
precipitated by increasing concentrations of GuHCl in combination with detergent and high 
salt concentration at low pH [77]. This method was further optimized for a more sensitive 
quantification of GAGs in biological fluids (blood plasma, urine or wound fluid) [78]. 
Attention should be paid when choosing the supplier of alcian blue, because the solubility of 
alcian blue in GuHCl has a major impact on the success of the assay [77]. In all dye-binding 
assays interferences from other proteins, nucleic acids or hyaluronan are still noticeable to a 
certain degree. Therefore their application for a sensitive detection is limited, but they can be 
successfully employed to monitor the enrichment of PGs in fractions of interest along 
different steps of a purification protocol.  
The ability of cationic dyes to bind strongly to GAGs is taken into account when 
developing specific staining methods to visualize PGs after electrophoretic separation. Alcian 
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blue or toluidine blue [79] are traditionally employed for staining PGs. McDevitt and 
Muir[80] developed a composite acrylamide-agarose (1.2% acrylamide, 3% cross linker and 
0.6% agarose) gel to separate cartilage PGs. For staining the PGs they used 0.2% toluidine 
blue in 0.1% acetic acid (alcian blue stains agarose and therefore was not suitable). Gradient 
SDS-PAGE systems for PGs have also been used, the most common gradients being in the 
range of 3 to 20% acrylamide [81,82]. The staining methods are characterized by low 
sensitivity, requiring microgram amounts of each proteoglycan for detection. In order to 
increase sensitivity, silver enhancement methods have been described [83,84]. Alcian blue is 
used as the primary staining agent, binding directly to the proteoglycans, with staining being 
subsequently enhanced by a neutral silver stain. A twofold increase in sensitivity as compared 
to alcian blue alone is obtained. Nonglycosylated proteins stain weaker than PGs. 
Radiolabeled PGs separated by composite or SDS-PAGE gels can be visualized by 
fluorography [85,86]. 
 
2.3 GAG analysis 
 
The early work of Meyer and others [87] has established the structure of the basic repeating 
units of each group of sulfated GAGs. Over the years it has, however, become apparent that 
GAG structure is very heterogeneous with respect to position and distribution of D-glucuronic 
and L-iduronic acid groups and the content and location of sulfates. Very detailed information 
about the structure of GAGs is needed in order to elucidate structure-function relationships. 
PGs are often involved in biological processes necessitating interactions via well defined 
GAG sequence motives with defined sulfation patterns. This can be illustrated by the fact that 
pathogens (viruses, parasites, and bacteria) use cell-surface CS/DS and HS with definite 
sulfation patterns and chain lengths for their attachment to host cells and tissues [88] and that 
a defined sulfated heparin pentasaccharide unit is critical for the activation of antithrombin 
III, a major controlling element in the coagulation cascade [89]. The various sulfation patterns 
in CS have also been suggested as a marker to distinguish osteoarthritis from normal aging 
[90], since the sulfation pattern of low molecular weight dermatan sulfate plays a key role in 
its antithrombotic activity in blood vessels.  
 
2.3.1 Intact GAGs 
 
Information about the charge density, polydispersity, molecular size and GAG type can be 
obtained from the analysis of intact GAGs. Since the detailed structure of 
glycosaminoglycans cannot be currently assessed at the level of intact proteoglycans, their 
study involves as a first step the release of the GAG chains from the protein cores. Alkaline β-
elimination [91] (used also in the Carlson degradation procedure) and hydrazinolysis [92] are 
the two most commonly used chemical cleavage methods available for detaching the O-linked 
GAGs from proteoglycan protein cores. More recently, enzymatic cleavage by cellulases, a 
class of enzymes with endo-β-xylosidase activity, have also been described to release intact 
GAG chains attached to peptides [93,94]. The cellulases from A. niger and Patinopecten act 
on the linkage region (Xyl-Ser) between a core peptide and a GAG chain by hydrolyzing the 
peptide. Patinopecten endo-β-xylosidase catalyzes hydrolysis of long GAG chains, hardly 
cleaving short chains, while for A. niger endo-β-xylosidase the enzymatic activity is greater 
with shorter GAG chains [93]. 
Once GAGs have been released from the protein cores, the resultant mixture may be 
fractionated by ion exchange chromatography and subjected to further separation by 
electromigration methods. All GAG species are amenable to electrophoresis on cellulose 
acetate membranes [95], agarose gels [96,97], or polyacrylamide gels and classified according 
Proteoglycan purification and analysis 
 
19 
to the mobility of standards. Improved detection limit may be achieved by combining 
different staining agents, like sequential staining with toluidine blue and Stains-All [97], 
which allows detection of submicrogram quantities of proteoglycans. An example of the 
separation and detection of a mixture containing 0.5 µg CS and 0.5 µg DS on agarose gel is 
presented in Fig. 3. Electrophoresis on cellulose acetate membrane is still the first choice for 
the analysis of clinical samples, due to its simplicity, low cost of analysis, and the ability to 
process several samples at the same time. Bands are visualized after colorimetric reaction 
with a cationic dye (mainly toluidine blue) and quantified using image analysis systems. Due 
to the heterogeneity of GAGs, bands are diffuse and details about minor structural changes or 
the sites of sulfation can not be obtained. Microchip electrophoresis with in situ fluorescent 
detection using ethidium bromide has been proposed as an alternative to cellulose acetate 
electrophoresis [98], offering the same sensitivity and shortening the analysis time to 150 s. 
Electromigration procedures employed to analyze GAG mixtures have been recently reviewed 
[99]. 
SEC [100] or capillary electrophoresis [101,102] may be also used for intact GAG 
analysis. Intact HA has been analyzed by CE under both normal and reversed polarity. In 
normal polarity (phosphate borate buffer, pH 9) it appears as a single broad peak [103], while 
in reversed polarity under weak acidic condition it migrates as a narrow peak [104]. CE 
measurements of HA in biological matrices (e.g. synovial fluid) is affected by the interaction 
with proteins, which may be overcome by the addition of SDS [102], also used for the 
analysis of long HA derived oligosaccharides [105]. Intact HA was also detected utilizing 
copper complexes [106], but compared to other copper-GAG complexes, HA gives low 
detection sensitivity. When separated in a capillary filled with a polyacrylamide gel, HA 
oligomers show a linear relationship between migration times and degree of polymerization 
[107]. 
The requirements for establishing the biological function of GAGs call for very 
detailed sequence information, which can not be obtained from the analysis of intact GAGs. 





Fig. 3. (A) Separation of 0.5 µg of chondroitin sulfate and 0.5 µg of dermatan sulfate by discontinuous 
agarose-gel electrophoresis in 0.05 M HCl/0.04 M barium acetate combined with the visualization 
technique using toluidine blue/Stains-All. (B) Densitometric scan of the gel. (Reprinted from ref. [97] 

































2.3.2 GAG-derived oligosaccharides 
 
GAG structure is traditionally studied by scission of the chains with specific enzymes in order 
to produce GAG-derived oligosaccharides. A large variety of degrading enzymes for all GAG 
types is nowadays commercially available. These enzymes are divided into two distinct 
classes: prokaryotic enzymes, which depolymerize GAGs by an elimination mechanism and 
eukaryotic enzymes, which act by hydrolysis [108]. Each cleavage, with either class of 
enzyme, creates a free reducing aldehyde group that can be labeled with fluorescent dyes. The 
most commonly used enzymes belong to the chondro/dermato lyase and heparin/HS-lyase 
families. These enzymes act on the β(1→4) bond between hexosamine and uronic acid and 
produce disaccharides with a double bond between C4 and C5 of uronic acid, which absorbs 
strongly at 232 nm. 
 
Table 1. Different glycosydases employed for GAG digestion. 
 
Enzyme name Enzyme source Enzyme substrate 
Heparin lyase I Flavobacterium heparinum Heparin HS 
Heparin lyase II Flavobacterium heparinum Heparin HS 
Heparin lyase III Flavobacterium heparinum HS 




Chondroitin Lyase AC Arthrobacter aurescens Flavobacterium heparinum 
CS (glucuronic acid) 
DS(glucuronic acid) 
HA 
Chondroitin Lyase B Flavobacterium heparinum 
DS 
Cleaves amino sugars 
attached to iduronic acid 
Testicular hyaluronidase Bovine/sheep testes 
Hyaluronan 
CS 
Hyaluronidase Streptomyces hyalurolyticus HA 
Hyaluronidase Streptococcus dyslatea HA CS unsulfated regions 
Endo-β-galactosidase E. freudii KS 
Keratanase I Pseudomonas species KS 
Keratanase II Bacillus species KS 
 
An overview of the most common enzymes employed for GAG degradation is 
presented in Table 1. HA, CS and DS are decomposed in disaccharides by chondroitinases 
(ABC, AC and B). These enzymes have specificities for chondroitin sulfate (ABC and AC) 
and dermatan sulfate (ABC and B), while chondroitinase ABC cleaves also hyaluronan but 
less effectively. Testicular hyaluronidase degrades both hyaluronan and chondroitin sulfate 
while the hyaluronidase from Streptomyces is specific for hyaluronan. Keratan sulfate can be 
depolymerized by endo-β-galactosidase from E. freudii or keratanases from Pseudomonas or 
Bacillus species. Heparin and heparan sulfate are cleaved by different heparin liases. Each 
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heparinase can yield a different pattern of products, while their combined use yields 





Fig. 4. Structures of the major disaccharide repeating units found in different types of 
glycosaminoglycans. Heparin, HS and KS have diverse sequences where X = SO3- or H and Y = SO3-, 




Compositional analysis of GAGs represents a major methodological challenge in 
terms of sample complexity and can be compared to a certain extent with peptide mapping of 
proteins. Differential treatments of the same GAG chain with all the available specific lyases 
generate oligosaccharide maps, similar to the peptide maps derived from proteins. 
Recently, Iwafune and coworkers proposed a method for estimating the molecular 
weight and degree of sulfation of intact GAGs, liberated from PG extracts by digestion with 
cellulase from Aspergillus niger [109]. Size exclusion chromatography on a Shodex OHpak 
SB-803HQ column was used to estimate the molecular weights of GAG species, while anion 
exchange on a TSKgel DEAE-5PW column estimates the numbers of sulfates per 
disaccharide.  
 
High performance liquid chromatography (HPLC) 
 
During the last years improved sensitivity of detection systems for liquid chromatographic 
and electrophoretic instruments has made separation and quantification of very low amounts 
of GAGs possible. Different types of chromatography such as normal phase, reversed-phase, 
ion-pair and ion-exchange have been used for disaccharide and oligosaccharide analysis. 
Analysis of unsaturated disaccharides is simple and rapid, without the need for derivatization. 
However, derivatisation increases the sensitivity of detection and therefore, derivatization has 
been proved useful for the detection of both saturated and unsaturated disaccharides. The 
most common agents employed for pre-column derivatization are: 2-Aminoacridone (2-
AMAC) [110], 2-Aminopyridine (2-AP) [111], 2-Aminobenzamide (2-AB) [112], and 
dansylhydrazine [113]. 
HPLC methods do not generally provide complete sequence information of the GAG 
chain, but are able to reveal the sulfation pattern/degree of modification. Quantitative or 
qualitative changes (molecular size, charge density) can be revealed by HPLC, providing 
information about the development and progress of a certain disease, for instance is the case 
in different neoplastic transformations [114,115]. 
First columns employed for the separation of GAG derived oligosaccharides used 
amino-bonded silica as packing material and separation was performed isocratically [116]. 
Nowadays, reversed phase chromatography together with ion-pairing of glycosamonoglycans 
with hydrophobic amines are more widely used [117,118]. 
Different GAG chains obtained from human gastric carcinoma (HGC) and human 
normal gastric mucosa (HNG) were fractionated by anion exchange chromatography (AEC) 
on DEAE-Sephacel column, revealing the presence of three different populations (I, II, and 
III) in both normal and cancerous tissue [115] (Fig. 5). Quantitative differences in populations 
I and II were revealed and subsequent analysis showed a significant increase in HA and CS 
(population I) and a decrease in HS (population II) in the samples originating from carcinoma 
tissue. 
Ion-pair reversed-phased HPLC, employing binding of a tetrabutylammonium 
hydrogen sulfate (TBA) cation to the anionic charges of oligosaccharides, offers high 
separation for all non-, mono-, di- and trisulfated disaccharides [119]. Gel permeation 
chromatography on a Sepharose CL-6B column has been used to determine the absolute 
content and the size distribution of digested dermatan sulfate [120]. 
Endogenous unsaturated disaccharides from human plasma, produced after digestion 
with chondroitinase ABC were separated and quantified using a Symmetry C-18 analytical 
column [121]. The separation was performed with gradient elution starting with 96% eluent A 
(0.8 mM tetrabutylammonium hydrogen sulfate and 2 mM sodium chloride) and 4% 
acetonitrile, to 47% eluent A, 6% acetonitrile and 47% water. The absorbance of the eluate 
was monitored at 230 nm.  






Fig. 5. Fractionation of glycosaminoglycan chains from human normal gastric mucosa (○) and human 
gastric carcinoma (●) by anion-exchange on a DEAE-Sephacel column. GAGs from both normal and 
cancerous tissues are separated in three different populations: I, II and III. (Reprinted from ref. [97] 
Copyright © 2005, with permission from Elsevier.) 
 
All known unsaturated disaccharides (non-, mono-, and di-sulfated), derived from CS, 
DS and HA were successfully resolved and detected using HPLC with fluorimetric detection 
after derivatization with dansylhydrazine [113]. The column used was a µ-Bondapack NH2 
(aminopropylmethylsilyl bonded amorphous silica) with isocratic elution in acetonitrile/100 
mM acetate buffer (90/20), pH 5.6. The advantages of the method lie in good resolution, high 
sensitivity (50 pmol) and a short analysis time (50 min). 
 
 Capillary electrophoresis (CE)  
 
CE has several advantages over a variety of other analytical methods: high sensitivity, high 
separation efficiency, on-line detection, simple operation, short analysis time, automated and 
reproducible analysis, and very low consumption of samples and buffers. The low quantities 
of samples processed make the method unsuited for preparative work.  
The driving forces in CE are the electroosmotic flow (EOF) and electrophoresis. For 
GAG analysis CE in both normal (positive) and reversed (negative) polarity may be used. 
Normal polarity employs a basic or neutral buffer and requires sample application at the 
anode and detection at the cathode. Negatively charged species are prevented from migrating 
out of the capillary by the dominant EOF. In reversed polarity, an acidic buffer is used and the 
sample is applied at the cathode and detected at the anode. At pH< 3 the silanol residues of 
the internal wall of the capillary begin to lose their negative charges resulting in the reduction 
of the electroosmotic flow. Therefore the dominant force in the separation becomes 
electrophoresis and only anionic species migrate through the capillary towards the detector, 
making this method useful for the analysis of acidic carbohydrates [122]. Improved resolution 
is obtained in reversed polarity as compared with normal polarity. Sulfated GAGs develop a 
high electrophoretic mobility (EM) even at low pH, which may be reduced by adding ion-
pairing reagents to the operating buffer.  
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CE has been successfully applied to the separation, characterization (in terms of the 
average number of sulfates per repeating unit), quantitation, and size determination of intact 
GAGs or oligosaccharides derived after enzymatic digestion. The possibility for size 
determinations are an advantage over the conventional chromatographic techniques. 
The first application of CE to the analysis of disaccharides derived from CS, DS, and 
HA was simultaneously reported in 1991 by Al-Hakim and Linhardt [123] and Carney and 
Osborne [105], using normal polarity in a basic borate buffer. The method was later 
successfully applied to disaccharides derived from heparin and HS [124]. Under normal 
polarity, improvement in resolution was obtained by applying micellar electrokinetic capillary 
electrophoresis in basic borate buffer using cetyltrimethylammonium bromide as ion-paring 
and micelle-forming agent [125]. Oligosaccharides from HA were well separated according to 
size by CE in a 0.1 M Tris-0.25 M borate buffer, pH 8.5, containing 10% polyethylene glycol 
(PEG) 70000, with detection at 200 nm [126].  
Capillaries filled with polyacrylamide gel were used to separate CS-derived 
oligosaccharides produced by limited digestion of GAGs with different lyases [25] and these 
gels may prove effective in determining the degree of polymerization [127]. Separation of CS 
and DS was achieved by reversed-polarity CE with sensitive detection at 240 nm, based on 
the formation of a copper (II) complex in copper sulfate solution of pH 3.0 [106]. For the 
separation of non-, mono-, and disulfated disaccharides derived from CS/DS chains, the 
conditions were optimized during the last years by using pyrazolone derivatives [128] (in 100 
mM borate buffer at pH 9.0) permitting an efficient and complete separation. Analysis of 
underivatized CS disaccharides from mink skin is possible using micellar electrokinetic 
capillary chromatography (MECC) in the presence of cetyltrimethylammonium bromide, pH 
7.0, with direct UV detection at 232 nm [125]. CS and HS derived di- and oligosaccharides 
were fluorescent labeled with 2-AMAC, separated by CE and detected by UV at 254 nm. The 
sensitivity was limited, due to the lack of a fluorescent detector [110]. Digestion of DS with 
chondroitinases ABC, AC and B, results in unsaturated disaccharides having various sulfation 
positions and sizes. Using reversed polarity all of them can be separated in one run, using 
fused-silica capillary and phosphate buffer (pH 3.0). Detection at 232 nm offers sharp and 
symmetrical peaks and concentration as small as tens of pmol/l of each disaccharide can be 
reliably detected [129].  
Various synthetic heparins and their fragments obtained by heparinases action were 
analyzed in phosphate buffer at pH 3.0 [101]. The method could be useful for assessing the 
purity of the low-molecular weight heparins. CE separation in a reversed polarity mode, using 
phosphate buffet at pH 3.5 can separate all twelve known isomeric disaccharides within 15 
min [130]. 
CE with indirect UV detection overcomes the difficulties encountered with the 
analysis of carbohydrates that lack chromophores in their structures [127]. The principle of 
this detection consists in chromophore displacement by the analyte molecule, resulting in 
negative peaks. Buffers of benzene-1,2,4,-tricarboxylic acid and of 5-sulfosalicylic acid are 
generally used [131]. 
On-line CE-MS has been performed using different ionization techniques: 
electrospray, fast atom bombardment, and time-of-flight. The use of positive polarity CE with 
negative MS ionization seems to be the best approach to analyze complex oligosaccharide 
mixtures [132]. The applications of CE coupled to different MS detection for the analysis of 
biomolecules has been recently reviewed [133].  
More details about capillary electrophoresis for the analysis of GAGs and GAG 
derived oligosaccharides may be found in several reviews [134,135], which have covered 
only this technique.  
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Fluorophore assisted carbohydrate electrophoresis (FACE) 
 
A recently developed technique based on slab gel electrophoresis is fluorophore assisted 
carbohydrate electrophoresis or FACE. The technique was originally developed by Jackson 
and Williams [136,137] for the analysis of glycoprotein-derived carbohydrates labeled with 8-
aminonapthalene-1,3,6 trisulphonate (ANTS) and further adapted to the analysis of GAG 
derived disaccharides and oligosaccharides. HA and CS from cartilage were digested with 
hyaluronidase/chondroitinase, labeled with AMAC [119,138] or ANTS [138] and subjected to 
FACE. This method permits separation of charged or uncharged mono- or oligosaccharides 
with high resolution and can detect single hydroxyl anomeric differences between mono- and 
oligosaccharides with otherwise identical molecular weight, charge and sequence. In addition 
to separating low molecular weight oligosaccharides, an HA polymer preparation with an 
average molecular weight of several tens of thousands was separated into each chain length 
component [138]. The sensitivity of the method is in the ng range and several samples can be 
analyzed in the same gel. 
 
Spectroscopic techniques applied to GAGs 
 
Fully characterization of GAGs requires detailed information about the fine structural 
composition of the different constitutional units of the polymer. Although chromatographic 
and electrophoretic techniques used for the separation/detection can provide a rough 
estimation of the structure/identity by comparison with known standards, more powerful 
techniques are necessary to fully sequence the compositional units. For this purpose Nuclear 
Magnetic Resonance (NMR) and mass spectrometry are the techniques that offer the best 
capabilities.  
1H-NMR and 13C-NMR have been used for the characterization of oligosaccharides 
from chondroitin/dermatan sulfates [139,140] and heparan sulfate [141,142]. However, a 
major drawback of this technique is the high amount of saccharide required (around 5 mg) 
with enough purity. 
Mass spectrometry has become in the last years the most important tool for GAG 
characterization. This is due mainly to the high sensitivity (low femtomol range) as well as 
the possibility of on-line coupling with separation techniques such as liquid chromatography 
[117,143] or capillary electrophoresis. The way mass spectrometry techniques have been 
applied to GAG analysis has evolved during the years, following the technical developments 
in the field. First attempts for MS analysis of oligosaccharides used fast atom bombardment 
(FAB) ionization, where the oligosaccharides were ionized as salt adducts. The method was 
able to detect up to 10 nmol octasaccharides derived from heparin [144,145]. However, 
considerable loss of SO3 took place, making difficult the determination of degree of sulfation.  
 It must be born in mind that the sulfate groups attached to GAG oligosaccharides are 
very labile constituting a big challenge for MS analysis. In order to prevent their loss mild and 
soft ionization techniques are preferred. MALDI-TOF mass spectrometry has been used to 
determine the sequences of purified GAG molecules [146]. However, sulfated GAGs ionize 
poorly when mixed directly with any of the matrixes commonly used for MALDI-TOF MS 
[147]. A strategy followed to circumvent this fact has been paring the oligosaccharide with a 
basic peptide, to form a neutral complex which ionizes readily allowing to determine the mass 
of the peptide-oligosaccharide complex [147]. The oligosaccharide sequence can be figured 
out indirectly by measuring the mass before and after partial enzymatic or chemical digestion 
of the complex. A clear limitation of this methodology is the impossibility to perform direct 
structural analysis. Although the oligosaccharide composition can be deduced from the 
molecular weight alone, the structural information is limited because stereoisomers and 
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positional isomers cannot be distinguished. Moreover, the procedure is not quantitative. These 
restrictions together with the necessity to purify GAG oligosaccharides prior to MALDI-TOF 
make this technique better suited for a first evaluation of chain length distribution before 
applying other methodologies [148]. Undoubtedly electrospray (ESI) ionization is nowadays 
the most widely chosen approach for GAG analysis. Sulfated GAG oligosaccharides are 
easily detected using electrospray (ESI) mass spectrometry in the negative ion mode. 
 ESI-MS/MS was used to characterize KS oligosaccharide mixtures without prior 
purification or chromatographic separation [149]. Nevertheless, when using flow injection 
analysis extensive optimization of the MS parameters is required to distinguish between 
isomers. ESI spectra of sulfated GAGs are quite complex (when compared with other 
biomolecules such as peptides) due to several factors: a) high degree of heterogeneity of chain 
lengths in biological samples; b) formation of adducts between the sulfate groups and 
different cations to varying degrees; c) the molecules are fragile and may fragment during 
ionization loosing sulfate and d) a range of charge states? can be detected for each molecule 
[150]. Therefore there is a need for up-front separation of the oligosaccharides generated in 
enzymatic GAG digests before sequence assignment by MS/MS, in order to reduce the 
complexity of the resulting mixtures and to separate the isomers. For this purpose, CE and 
different types of liquid chromatography can be interfaced with MS. At first sight CE is the 
ideal separation technique for GAG derived sulfated saccharides due to their ionic character 
and polarity. Fractions separated by CE have been further characterized off-line by negative 
ESI/MS [151]. However, on-line CE/MS have been scarcely used in GAG analysis. Known 
limitations are the lack of sensitivity due to the inherent low loading capacity of CE and the 
loss of resolution in the interface with the mass spectrometer when using any sheath liquid. 
Useful application to real complex and low concentrated biological samples can only be 
achieved using sheathless approaches [152,153]. 
A SEC step prior to LC/MS analysis efficiently simplifies the composition of GAG 
entering the mass spectrometer [150,154], affording compositional mapping of 
oligosaccharides generated by hyaluronidase digestion of CS. Adding 10 mM HCl to the 
solvent eliminates sodium adduction and permits analysis of disaccharides produced by 
chondroitinase ABC digestion and determination of ratios of sulfation positions using 
multiple reaction monitoring.  
Strong anion exchange LC although commonly used in fractionation of GAG of 
oligosaccharide mixtures is difficult to interface with MS and a good alternative has been 
found using ion-paring reversed phase LC. This type of chromatography has been applied to 
the analysis of heparin oligosaccharides combined with ESI-MS. The necessity of utilizing 
volatile pairing agents has led to the use of alkyl ammonium acetates or dibutyl ammonium 
acetate [118], instead of tetraalkyl ammonium salts (which provides excellent 
chromatography). Even with this, the achievement of reasonable ionization of heparin was 
critical. Improvement of the method was obtained by introducing an on-line cation exchange 
step (using a Dionex ASRS-Ultra II Column) before the mass spectrometer [155], which 
removed the ammonium ions.  
Easy and quantitative direct analysis of disaccharides released enzymatically from 
proteoglycans has been achieved in our group using porous graphitized carbon as reversed 
phase chromatographic stationary phase and on-line negative ESI/MS detection [143]. The 
high resolution power of this material allowed distinguishing between isomers differing in the 
sulfate position (4 or 6) utilizing a simple mobile phase composed of water/acetonitrile in 
0.1% formic acid (see Fig. 6). A correct assignment of the sulfation position is obtained from 
the fragmentation spectra (MS2), based on the ratio of the fragment ions (Fig. 7). Graphitized 
carbon columns have been used also for the separation and characterization of larger 
oligosaccharides fragments derived from HS, heparin, HA and KS [156]. 






Fig. 6. LC-MS separation of positional isomers of standard CS disaccharides using a graphitized 
carbon column. (A) standard disaccharides sulfated in position 4; (B) standard disaccharides sulfated 




Fig. 7. MS/MS spectra corresponding to each isomer of both disaccharides (sulfated in position 4 or 6) 
presented in Fig 6. The ratios of the different fragment ions depend on the position of the sulfate 
group, the most intense fragment ions being at m/z = 300.1 (sulfate in position 4) and m/z = 282.0 
(sulfate in position 6). (Reprinted from ref. [142] Copyright © 2005, with permission from Elsevier.) 
 
2.4 Conclusions and future perspectives 
 
In the past decades the study of PGs has gained increasing importance due to their 
involvement in a variety of biological processes. This class of macromolecules has captured 
the attention of many researchers, which has triggered significant methodological 
developments in the analytical techniques employed for PG characterization. Both protein 
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cores and GAG chains are investigated in order to gain a deeper understanding of the 
structure-activity relationships as well as the biological role of a given PG.  
The polyanionic nature of proteoglycans is the most important molecular property, 
which is taken into account when developing purification strategies. In addition, tissue 
localization, molecular size, and solubility of a given PG are important features when 
developing a purification strategy. Although many techniques are at the researcher’s disposal, 
the most generalized approach involves PG extraction with a chaotropic agent (most 
commonly 4 M GuHCl) followed by anion exchange and size exclusion chromatography. 
Nondenaturing buffers are required when the interest lies in studying structure-activity 
relationships in more detail and when preserving the biological function of the isolated PG is 
required. Advances in the chemistry of chromatographic supports have enabled the 
application of HPLC for the isolation and fractionation of PGs with an increased resolving 
power. Reversed phase chromatography and affinity chromatography using immobilized 
lectins result in high purity PGs when used as the last purification steps. 
An increasing number of derivatizing agents facilitate more sensitive UV or 
fluorescent detection of GAG derived oligosaccharides in chromatographic and 
electrophoretic techniques.  
Characterization of oligosaccharides derived enzymatically from different GAGs is an 
important step toward the complete understanding of the relation between their chemical 
structure and biological functions. During the past decade, MS has become the key 
methodology in the structural elucidation of GAGs. Technical developments in MS, 
especially the soft ionization of thermolabile biomolecules, have allowed studying complex 
sulfated oligosaccharides, as for example derived from highly sulfated heparins. Based on 
fragmentation patterns, detailed structural information about the number and position of 
sulfate groups can be determined and thus correlated to biological activity. 
Methodological advances continue to drive the field of PG purification and 
characterization. For example, the development of monolithic chromatography materials with 
freely accessible throughpores, overcomes some of the limitations associated with packed 
columns when it comes to throughput and diffusion limited mass transfer. Monolithic 
columns offer high efficiency, fast separation, and high binding capacity at a lower pressure 
compared to conventional HPLC resins. For all these considerations we think that monolithic 
columns may find more widespread applicability for the fractionation of intact proteoglycans. 
Implementation of microfluidic LC-MS systems (such as the recently introduced chip 
LC-MS system) operated at flow rates of some hundred nanoliters per minute promises to 
increase sensitivity further and will likely also enter the area of glycosaminoglycan analysis. 
This will permit analysis of biological samples where previously sample amount and 
concentration were the limiting factors.  
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Purification of decorin core protein from human lung tissue  
 
 
An adapted version of this chapter has been published as: Mihaela Didraga, Begona Barroso, 
Marcel de Vries, Huib Kerstjens, Dirkje Postma, and Rainer Bischoff, J Chrom A 1123 (2006) 
151. 
 
A chromatographic method to purify decorin core protein from human lung tissue is 
described. The method is simple and rapid, using a combination of two-anion exchange and 
one reversed phase chromatography steps and the enzymatic digestion with chondroitinase 
ABC. SDS-PAGE analysis of the final product revealed a single 42 kDa protein band, which 
was recognized by anti-decorin antibodies upon Western blotting and identified by mass 
spectrometry. Further digestion with PNGase F evidenced the presence of N-linked 
oligosaccharides on the core protein. Using this method we purified decorin protein core with 
the attached N-linked oligosaccharides from two different locations of a healthy human lung 
and the same locations of an emphysematous human lung. The described strategy forms the 
basis for studying structural alterations of decorin related to the pathology of diseases where 














The extracellular matrix (ECM) is a complex network consisting mainly of collagens, elastin, 
noncollagenous glycoproteins, and proteoglycans (PGs). In addition to filling the space 
between cells, ECM plays a unique role in building a scaffold for cells, thus maintaining the 
structural integrity of many tissues. Although representing a low percentage of the total ECM 
proteins, proteoglycans are functionally very important being involved in a variety of 
processes like tissue organization [1], regulation of tissue mechanical properties [2], 
modulation of growth-factor activities [3], and regulation of collagen fibrillogenesis [4,5]. 
Covalently attached to their backbone protein cores, proteoglycans carry as hallmark 
glycosaminoglycan (GAG) chains, polymeric structures composed of repeating disaccharide 
units. Depending on the disaccharide composition, GAGs can be divided into four main 
categories: chondroitin sulfate (CS) and dermatan sulfate (DS), heparin and heparan sulfate 
(HS), keratan sulfate (KS), and hyaluronan (HA). 
Decorin is the archetype of the small leucine-rich repeat proteoglycan (SLRP) family 
and is widely distributed in a variety of connective tissues. Its mature protein core (without 
the signal peptide and the pro-peptide) consists of 329 [6] or 330 [7] amino acids and is 
decorated with one chondroitin/dermatan sulfate glycosaminoglycan chain at Serine 4 [8] and 
two or three N-linked oligosaccharides near the C-terminus [9,10]. Molecular modeling of 
decorin [11] has revealed an open horseshoe structure allowing an extensive binding area, 
which favors interactions with the triple helix of collagens [12,13] and can adjust to the 
specific requirements of other interacting molecules. It is thus not surprising that a 
considerable number of cytokines, growth factors and adhesion molecules bind to decorin and 
participate not only in matrix assembly, but also in the control of cell proliferation and tissue 
morphogenesis [14]. The attached negatively charged chondroitin/dermatan sulfate 
glycosaminoglycan confers polyanionic properties to decorin and by its large hydration 
capacity regulates lung tissue viscoelasticity [15]. The protein core of decorin contains as a 
central domain a series of 12 leucine-rich repeats (LRR) flanked by cysteine-rich regions. The 
central region of the LRR, located between the fourth and the sixth repeat, is thought to be 
responsible for the collagen binding activity of decorin and other members of the SLRP 
family [16]. 
 As a regulator of growth factors and collagen fibrillogenesis, decorin contributes 
directly to the proper ECM assembly. Therefore, in diseases associated with an altered ECM 
organization it is expected that decorin may play a major role. This has already been 
established in pulmonary [17,18], joint [19], cardiovascular [20], and renal [21] diseases. The 
implication of several other proteoglycans (e.g. versican, perlecan, biglycan, hyaluronan) in 
the mechanism of pulmonary diseases like fibrosis [22], asthma [23], lung edema [24] or 
emphysema [17] has been demonstrated. A more complete overview of proteoglycans 
involved in lung pathophysiology is presented in [25]. The study of decorin in all mentioned 
diseases is based on measurements of mRNA levels, immunohistochemistry studies or 
quantitation of decorin associated with the cells or in cell culture supernatants. While of 
importance, none of these methods offer any structural information about decorin in relation 
to the disease state and it is not established so far whether only decorin production is 
diminished and/or whether structural alterations (e.g. degradation, altered N-glycosylation) of 
decorin take place. In order to address these questions, comparative structural characterization 
of decorin purified from diseased and normal tissue is necessary. 
In our research we are interested to identify the structural alterations that decorin 
undergoes during chronic inflammation in lung emphysema. Our group previously has found 
diminished immunohistochemical staining of decorin in the peribronchiolar area of lung 
tissue from patients with severe emphysema as compared to lung tissue from control subjects 
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[17] and dysregulation of decorin production by lung fibroblasts of patients with severe 
emphysema after modulation with cytokines [26]. Furthermore, it has been observed that 
matrix metalloproteinases (MMPs), which are activated during pulmonary inflammation, can 
degrade decorin [27] and other structural proteins of the alveolar wall in emphysematous lung 
tissue [28]. 
In the present work we report the development of an improved method for the 
purification of decorin core protein that was for the first time applied to lung tissue. The 
method is simple and rapid, using a combination of two-anion exchange and one reversed 
phase chromatography steps. Moreover, this method allows the study of other proteoglycans 
from the CS/DS family and estimates the ratio between decorin and other family members. It 
is likely that the described method can be applied for the purification of decorin from other 
types of tissue. 
 




Human lung tissue was obtained from the Department of Pathology of the University Medical 
Center Groningen based on protocols approved by the medical ethics committee. The 
classification as normal or emphysematous lung tissue was made based on histological 
examination of tissue performed by a pulmonary pathologist. The control lung presented only 
mild changes related to smoking, with limited airspace enlargement and some goblet cell 
hyperplasia in the airways. No major pathology was present.  
Chondroitinase ABC, affinity purified from Proteus vulgaris, chondroitin sulfate A 
sodium salt from bovine trachea, phenylmethylsulphonyl fluoride (PMSF), Protease inhibitor 
cocktail for mammalian tissues (containing 4-(2-aminoethyl)benzenesulfonyl fluoride 
(AEBSF), pepstatin A, E-64, bestatin, leupeptin, and aprotinin), decorin from bovine articular 
cartilage (salt free, lyophilized powder), PNGase F from Chryseobacterium (Flavobacterium) 
meningsepticum, and propylene glycol were purchased from Sigma–Aldrich Inc. (St. Louis, 
MO, USA). HiTrap Q-Sepharose columns were from Amersham Biosciences Benelux 
(Roosendaal, The Netherlands). The reversed phase column was a Protein C4 column 
(2.1 mm I.D. × 250 mm length), obtained from Vydac (Hesperia, CA, USA). The Protein 
Desalting Spin Columns were purchased from Pierce Biotechnology Inc. (Rockford, IL, 
USA). The Micro BCA™ Protein Assay Reagent Kit was from Pierce (Perbio Science, Etten-
Leur, The Netherlands) and the Blyscan™ Sulfated Glycosaminoglycan Assay Kit from 
Biocolor Ltd. (Newtownabbey, Northern Ireland). The stirred ultrafiltration cell Amicon 8050 
(50 ml), the ultrafiltration membrane Biomax PBGC (10.000 NMWL), and the Stericap™ 
PLUS filtration systems were from Millipore (Millipore Corporation, Bedford, USA). 
Ethylenediaminetetraacetic acid disodium salt (EDTA), Tris–hydrochloride (Tris–HCl), and 
glycine were from Duchefa Biochemie B.V. (Haarlem, The Netherlands). All common 
laboratory reagents were obtained from Merck (Darmstadt, Germany). 
The monoclonal antibody 6D6 directed against bovine decorin core protein was a gift 
from Prof. Dr. P.G. Scott (Department of Biochemistry, University of Alberta, Edmonton, 
Canada). The epitope recognized by this monoclonal antibody has been previously described 
[29,30]. This antibody cross-reacts with decorin from most mammalian species and 
consequently was used for following the purification of decorin from human lung tissue. 
 




Lung tissue was freed of blood by perfusion with phosphate buffered saline (PBS). The left 
upper lobe (peripheral parenchymal tissue, including a minor amount of small airways) was 
used for the purification. This lung area was cut into small pieces (1–2 cm3), immediately 
frozen in isopentane and stored at −80 °C until use. Lung pieces (25 g frozen tissue) were 
homogenized with a blender and incubated with 100 ml/g tissue extraction buffer (50 mM 
sodium acetate, 300 mM NaCl, pH 6.0, containing 20% (v/v) propylene glycol, 10 mM 
EDTA, 1 mM PMSF, supplemented with 0.04% (v/v) ready-made solution of protease 
inhibitor cocktail) for 20 h at 4 °C with continuous stirring, as described by Brown et al. [31]. 
The resulting extract was centrifuged at 40,000 × g for 30 min (4 °C) using an Avanti™ J-30 
centrifuge (Beckman Coulter) equipped with a JA-3050 rotor. The pellet was re-extracted in 
500 ml extraction buffer followed by centrifugation in the same way as described above. 
Supernatants were combined and filtered through Stericap™ PLUS filters (0.22 µm pores) 
under vacuum. The total protein content of the extract was measured using the bicinchoninic 
acid (BCA) assay, and glycosaminoglycans were quantitated using the Blyscan™ assay kit 
(see Section 2.3). 
The first two chromatographic steps were performed using an AKTA basic fast 
protein liquid chromatography (FPLC) system (Amersham Biosciences) and the UV 
absorbance at 280 nm (A280) was monitored. Ten percent of the lung extract was loaded on 
two HiTrap-Q Sepharose columns (5 ml each), tandem connected, and equilibrated with the 
extraction buffer. The column was operated at 4 ml/min flow rate. After loading the sample, 
the column was washed with extraction buffer until A280 decreased to baseline followed by 
five column volumes with buffer containing 50 mM sodium acetate and 300 mM NaCl, pH 
6.0. The proteoglycan containing fraction was eluted with 1.5 M NaCl, 50 mM sodium 
acetate, pH 6.0 in a single peak. Measurements of sulfated GAGs and Western blot analysis 
showed the presence of proteoglycans and decorin, respectively, in this fraction. GAG 
containing fractions were pooled, further concentrated (to approximately 5 ml) and subjected 
to buffer exchange into 10 mM Tris–HCl, pH 7.8. 
Isolated proteoglycans were digested with chondroitinase ABC (as described in 
Section 2.4) in order to remove the chondroitin/dermatan sulfate chains. Following digestion, 
the volume of the sample was adjusted to 75 ml using a buffer containing 50 mM sodium 
acetate, 250 mM NaCl, pH 6.0 and the sample was loaded on the same 10 ml tandem HiTrap-
Q Sepharose column, previously equilibrated in the buffer mentioned above. The column was 
washed with the equilibration buffer until A280 decreased to baseline. The flow through 
fraction, containing mainly the protein cores from CS/DS proteoglycans, decorin being one of 
them, was collected and further concentrated to 3 ml. The proteoglycans resistant to 
enzymatic deglycanation were eluted with 1.5 M NaCl, 50 mM sodium acetate, pH 6.0. 
Decorin was purified by reversed phase HPLC on a Vydac C4 column (2.1 mm 
I.D. × 250 mm length) operated at 250 µL/min flow rate using a Merck Hitachi Liquid 
Chromatography system equipped with an L-7200 autosampler. Mobile phase A consisted of 
0.1% TFA in ultra pure water and mobile phase B of 0.1% TFA in acetonitrile. Separation 
was performed with an increasing gradient of B (5–95% in 75 min) with detection at 214 nm. 
Following each chromatographic step, Western blot analysis was performed in order to trace 
decorin. During the whole protocol, concentration and buffer exchange steps were performed 
using the Amicon 8050 ultrafiltration cell. 
 
3.2.3 Quantitation of total GAG and total protein 
 
Total sulfated GAGs were quantitated using the Blyscan™ Sulfated Glycosaminoglycan 
Assay Kit, according to the manufacturer's instructions. The assay is based on a colorimetric 
reaction between the negatively charged GAGs and the positively charged dye dimethyl-
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methylene blue (DMB). Concentrations were determined from standard curves of chondroitin 
sulfate A. The total protein content of samples was determined using the BCA assay kit, from 
standard curves of bovine serum albumin (BSA). 
 
3.2.4 Chondroitinase ABC digestion 
 
Pooled chromatographic fractions containing proteoglycans after the first anion exchange step 
were subjected to buffer exchange into 10 mM Tris–HCl, pH 7.8, and preconcentrated using 
the stirred ultrafiltration cell to 1.4 mg/ml total GAG. Proteoglycans were incubated overnight 
with chondroitinase ABC (2.8 mU/µg GAG) at 37 °C, to ensure complete digestion of GAG 
chains. Completeness of the enzymatic digestion was monitored by quantifying the sulfated 
disaccharides liberated from the GAG chains at different time intervals by LC–MS [32]. 
When further addition of the enzyme did not produce any increase in the amount of 
disaccharides it was considered that the digestion was completed under the given conditions. 
 
3.2.5 SDS-PAGE and Western blot analysis 
 
For SDS-PAGE analysis, a Miniprotean III system from Bio-Rad (Hercules, CA, USA) was 
used. Aliquots of pooled chromatographic fractions were analyzed by SDS-PAGE and/or 
Western blotting. Samples eluted with high salt concentrations were subjected to buffer 
exchange with 10 mM Tris–HCl, pH 7.8 (using protein desalting spin columns, according to 
the manufacturer's instructions) prior to SDS-PAGE analysis. For gel electrophoresis 10 µL 
samples were mixed with 10 µL loading buffer (2% SDS, 350 mM DTT, 25% (v/v) glycerol, 
0.01% Bromophenol Blue in 62.4 mM Tris–HCl, pH 6.8) and boiled for 5 min. Proteins were 
separated on a 12.5% SDS-polyacrylamide gel under reducing conditions. Gels were either 
stained with Coomassie® Brilliant Blue R or electrophoretically transferred to a 
polyvinylidene-difluoride (PVDF) membrane (using the Miniprotean III blotting system) in 
25 mM Tris–HCl, pH 8.3, and 192 mM glycine containing 20% (v/v) methanol (350 mA for 
1 h). Membranes were blocked for 30 min with 5% Protifar non-fat milk (Nutricia, 
Zoetermeer, The Netherlands) in TBS-T buffer (10 mM Tris, 137 mM NaCl, and 0.05% 
Tween 20, pH 8.8), and incubated for 2 h at room temperature (RT) with the 6D6 monoclonal 
antibody directed against decorin (1:150) in 1% BSA in PBS (140 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, and 1.8 mM KH2PO4, pH 7.4). Blots were washed with TBS-T and 
incubated with the secondary goat anti-mouse IgG antibody coupled to alkaline phosphatase 
(Sigma–Aldrich, St. Louis, MO, USA) at a dilution of 1:15000 in TBS-T buffer, for 1.5 h at 
RT. Blots were washed with TBS-T and incubated 10 min with AP buffer (100 mM Tris, 
100 mM NaCl, 5 mM MgCl2, pH 9.5). Proteins were visualized by a colorimetric reaction 
after incubation of the blots with 0.4 mM nitro blue tetrazolium (NBT) and 0.4 mM 5-bromo-
4-chloro-3-indolyl-phosphate (BCIP) in AP buffer. The reaction was stopped by washing the 
membranes with ultra-pure water. 
 
3.2.6 “In gel” tryptic digestion 
 
After excision, gel pieces were transferred to 1.5 ml Eppendorf tubes. The Coomassie® 
Brilliant Blue R stain was removed by washing the gel pieces with 25 mM ammonium 
bicarbonate and acetonitrile. Gel pieces were completely dried using a CentriVap 
Concentrator (LABCONCO, The Netherlands). Proteins were reduced with 20 µL of 10 mM 
DTT in 0.1 M ammonium bicarbonate for 30 min at 56 °C. Excess liquid was removed and 
proteins were further alkylated using 20 µL of 55 mM iodoacetamide (IAA) in 0.1 M 
ammonium bicarbonate for 30 min at RT in the dark. Excess liquid was removed and gel 
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pieces were washed again as previously described and completely dried. Twenty microliters 
of 10 ng/µL cold bovine trypsin (Promega Corporation, Madison, USA) were added and the 
tubes were kept on ice for 30 min. Excess trypsin solution was replaced with the same volume 
of 25 mM ammonium bicarbonate and digestion performed overnight at 37 °C. Excess liquid 
after the digestion was transferred to a new tube. Twenty microliters of 5% (v/v) aqueous 
formic acid were added and the tubes let to stand at RT for 15 min. Twenty-microliter 
acetonitrile were added and after 15 min the excess liquid was removed and combined with 
the excess liquid resulting after tryptic digestion. The combined extract was completely dried 
and peptides reconstituted in 20 µL of 5% formic acid and further analyzed by LC–MS/MS. 
 
3.2.7 PNGase F digestion of the intact protein core  
 
N-linked oligosaccharides attached to the intact decorin core protein were enzymatically 
released using PNGase F. In order to deglycosylate the intact protein core, we used a 
procedure adapted from Barroso et al [33], which was in brief: 20 µg of decorin core protein 
reconstituted in 35 µL of 1 mg/ml N-octylglucoside, pH 7.5, were boiled at 100°C for 2 
minutes, cooled at RT and incubated with 0.5 µl of PNGase F stock solution (5 units/µL) for 
48 h, at 37°C, using an Eppendorf Thermomixer.  
 
3.2.8 Liquid chromatography–Mass Spectrometry (LC-MS) 
 
The HPLC part of the analytical system consisted of an Agilent Series 1100 capillary LC 
system (Waldbronn, Germany). Peptides were separated on an Atlantis™ dC18 NanoEase™ 
Column (Waters Corporation, Milford, MA, USA), 300 µm I.D. × 150 mm length operated at 
5 µL/min flow rate. Mobile phase A consisted of 0.1% formic acid in ultra pure water and 
mobile phase B of 0.1% formic acid in acetonitrile. Separation was performed with an 
increasing gradient of B (5–90% in 60 min). The peptides were detected by an Agilent SL 
ion-trap mass spectrometer equipped with an ESI source operated in positive mode. MS data 
were acquired over a scan range of 50–1500 a.m.u. at 5500 m/z per second scan rate. For the 
MS/MS analysis doubly charged ions were preferred and the fragmentation cut-off was set to 
27% of the m/z of the respective precursor ion. 
 
3.2.9 Matrix-assisted laser desorption ionisation (MALDI)–Mass Spectrometry 
 
MALDI analysis was performed in the positive ionization mode using a Voyager DE Pro 
instrument (Applied Biosystems, Framingham, MA, USA). The intact protein core 
preparations spectra were acquired in linear mode with delayed extraction using a two point 
external calibration with an intact BSA preparation (m/z of 66,431 Da and 33,216 Da for the 
singly and doubly charged ions, respectively). Sinapinic acid (SA) was used for matrix 
preparation. Prior to the analysis, 7 µL of the intact decorin core protein preparations were 
desalted and concentrated using C8 Stage tips (Proxeon, Odense, DK), according to the 
manufacturer's instructions. Finally, the samples were eluted with 1 µL of 5 mg/ml SA in 50% 




3.3.1 Decorin purification 
 
An overview of the purification protocol is presented in Fig. 1 and the results are summarized 
in Table 1.  





Fig. 1. Schematic representation of the method used for decorin purification. The concentration and 
buffer exchange steps will be referred to in Table 1 as “Amicon cell 1” and as “Amicon cell 2”.  
 
Table 1. Purification of decorin core protein from 25 g human lung tissue  
 







Lung extract 2500 10.5 315.2 0.033 
First AEC 180 7.8 23.1 0.327 
Amicon cell 1 5 3.2 11.5 0.278 
Second AEC 115 nac 1.3 na 
Amicon cell 2 3 na 0.9 na 
RP-HPLCd 12 na 0.173 na 
 
Final yield of purified decorin was 173 µg. Decorin was quantified by HPLC from a calibration curve 
using as standard bovine decorin. 
a Total GAG was measured using the Blyscan kit. 
b Total protein was measured using the BCA assay. 
c na = not applicable (due to the enzymatic digestion of CS/DS chains). 
d Fractions containing decorin, collected from RP-HPLC (successive injections) were pooled together 
and the solvent was totally evaporated under a flow of nitrogen. 
 
Two hundred and fifty milliliters crude lung extract were loaded onto the 10 ml 
HiTrap-Q Sepharose tandem column in each of 10 successive runs and a representative 
chromatogram is shown in Fig. 2. Washing of the column with 0.3 M NaCl resulted in the 
elution of a small protein fraction (F1), containing weakly bound components. This fraction 
was collected and subjected to Western blot analysis, which demonstrated that decorin was 
not present (data not shown). Proteoglycans captured by anion exchange chromatography 
eluted with 1.5 M NaCl as a single peak (F2). Western blot analysis of this fraction revealed 
the presence of decorin which migrated as a broad band around 100 kDa (Fig. 3b, lane 1). On 
SDS-PAGE no band was visible at the molecular weight of the corresponding blot (Fig. 3a, 
lane 1). The flow through fraction contained approximately 90% of the proteins loaded and 
did not contain detectable amounts of GAG.  
Human Lung Extract




Digestion with  
Chondroitinase ABC
Flow through:  













Fig. 2. Anion exchange chromatography of human lung extract. Lung extract (250 ml from a total of 
2500 ml) was applied to a 10 ml HiTrap Q Sepharose tandem column at 4 ml/min in the presence of 
0.3 M NaCl. During washing, a small amount of proteins eluted (F1) while proteoglycans were eluted 




Fig. 3. SDS-PAGE (a) and Western blot (b) analysis of fractions containing decorin. Lane 1: fraction 
F2 (see Fig. 2) at 1.5 M NaCl after first AEC; lane 2: collected peak after first AEC digested with 
chondroitinase ABC; lane 3: flow-through fraction collected from second AEC after 33-fold 
concentration; lane 4: decorin core protein purified by reversed phase HPLC; lane 5: prestained 
molecular weight marker. The gel was stained with Coomassie® Brilliant Blue R concentrate (Sigma). 
 
Enzymatic digestion with chondroitinase ABC selectively removed the 
chondroitin/dermatan sulfate chains from decorin and other proteoglycans belonging to the 
CS/DS class. Western blot analysis of the digest revealed a shift of the band corresponding to 
glycanated decorin (Fig. 3b, lane 1) to a much sharper band with a molecular weight of 
slightly less than 50 kDa (Fig. 3b, lane 2). This molecular weight is consistent with literature 
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data and corresponds most likely to the N-glycosylated decorin core protein [31,34]. It is 
again not possible to discern a band corresponding to this Western blot upon SDS-PAGE 




Fig. 4. Anion exchange chromatography of proteoglycans after deglycanation with chondroitinase 
ABC. Fraction F2 (see Fig. 2) was treated with chondroitinase ABC and loaded onto the same column 
at 3 ml/min in the presence of 0.25 M NaCl. Decorin core protein was recovered in the flow through 
fraction (see lane 3 of Fig. 3b) while proteoglycans resistant to deglycanation and digested GAGs were 
eluted with 1.5 M NaCl (F).  
 
Decorin core protein was further enriched by a second HiTrap-Q Sepharose 
chromatography step (Fig. 4). Without the highly charged CS chain, decorin core protein was 
this time recovered in the flow through fraction (1.3 mg protein; no detectable GAGs) while 
the GAGs and other proteoglycans resistant to enzymatic deglycanation eluted with 1.5 M 
NaCl (fraction F in Fig. 4; 6.2 mg protein; 3.2 mg GAGs). Only weak traces of decorin were 
identified in the 1.5 M NaCl fraction by Western blot analysis (data not shown). SDS-PAGE 
analysis of the flow through fraction showed at this stage a band with a molecular weight 
corresponding to that of decorin core protein as detected by Western blot analysis (Fig. 3a and 
b, lane 3).  
The flow through fraction from the second anion exchange column was concentrated 
to 3 ml using the stirred ultrafiltration cell and decorin was further purified by reversed phase 
HPLC (successive injections of 200 µL each corresponding to 60 µg total protein) (Fig. 5). 
Decorin core protein appeared as the single, most intense peak eluting at approximately 55% 
acetonitrile. SDS-PAGE analysis revealed a single band at the expected molecular weight 
(Fig. 3a, lane 4) that was positive upon Western blotting (Fig. 3b, lane 4). In order to quantify 
the amount of purified decorin core protein a calibration graph was prepared by HPLC using 
bovine decorin previously digested with Chondroitinase ABC and quantified using the BCA 
assay. The calibration was linear between 1 and 12.5 µg total injected amount 
(y = 5.1 × 105 + 6.6 × 105 (r2 = 0.992)) with detection at 214 nm. Overall 173 µg decorin core 
protein were purified from 25 g lung tissue (purification factor: approximately 1800-fold 

























based on the amount of initially extracted protein; see Table 1). The described purification has 




Fig. 5. Reversed phase chromatography of decorin preparation. From the 33-fold concentrated flow 
through collected after the second AEC step, 200 µL (60 µg total protein) were applied to a Vydac 
protein C4 column (250 mm × 2.1 mm, 0.25 ml/min, 214 nm). Decorin eluted as the most abundant 




Fig. 6. LC–MS/MS analysis of the SDS-PAGE band (see Fig. 3a, lane 4) after “in gel” tryptic 
digestion. The identified peptides are numbered and their corresponding sequence is presented in 
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3.3.2 Decorin analysis 
 
For positive identification of the protein, the gel band was excised and subjected to “in gel” 
digestion with trypsin followed by LC–MS/MS analysis (Fig. 6). Several peptides in the range 
of 623.6–1325.2 a.m.u. were sequenced by MS/MS. Acquired MS/MS spectra were 
introduced into a Mascot Sequence Query of the SwissProt (version 48.6) database, with the 
taxonomy restricted to Homo sapiens. The following search criteria were used: peptide mass 
tolerance of ±1.0 Da, carbamidomethyl (C) as fixed modification, and oxidation of 
methionine as variable modification. A match was considered significant when the score 
exceeded 70 (p < 0.005). All the peptides searched had a score higher than 70 and they were 
identified as belonging to human decorin (accession number P07585). No peptides 
corresponding to any other protein were found. The amino acid sequence of the identified 
decorin peptides and their position in the protein core is summarized in Table 2. The peptides 
were identified as belonging to human decorin (accession number P07585) according to 
SwissProt (version 48.6) database. The numbers in the left column correspond to the peptides 
from Fig. 6. 
 
Table 2. List of peptides identified by LC–MS/MS from “in gel” tryptic digested decorin after 
purification and SDS-PAGE analysis 
 
No. Peptide mass (a.m.u.) 
Peptide's posiotion 
in the protein core Peptide sequence Remark 
1 1165.4 93–102 (K)ITEIKDGDFK(N) Missed cleavage 
2 1248.6 106–116 (K)NLHALILVNNK(I)  
3 1115.6 120–130 (K)VSPGAFTPLVK(L)  
4 623.6 134–138 (R)LYLSK(N)  
5 1325.2 188–200 (K)SSGIENGAFQGMK(K)  
6 779.4 201–206 (K)KLSYIR(I) Missed cleavage 
7 703.4 236–242 (R)VDAASLK(G)  
8 982.4 273–280 (R)ELHLDNNK(L)  
9 696.2 346–350 (R)CVYVR(S) Carbamido-methylation 
 
MALDI spectra corresponding to approximately 95 pmol purified decorin core protein 
before and after PNGase F treatment are presented in Fig. 7a and b, respectively. Digestion of 
the purified decorin core protein with PNGase F ascertained that it was N-glycosylated as 




The collagen–elastin–proteoglycan matrix is the key component of lung parenchyma. 
Although collagen and elastin have been widely studied, little attention has been paid to the 
proteoglycan component. The exact composition and distribution of proteoglycans within 
lungs has not been fully established although the presence of proteoglycans from all four 
classes has been reported [35-37]. Immunohistochemical studies localized them mainly in the 
basement membrane, associated with collagen fibrils, in blood vessel walls and in the 
subepithelial layer of airways. With respect to the leucine-rich repeat PGs it has been shown 
by immunoblotting that lumican is most abundant, while biglycan, decorin and fibromodulin 
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are present in low amounts in adult human lungs [36]. Although it is not an abundant 
component of lung, decorin accomplishes important biological functions via interactions with 
other proteins including fibronectin, TGF-β, membrane receptors and some types of collagen 
[38]. 
In order to gain more information about proteoglycans from human lung tissue, we 
developed a purification method for decorin with the final goal of characterizing it at the 
primary structure level. We considered in our approach the complexity of the previously 
described purification protocols [27,34]. It is advantageous to reduce the number of steps in 
purification strategies, especially when applied to low abundance proteins in a particular 
tissue, in order to increase the overall purification yield. Therefore, the strategy we developed 
consists only of two-anion exchange and one reversed phase chromatography steps. Anion 
exchange chromatography (AEC) has been routinely used for isolating proteoglycans 
possessing few GAG chains and having thus a relatively low ratio of GAG to total protein (as 
for the small leucine-rich proteoglycans). These proteoglycans bind strongly to the AE resins 
due to the negative charges contributed by sulfate and carboxylate groups. Except HA, which 
is the only non-sulfated GAG, all other GAGs and PGs bind strongly to the first AE column 
and are recovered in a single fraction by step elution at high ionic strength. Enzymatic 
treatment of the proteoglycan pool with chondroitinase ABC selectively removes only GAGs 
belonging to the CS/DS class. Therefore, rechromatography of the digest on the AE column 
resulted in the enrichment of the protein cores from this particular class of proteoglycans in 




Fig. 7. MALDI-TOF mass spectra corresponding to the purified decorin core protein desalted and 
concentrated using C8 Stage tips. (a) Decorin core protein prior to and (b) after treatment with 
PNGase F. The two peaks with the molecular weights of 21,413 and 42,553 Da (a) and 17,292 and 
34,515 Da (b) correspond to doubly and singly charged ions from decorin core protein with or without 
N-linked oligosaccharides attached. 
 
Reversed phase chromatography has not been exploited for the purification of 
proteoglycans, while affinity chromatography using lectins was preferred as the last 
purification step [31]. The use of reversed phase chromatography has the advantage to 
provide resolution between decorin and other copurified proteins. It offers in this way the 
possibility to profile the proteoglycans from the CS/DS class and to gain more insight into the 
proteoglycan composition of lung tissue. This option of “proteoglycan profiling” will be 
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chromatogram obtained from the C4 column points to decorin as the most abundant CS/DS 
proteoglycan in normal lung tissue, while lumican, a KS proteoglycan, appeared as the most 
abundant leucine-reach repeat proteoglycan in an adult human lung extract [32], when 
analyzed by Western blot. 
Considerable progress has been made in glycobiology and important biological 
functions have been assigned to carbohydrates attached to proteins like the stabilization of 
protein structure, correct protein folding, cellular trafficking and protein–protein interactions. 
In several diseases like cancer [39] and inflammatory bowel disease [40] changes in 
glycosylation have been shown to be part of the disease mechanism, pointing once more to 
the importance of correct glycosylation. In another example, alterations in the N-glycans of 
α1-acid glycoprotein in chronic and acute inflammation were revealed by MALDI analysis 
[41]. These results strengthen our hypothesis that impaired decorin glycosylation may play a 
role in chronic inflammation during emphysema development and progression.  
Based on the described purification method we aim to investigate whether decorin 
suffers structural alterations during chronic pulmonary inflammation, which may lead to 
emphysema. In order to assess this it is necessary to compare decorin purified from healthy 
and diseased tissue, at the level of both the primary amino acid structure and the N-glycans. 
Therefore, using the purification method described here, we purified decorin protein cores 
with the attached N-linked glycans from two different locations of a control lung and the 
same two locations of an emphysematous lung. For all four batches of purified decorin we 
investigated the occupancy of glycosylation sites as well as the populations of N-linked 
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Glycosylation site occupancy in human lung decorin 
 
 
Mihaela Didraga, Begona Barroso, Marcel de Vries, Huib Kerstjens, Dirkje Postma, Wim 
Timens, and Rainer Bischoff 
 
Decorin is a small leucine-rich repeat proteoglycan, presenting three consensus sequences for 
the attachment of N-linked glycans on its protein core. We have previously shown that 
decorin may contribute to emphysema development, since it is immunohistochemically 
reduced in lung tissue of patients with severe emphysema. We purified decorin protein core 
with the attached N-linked oligosaccharides from two locations of a healthy human lung and 
similar locations of an emphysematous human lung. SDS-PAGE analysis of the four batches 
of purified decorin revealed a broad band in three of the preparations (both locations of the 
emphysematous lung and the lower lobe of the control lung) and a sharper band in the upper 
lobe of the control lung. MALDI-TOF-MS analysis of glycosylated decorin protein cores 
revealed that the broad band consists of two components of different molecular weights, the 
higher molecular weight component being more abundant and the only constituent of the 
sharp band. We set out to investigate whether the two decorin components differ in the degree 
of glycosylation of the same protein core. Therefore, using MALDI-TOF-MS and LC-
MS/MS, we studied the occupancy of all three potential glycosylation sites in each of the four 
decorin preparations. Tryptic decorin peptides, in combination with PNGase F treatment were 
used for this purpose. Our data suggest that all three glycosylation sites are variably occupied 
by N-Glycans in human lung decorin, but further experiments are needed in order to confirm 








Decorin is a ubiquitous component of the extracellular matrix of many tissues. It may 
contribute to development of COPD since we previously showed less decorin and biglycan 
staining in lung tissue of emphysema patients, and less decorin production by fibroblasts of 
emphysema patients compared with healthy controls [1-3]. Moreover, we showed that decorin 
production by fibroblasts was more strongly inhibited by TGF-beta [4]. The protein core of 
decorin is divided into several distinct structural domains, comprising: 1) a 16 amino acid 
signal sequence that targets the protein to the rough endoplasmic reticulum; 2) a 14 amino 
acid propeptide with an as yet undetermined function; 3) a glycosaminoglycan (GAG) 
acceptor region, containing a serine substituted with a chondroitin/dermatan sulfate (CS/DS) 
chain; 4) a hyper-variable cystein globular domain; 5) a leucine-rich repeat (LRR) domain 
composed of 12 regions containing towards the C-terminus three N-linked oligosaccharide 
attachment sites (Asn211, Asn262, and Asn303), and 6) a carboxy-terminal globular domain. The 
mature protein core is devoid of signal and propeptide domains. A schematic representation of 
decorin core protein domains is depicted in Fig. 1. LRR motifs with leucines in conserved 
positions are found in other proteoglycans like biglycan, fibromodulin and lumican. The 
highest structural homology exists between decorin and biglycan. Biglycan consists of a 
protein core of 368 amino acids [5], which, similar to decorin, may be post-translationally 
modified with CS/DS glycosaminoglycan chains (at Ser42 and Ser47), and N-linked 
oligosaccharides (at Asn270 and Asn311). Because of their high structural similarities, decorin 
and biglycan are usually studied together, and structural features revealed in one protein may 




Fig. 1. Schematic representation of different domains present on the decorin protein core. 
 
Several glycoforms of both decorin and biglycan have been isolated from tissues and 
cell extracts. Human recombinant glycoforms of decorin and biglycan were studied by 
transient eukaryotic expression using the vaccinia virus/T7 bacteriophage expression system 
in conjunction with a polyhistidine fusion vector [6,7]. This expression system is capable of 
the complex post-translational modifications of the two proteoglycans, including correct 
glycosylation and folding of the protein cores. Both decorin and biglycan are expressed as 
two forms: a proteoglycan form and a core protein devoid of the glycosaminoglycan chain(s). 
In addition, decorin core protein is differentially substituted with N-linked oligosaccharides 
with two or three sites being utilized. Quantitation of the recombinant decorin indicates that 
up to 30-40 mg of decorin / 109 cells were secreted per 24 h, about 75% as a proteoglycan 
form and the reminder as core glycoprotein [6]. 
Aberrant glycosaminoglycan substitution of decorin and biglycan has been found in 
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umbrella term of Ehlers-Danlos syndrome [8-10]. The abnormal GAG chain substitutions 
likely result from reduced endogenous xylosyltransferase activity [8,11]. It has been observed 
that non-proteoglycan forms of decorin and biglycan increase with age in human articular 
cartilage [12]. For biglycan the change in abundance of the non-proteoglycan form is also 
accompanied by a change in structure, as the young juvenile specimens exhibited a single 
non-proteoglycan protein core, whereas the adult also had an additional smaller component 
[13,14]. In contrast with biglycan, only one form of the protein core, differentially substituted 
with N-linked glycans, has been observed for decorin [6,13,15].  
N-linked glycosylation of proteins plays important roles in several physiological and 
biochemical processes including stability, solubility, biological activity, and in vivo clearance 
rate [16]. N-glycosylation of proteins occurs on the Asn-X-Ser/Thr sequence, the final 
oligosaccharide structure being both species- and tissue-specific. N-glycosylated proteins may 
exhibit both macroheterogeneity (variable occupancy of glycosylation sites) and 
microheterogeneity (variable degree of trimming and elongation of the glycan attached to one 
glycosylation site). It is estimated that 10-30% of glycosylation sites in glycoproteins remain 
unoccupied [17]. Hence each glycosylation site may exhibit variable occupancy, in that a site 
may be fully occupied, partially occupied or totally unoccupied [18]. In proteins with multiple 
glycosylation sites, glycosylation on one site may hinder occupancy and/or processing of 
glycosylation at the other glycosylation sites(s) [19]. In congenital disorders of glycosylation 
(CDG), deficiency in both macro- and micro-heterogeneity of transferrin is implicated in 
disease pathology and the degree of N-glycosylation site occupancy (incomplete occupancy) 
correlates with the severity of the disease [20]. In several other diseases like cancer [21], 
inflammatory bowel disease [22], or chronic and acute inflammation [23], alteration of N-
glycans has been reported. These findings underline the importance of investigating decorin 
N-glycosylation in chronic inflammation during emphysema development and progression 
[1,2]. 
For understanding carbohydrate-protein interactions at a molecular level it is thus 
indispensable not only to identify the structures of the carbohydrate moieties, but also to 
determine to which of the Asn-X-Ser/Thr sequons they are attached, i.e. which of the 
potential N-glycosylation sites are in fact used. Several recent reports [24-26] have 
established that mass spectrometric techniques such as matrix-assisted laser 
desorption/ionization-time of flight (MALDI-TOF) or electrospray ionization (ESI) mass 
spectrometry with or without preceding HPLC and in combination with PNGase F treatment 
are suited to analyze whether consensus sequences for N-glycosylation are glycosylated or 
not. 
We purified decorin protein core with the attached N-linked glycans, but devoid of the 
glycosaminoglycan chains from the upper and lower lobes of a healthy control human lung 
and two similar locations of an emphysematous lung. The purification was performed 
according to the method described in Chapter 3 [27]. Upon SDS-PAGE and Western blot 
analysis, the four batches of purified decorin could be divided into two subpopulations: a 
broad band form found in three of the preparations (both locations of the emphysematous lung 
and the lower lobe of the control lung) and a sharper band found only in the upper lobe of the 
control lung. MALDI-TOF-MS analysis of glycosylated decorin protein cores from all four 
batches revealed that the broad band consists of a higher molecular weight abundant 
component and a lower molecular weight less abundant one, and that the sharp band contains 
only the higher molecular weight component. Decorin protein core visible on SDS-PAGE as a 
broad band is the most common form reported in the literature [6,13,28] and it has been 
shown that enzymatic treatment with PNGase F further resolved this preparation into one 
sharp band of lower molecular weight, when analyzed by SDS-PAGE. These experiments 
suggest that decorin protein core could have two or three glycosylation sites occupied by N-
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glycans. In the present work, using MALDI-TOF-MS and LC-MS/MS, we investigated the 
occupancy of glycosylation sites in all four batches of purified decorin, with the goal of 
presenting a more detailed view regarding N-glycosylation site occupancy of human lung 
decorin. Our results indicate variable glycosylation site occupancy at all three glycosylation 
sites in human lung decorin. No emphysema related changes with respect to glycosylation 
sites occupancy were found. 
 




Decorin core protein was purified from human lung tissue using the chromatographic method 
described in Chapter 3 [27]. In the present study we investigated the occupancy of 
glycosylation sites of decorin protein core purified from two different areas (upper and lower 
lobes) of one healthy control and one emphysematous human lung. Human lung tissue was 
obtained from the Department of Pathology of the University Medical Center Groningen 
based on protocols approved by the medical ethics committee. The classification as normal or 
emphysematous lung tissue was made based on histological examination of tissue performed 
by a pulmonary pathologist (WT). The control lung presented only mild changes related to 
smoking, with limited airspace enlargement and some goblet cell hyperplasia in the airways. 
No major pathology was present.  
The enzymatic in-solution N-deglycosylation kit containing Peptide N-Glycosidase F 
(PNGase F) from Chryseobacterium (Flavobacterium) meningosepticum was purchased from 
Sigma-Aldrich Inc. (St. Louis, MO, USA). All common laboratory reagents were obtained 
from Merck (Darmstadt, Germany). SDS-PAGE and Western blot analysis, as well as the 
chondroitinase ABC digestion were performed as described in Chapter 3 [22]. The 
monoclonal antibody 6D6 directed against bovine decorin core protein was kindly provided 
by Prof. Dr. P.G. Scott (Department of Biochemistry, University of Alberta, Edmonton, 
Canada). The epitope recognized by this monoclonal antibody has been previously described 
[29,30]. This antibody cross-reacts with decorin from most mammalian species and 
consequently was used for following the purification of decorin from human lung tissue by 
immunoblotting. 
 
4.2.2 “In solution” tryptic digestion 
 
Approximately 20 µg purified decorin were reconstituted in 60 µL of 100 mM ammonium 
bicarbonate, reduced with 1,4-dithiothreitol (ratio 1:100, w/w) for 30 min at 56 °C and 
alkylated with iodoacetamide (ratio 1:200, w/w) for 30 min in the dark. The resulting decorin 
solution was brought to 250 µL with 100 mM ammonium bicarbonate and desalted using a 
1 ml PD-10 column. The sample was collected in 350 µL of 25 mM ammonium bicarbonate 
buffer, pH 7.5 and digested with trypsin (ratio 1:20, w/w) overnight, at 37 °C. Half of the 
sample was kept as such for MALDI-TOF-MS analysis and the other half was further 
subjected to PNGase F digestion. 
 
4.2.3 PNGase F digestion 
 
N-linked oligosaccharides attached to the intact decorin core protein or to tryptic decorin 
peptides were enzymatically removed using PNGase F. Following tryptic digestion of the 
protein core, 175 µL tryptic digest were incubated with 0.5 µL of PNGase F stock solution (5 
units/µL) overnight, at 37°C using an Eppendorf Thermomixer. In order to deglycosylate the 
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intact protein core, we used a procedure adapted from Barroso et al. [31], which was in brief: 
20 µg of decorin core protein reconstituted in 35 µL of 1 mg/ml N-octylglucoside, pH 7.5, 
were boiled at 100°C for 2 min, cooled at room temperature and further incubated with 0.5 µL 
of PNGase F stock solution for 48 h, at 37°C.  The PNGase F digests were subjected to 
MALDI-TOF-MS analysis in order to study the occupancy of the glycosylation sites.  
 
4.2.4 Matrix-Assisted Laser Desorption Ionisation-Time of Flight-Mass Spectrometry 
(MALDI-TOF-MS) 
 
MALDI-TOF-MS analysis was performed in the positive ionization mode using a Voyager 
DE Pro instrument (Applied Biosystems, Framingham, MA, USA). Peptide Mass Fingerprint 
(PMF) spectra were acquired in reflectron mode with delayed extraction. For the peptide 
preparations mono-isotopic molecular masses were measured using either a two point external 
calibration (singly charged BSA tryptic fragments with molecular masses of 927.49 Da and 
2045.03 Da) or a two point internal calibration (singly charged trypsin autodigestion peaks 
with molecular masses of 842.51 Da and 2211.10 Da). For the intact protein core preparations 
spectra were acquired in linear mode with delayed extraction using a two point external 
calibration with an intact BSA preparation (m/z of 66431 Da and 33216 Da for the singly and 
doubly charged ions, respectively).  α-Cyano-4-hydroxycinnamic acid (CHCA) and sinapinic 
acid (SA) were used for the analysis of peptides and intact decorin, respectively. 
Approximately 95 pmol intact decorin protein core (7 µL sample) were concentrated using C8 
Stage tips (Proxeon, Odense, DK), according to the manufacturer’s instructions. In the same 
way 5 µL of the decorin peptide preparation were treated using C18 Stage tips. Finally, the 
samples were eluted with 1 µL of a 5 mg/ml CHCA or 5 mg/ml SA in 50% ACN containing 
0.1% TFA and directly spotted on a stainless steel MALDI target. 
 
4.2.5 Liquid Chromatography - Mass Spectrometry (LC-MS) 
 
Tryptic decorin peptides before and after PNGase F treatment were also analyzed by LC-
MS/MS using a nanoLC-ESI-MS-MS system (Agilent, Waldbronn, Germany) and a Q-Star 
XL API mass spectrometer (Applied Biosystems, MDS Sciex, Framingham, USA). For both 
systems eluent A consisted of 0.1% formic acid (FA) in ultrapure water and eluent B from 
0.1% FA in acetonitrile. 
The nano-LC-MS system was equipped with a microfluidics (chip-cube) interface 
(cat. No. G4240A) including a chip (cat. No. G4240-62001) with a 40 nL trap column (75 µm 
x 11 mm) and a 75 µm x 43 mm analytical column both containing C-18SB-ZX 5 µm 
chromatographic material. The interface contains a nanoelectrospray tip (2 mm length with 
conical shape: 100 µm od x 8 µm id) and was coupled online to an MSD-Trap-SL IT mass 
spectrometer. The interface was connected to an Agilent 1100 series HPLC system containing 
the following modules: nanopump, capillary pump and solvent degasser. Two µL tryptic 
decorin digest were injected and washed in the back flush mode for 4 min (0.1% aq. FA, 2 
µL/min) and then the trapping column was switched inline with the analytical column. The 
flow rate was set to 0.3 µL/min. after elution for 6 min with eluant A, a linear gradient from 0 
to 50% eluent B at 0.5%/min followed by a gradient from 50 to 70% at 1%/min of eluent B 
was run. Eluent B (70%) was maintained for 10 min. after each injection the inline trap and 
the analytical column were equilibrated with eluent A for 20 min at 2 and 0.3 µL/min, 
respectively. The ESI source was operated in positive mode. MS data were acquired over a 
scan range of 50-1500 a.m.u. After the LC-MS/MS analyses were performed, from the 
resulted files we generated Mascot Generic Files (MGF) using the Voyager DE Pro software. 
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MGF files were submitted to the Mascot Sequence Query of the SwissProt/Trembl (version 
48.6) database, with the taxonomy restricted to Homo sapiens. The following search criteria 
were used: peptide mass tolerance of ± 1.0 Da, carbamidomethyl (C) as fixed modification 
and oxidation of methionine as variable modification. Results were retrieved as list of 
peptides (queries) matching the protein sequences from the database. 
The Q-Star mass spectrometer was equipped with a nano-LC sprayer and operated 
under Analyst QS 1.1 control. Injected samples (10 µL tryptic decorin digest) were first 
trapped and desalted isocratically on an LC-Packings C18 µ-Precolumn cartridge (300 µm i.d. 
x 1 mm, PepMap C18, 5 µm, Dionex, Sunnyvale, CA, USA) for 5 min with 0.1% FA 
delivered by the auxiliary pump at 10 µL/min after which the peptides were eluted from the 
trap column and separated on an analytical C18 capillary column (75 µm i.d. x 15 cm, 
PepMap C18, 3 µm, 100 Å, Dionex, Sunnyvale, CA, USA) connected in-line to the mass 
spectrometer, at 200 nL/min using an increasing gradient of eluent B (2-50% in 50 min). The 
mass spectrometer was operated in information-dependent acquisition (IDA) mode. In MS 
mode, ions were screened from m/z 300 to 2500. In IDA mode, the three most intense peaks 
were selected and MS/MS spectra acquired when their intensities exceeded 50 counts. The 




4.3.1 SDS-PAGE and Western blot analysis 
 
Decorin core protein was purified from the upper and lower lobes of a healthy control human 
lung and two similar locations of an emphysematous lung, based on the purification method 
described in Chapter 3 [22]. Final purification yields of the four batches of human lung 
decorin were as follows: 173 µg for the upper control lobe; 290 µg for the lower control lobe; 
450 µg for the upper emphysematous lobe; 350 µg for the lower emphysematous lobe. In all 
cases 25 g lung tissue were used as starting material for purifying decorin. In order to quantify 
the amount of purified decorin we used the same calibration graph described in Chapter 3. 
The calibration graph was prepared by HPLC using bovine decorin previously digested with 




Fig. 2. SDS-PAGE (a) and the corresponding Western blot (b) analysis of decorin core protein 
purified according to [22]. Lane 1: decorin prepared from control upper lobe; lane 3: decorin prepared 
from control lower lobe; lane 5: decorin prepared from emphysematous lower lobe; lane 6: decorin 
prepared from emphysematous upper lobe; lane 2, 4, 7: prestained molecular weight marker. Gels 
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The four batches of purified decorin core protein with the attached N-linked glycans, 
but devoid of the glycosaminoglycan chain, were subjected to SDS-PAGE analysis under 
reducing conditions. The electrophoretic system and the working solutions/conditions were 
described in Chapter 3. Fig. 2a) presents the SDS-PAGE analysis of all four batches of human 
lung decorin. These bands were recognized by the 6D6 anti-decorin antibody upon Western 
blotting (Fig 2 b). Three of the preparations (obtained from both upper and lower lobe of the 
emphysematous lung and the lower lobe of the control lung) presented a broad band with a 
molecular weight of slightly less than 50 kDa. This molecular weight is consistent with 
literature data and corresponds to the N-glycosylated decorin core protein [6,13,28,32]. 
However, in the forth preparation obtained from the upper control lobe (Fig. 2a, lane 1) a 
sharper band was observed, overlapping with the upper part of the band observed for the other 
three preparations. The degree of purity obtained for decorin core protein preparations 
differed from batch to batch, as could be seen especially by Western blot analysis (Fig 2b). 
While in the upper control lobe preparation only the band corresponding to decorin core 
protein was visible in both SDS-PAGE and Western blot analysis (Fig. 2a-b, lane 1), in the 
other three preparations additional bands were observed. These bands were recognized by the 
6D6 antibody indicating that they are decorin-related. Bands situated at a molecular weight 
higher than the major decorin protein core band are most probably derived from the 
proteoglycan form of decorin (due to incomplete Chondroitinase ABC digestion). Bands 
situated lower than the major decorin protein core band may be degradation products of 
decorin.  
 
4.3.2 MALDI-TOF-MS analysis of the intact protein cores with and without N-glycans  
 
In order to investigate the differences between the two decorin glycoforms (broad versus 
sharp band) observed by SDS-PAGE and Western blot analysis, we first acquired MALDI-
TOF-MS spectra of the purified decorin protein cores with the N-glycans attached. To 
examine whether these differences are due to differential N-glycosylation of the same protein 
core, decorin was treated with PNGase F and again analyzed by mass spectrometry. 
Fig. 3 and Fig. 4 present the spectra acquired from the control and emphysematous 
lung, respectively. Spectrum corresponding to decorin protein core purified from the upper 
control lobe prior to PNGase F digestion (Fig. 3a) displayed a main peak at m/z 42553 Da and 
its corresponding doubly charged ion at m/z 21413 Da. After treatment with PNGaseF, the 
main peak at 42553 Da was reduced to a sharper peak at m/z 34515 Da (Fig. 3b). The 
spectrum corresponding to the decorin protein core purified from the lower control lobe prior 
to PNGase F digestion (Fig. 3c) displayed a main peak at m/z 42696 Da and a minor peak at 
m/z 38852 Da. The peak at m/z 21564 Da is the doubly charged ion corresponding to the peak 
at m/z 42696 Da. After treatment with PNGaseF, this decorin preparation displayed two 
peaks, at m/z 37102 Da and 34683 Da.  
Decorin protein core purified from both locations of the emphysematous lung behaved 
similarly to decorin purified from the lower control lobe. Thus, a major peak at m/z 42472 
(and its corresponding doubly charged ion at m/z 21241) and a minor peak at m/z 40200 were 
visible in the spectra acquired from decorin purified from the upper emphysematous lobe 
(Fig. 4a), prior to PNGase F digestion. Following enzymatic treatment, the corresponding 
spectrum displayed two peaks, at m/z 37072 and m/z 34723 (Fig. 4b). Similarly, the spectrum 
acquired from decorin purified from the lower emphysematous lobe before treatment with 
PNGase F displayed a main peak at m/z 42460 (and its corresponding doubly charged ion at 
m/z 21176) and a minor peak at m/z 40323 (Fig. 4c). After treatment with PNGase F two 






Fig. 3. MALDI-TOF mass spectra corresponding to the purified decorin core protein concentrated 
using C8 Stage tips. (a) Decorin core protein from upper control lobe prior (lane 1 in Fig. 2) and (b) 
after treatment with PNGase F; (c) decorin core protein from lower control lobe prior (lane 3 in Fig. 2) 
and (d) after treatment with PNGase F. 
 
Summing-up the results from Fig. 3 and Fig. 4, three of the decorin preparations 
presented a minor peak at m/z approximately 40200 and m/z 38850 in the spectra acquired 
prior to PNGase F treatment from the two emphysematous samples and the lower control 
sample, respectively. This peak was not present in the spectrum acquired from the upper 
control lobe sample. The preparations presenting the peak in their corresponding MALDI 
spectra showed broad bands upon SDS-PAGE analysis (Fig. 2a, lanes: 3, 5, 6), in contrast 
with the sharper band (Fig. 2a, lane 1) corresponding to the upper control lobe. It is thus likely 
that the appearance of broad bands is indicative of a mixture of two forms of decorin (major 
and minor, with the major component being of higher molecular weight). In particular, 
MALDI analyses indicate a small mass difference between the minor form of decorin from 
the lower control lobe (m/z 38850) when compared with the two emphysematous lung 
samples (m/z approximately 40200). 
Following PNGase F treatment, a peak of lower molecular weight is observed in all 
four preparations at m/z approximately 34700. An additional peak with m/z approximately 
37000 Da is present in the three preparations corresponding to the samples displaying the 
broad band on SDS-PAGE. The presence of the two peaks with a mass difference of 2300 Da 
in three of the preparations it is a puzzling result, as we expected that treatment with PNGase 
F will reduce both decorin forms to a single one, corresponding to the deglycosylated core 
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protein. The expected molecular weight of decorin when calculated based on its sequence is 
36326 Da. The 2300 Da difference does not correspond to the mass variation between the 
reported decorin protein core isoforms (see Table 3). Possible explanations for the presence of 
the peak at m/z approximately 3700 could be incomplete PNGase F digestion or proteolytic 
cleavage of decorin core protein. In order to confirm this observation, repetitions of the 
PNGase F digestions were performed for the three decorin preparations (lower control lobe, 
upper and lower emphysematous lobes) resulting in the same two peaks (at m/z 34700 and 
m/z 37000 Da) as before. Experiments with increased digestion time and/or an increased 
amount of PNGase F did not alter the results. However, despite the uncertainties related to the 
presence of the two peaks in the spectra acquired after PNGase F treatment, it is worth 
underlining the similarity between the MALDI spectra corresponding to the preparations 
derived from the broad band decorin form, before and after PNGase F treatment. This 
suggests that these forms are not due to an artefact of the purification process or an accidental 




Fig. 4. MALDI-TOF mass spectra corresponding to the purified decorin core protein concentrated 
using C8 Stage tips. (a) Decorin core protein from upper emphysematous lobe prior (lane 6 in Fig. 2) 
and (b) after treatment with PNGase F; (c) decorin core protein from lower emphysematous lobe prior 
(lane 5 in Fig. 2) and (d) after treatment with PNGase F. 
 
An aliquot of decorin purified from the upper emphysematous lobe and treated with 
PNGase F was analyzed by SDS-PAGE (Fig. 5). Several bands in the range of 37-25 kDa 
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antibody upon Western blotting (data not shown). This analysis suggests that decorin protein 




Fig. 5. SDS-PAGE analysis of purified decorin core protein from the upper emphysematous lobe. 
Lane 1: intact protein core; lane 2: decorin core protein digested with PNGase F; lane 3: prestained 
molecular weight marker.  
 




In order to investigate which asparagines on the four different preparations of purified decorin 
protein core were occupied by N-glycans, reduction and alkylation of the disulfide bridges 
was carried out, followed by proteolytic cleavage of decorin into glycopeptides carrying each 




Fig. 6. Schematic representation of decorin core protein showing the localization of the three tryptic 
peptides (amino acid 207-232 (1), amino acid 250-272 (2), and amino acid 293-320 (3)) containing 
predicted N-linked glycosylation sites. 
 
Peptides derived after digestion with trypsin and with or without subsequent digestion 
with PNGase F were subjected to MALDI analysis. PNGase F cleaves asparagine N-linked 
oligosaccharides at the β-aspartylglycosylamine linkage, converting asparagine (N) into 
aspartic acid (D) thus increasing the mass of the remaining peptide by 1 Da. Conversion of 
asparagine into aspartic acid would therefore indicate that the sites were occupied by N-
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indicate that the N-glycosylation site was not occupied. The absence of the molecular ion 
corresponding to the peptide containing either N or D would indicate that glycan is still 
attached to the corresponding site due to incomplete PNGase F digestion. The expected N-




Fig. 7. Mass spectra (a), (b), and (c) represent the signals corresponding to the protonated tryptic 
decorin peptides (1), (2), and (3), respectively, after PNGase F treatment confirming conversion of 
asparagine (N) into aspartic acid (D). Peptides were prepared from decorin purified from the upper 
control lobe.  
 
Fig. 7a-c shows the MALDI spectra of the three tryptic decorin peptides treated with 
PNGase F, prepared from decorin purified from the upper control lobe. The corresponding 
sequences with the glycosylated asparagine residues highlighted are also shown. The 
molecular weights for all three investigated peptides showed that the asparagines were 
converted into aspartic acids, confirming that these sites were occupied by N-glycans prior to 
PNGase F treatment. Correspondingly, the MALDI spectra acquired from a decorin 
preparation digested only with trypsin showed no signals at these m/z values (data not 
shown). Similar MALDI spectra were obtained for decorin peptides prepared from the upper 
and lower emphysematous lobes, showing no signal at the expected m/z values prior to 
PNGase F treatment, while the conversion of asparagines to aspartic acids was observed for 
all three investigated peptides after PNGase F treatment (data not shown). However, for the 
peptides prepared from the lower control lobe, the results were different. For two peptides 
(m/z 2744.44 and m/z 2383.20) no signals were observed in the sample digested only with 
trypsin, but after further digestion with PNGase F the corresponding peptides incorporating 
aspartic acid were present. For the third peptide (m/z 3159.5), signals were observed in the 
sample treated only with trypsin (corresponding to the peptide containing an asparagine 
residue) as well as in the sample treated with both trypsin and PNGase F (corresponding to 
the peptide containing an aspartic acid residue). The corresponding spectra are shown in Fig. 
8 a-b. These results suggest that the glycosylation site at Asn303 is partially occupied by N-
glycans. The results show that all three glycosylation sites in decorin purified from two 














































glycans while decorin that was purified from the lower lobe of the healthy control lung had 
two glycosylation sites fully occupied and one site (at Asn303) only partially occupied. While 
the functional significance of this difference is unclear, our results indicate that there are 




Fig. 8. Mass spectra represent the signals corresponding to one protonated tryptic decorin peptide (3) 
before (a) and after (b) PNGase F treatment. Before PNGase F treatment the peptide containing 
asparagine (N) is observed, corresponding to the non-glycosylated peptide. After PNGase F treatment 
the peptide containing aspartic acid (D) is observed, which is derived from the originally glycosylated 




Tryptic decorin peptides derived from all four locations were subjected to nanoLC-MS/MS 
analysis before and after PNGase F treatment using a microfluidics-based chipLC system. 
Decorin precursor (accession number NBHUC8 in SwissProt/Trembl (version 48.6)) was 
unambiguously identified as the first hit in both cases (see Tables 1 and 2) and PNGase F 
(accession number PNFMGF in SwissProt/Trembl (version 48.6)) was the second hit in case 
of PNGase F digestion. For decorin derived from three lung locations (upper control lobe, 
upper and lower emphysematous lobes) the expected glycopeptides were not detected in the 
samples treated only with trypsin due to their high molecular weight, which exceeded the m/z 
range of the ion trap mass spectrometer but their non-glycosylated counterparts were detected 
in the samples treated with trypsin and PNGase F for peptides with calculated masses of 
2382.23 Da or 2743.44 Da, which were present as triply charged ions. The third peptide 
containing Asn303 with a theoretical mass of 3158.53 Da was not detected in any of the 
samples. Possible explanations could be lower ionization efficiency for this peptide or strong 
binding to the chromatographic resin which prevented the elution of the peptide from the 
HPLC column. Table 1a-b lists the identified peptides retrieved from the Mascot search for 
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decorin purified from the upper control lobe before (a) and after (b) PNGase F treatment. 
Peptides incorporating glycosylation sites are enclosed in a black frame in section b). These 
results suggest that the corresponding glycosylation sites exist only in their glycosylated form 
in these locations. However, in the forth decorin preparation (lower lobe, healthy control 
lung) the glycosylation site at Asn262 (2383.2 Da) was present in its occupied and non-




Table 1. List of identified peptides retrieved from a Mascot search of MS/MS data for decorin purified 
from the upper control lobe, after trypsin digestion (a) and after combined treatment with trypsin and 
PNGase F (b). The black rectangle encloses the peptides containing predicted glycosylation sites. The 
results shown in Table 1 are also illustrative for decorin isolated from the upper and lower 
emphysematous lobes. 
 
In order to gain further insight into the peptide containing Asn303 from decorin 
purified from the lower lobe of the control lung, the tryptic peptide mixtures obtained before 
and after PNGase F treatment were analyzed by nanoLC-MS/MS on quadrupole-time-of-
flight mass spectrometer (Q-Star XL). This analysis showed that two glycosylation sites 
(tryptic peptide 207-232 and 293-320) are partially occupied. Fig. 9 shows the MS/MS 
spectrum of the peptide with molecular weight (MW) 2744.45 Da containing Asn210. 
In summary, the combined results from MALDI-TOF and LC-MS/MS indicate that in 





glycosylated. Our results provide evidence that variable glycosylation sites occupancy occurs 




Table 2. List of identified peptides retrieved from a Mascot search of MS/MS data for decorin purified 
from the lower control lobe, after trypsin treatment (a) and after combined treatment with trypsin and 




Decorin and biglycan share considerable structural similarity. Their protein cores are subject 
to a number of post-translation modifications. Various isoforms of the two proteoglycans 
have been reported in the literature, differing in the number of glycosaminoglycan (GAG) 
chains [33,34], their length and degree of substitution with iduronic acid [14], as well as in the 
size of the protein cores [14] or in the number of sites substituted with N-glycans [15,35]. 
Both decorin and biglycan exist also as non-proteoglycan forms, lacking the GAG chains 
[6,7,13]. These forms become more abundant with increasing age [13]. It is likely that many 
of the observed modifications have functional consequences, for example, in relation to lung 









Fig. 9. MS/MS spectrum of the peptide fragment with m/z 915.8 
(IADTNITSIPQGLPPSLTELHLDGNK, triply charged), acquired from decorin purified from the 
lower control lobe treated with trypsin and PNGase F. 
 
The protein core of decorin has three asparagines which can be substituted with N-
linked oligosaccharides (see Fig. 6), two of which (Asn262, and Asn303) are conserved in 
biglycan [36]. Variable degrees of N-linked oligosaccharide substitution have been reported 
for decorin, with two or three sites utilized [15,35] but detailed investigations to establish 
which site is occupied or not were not performed so far, especially for decorin obtained from 
natural sources. 
Using the vaccinia virus/T7 bacteriophage expression system, Ramamurthy et al found 
two classes of recombinant decorin expressed in HT-1080 cells: a proteoglycan form and a 
protein core form [6]. After chondroitinase ABC treatment, the proteoglycan form was 
converted to the protein core form, which was shown to consist of two components (~49 kDa 
and ~53 kDa). PNGase F treatment resolved this macroheterogeneity into a single band of 43 
kDa, when analyzed by SDS-PAGE. Similar forms, consisting of a doublet of bands, have 
been observed when decorin was isolated from other mammalian tissues [6,13,28]. The 
obvious conclusion emerging from these experiments is that the two forms of decorin protein 
core differ in the extent of N-linked oligosaccharide substitution, likely due to incomplete 
glycosylation at the three predicted N-glycosylation sites. Based on these earlier findings, we 
studied the occupancy of the glycosylation sites in decorin purified from different regions of 
one healthy and one emphysematous human lung, since we have earlier shown that 
diminished immunohistochemical staining of decorin is present in lung tissue from patients 
with severe emphysema [1]. Moreover, decorin production by lung fibroblasts of patients with 
severe emphysema is dysregulated after modulation with cytokines known to be important in 
smoking associated inflammation [2]. Our strategy for decorin purification was based on the 
capacity of the highly negatively charged GAG chain to bind strongly to an anion exchange 
resin [6] combined with chondroitinase ABC treatment and a final step of reversed-phase 
 +TOF Product (915.8): Experiment 2, 36.445 min from DCN_TRYP_PNG_C.wiff
a=3.56962086602432850e-004, t0=-3.49800754578968240e+001 R;
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HPLC [22]. Therefore, the batches of purified decorin contained only the N-glycosylated 
protein cores. 
Three out of four decorin batches that were purified displayed on SDS-PAGE a broad 
band consisting of the expected two components while the fourth one (upper lobe of the 
control lung) showed only the upper one of the two components. The upper component of the 
broad band was more abundant than the lower one in all preparations.  
After treatment with PNGase F, the decorin form purified from the upper control lobe, 
having a molecular weight of 42,553 Da, was resolved into a lower molecular weight form of 
34,515 Da (Fig. 3a-b). The mass difference between the two forms (before and after PNGase 
F treatment) is approximately 8 kDa and corresponds to the reported electrophoretic shift 
upon SDS-PAGE analysis. The MALDI-TOF-MS spectra of the other three decorin 
preparations appearing as broad SDS-PAGE bands displayed two peaks in the MALDI 
spectra acquired after digestion with PNGase F. As the peaks with approximately 42,500 Da 
and 34,500 Da were assigned to the higher molecular weight decorin component before and 
after PNGase F treatment, respectively, it is logical to assume that the peaks with 
approximately 38,800 Da (40,200 Da for samples derived from emphysematous tissue) and 
37,000Da correspond to the lower molecular weight decorin component before and after 
PNGase F, respectively. Considering earlier literature reports regarding the conversion of 
decorin protein core forms to a single band after PNGase F treatment, we expected to observe 
the same behaviour for all four preparations, namely the conversion to a form with molecular 
weight of 34,500 Da after PNGase F treatment. Further analyses are needed to interpret the 
presence of the peaks at 37,000 Da. Similar results were obtained with increased amounts of 
PNGase F and digestion time. One possible explanation could be that the lower molecular 
weight form of decorin core protein undergoes proteolytic cleavage during digestion with 
PNGase F, as the denaturing SDS-PAGE analysis of the PNGase F digest revealed multiple 
decorin peptides (Fig. 5). Intriguingly, these peptides were not visible by MALDI-TOF-MS 
analysis. This observation could be related to potential aggregation of the corresponding 
peptides triggered by decorin-decorin interactions promoted after removal of N-linked 
glycans from the protein core. It has been previously shown that removal of decorin N-linked 
glycans promotes self aggregation of the protein core [37] and that decorin is a dimmer in 
solution [38]. Despite these experiments, we cannot exclude the possibility of incomplete 
PNGase F digestion. One possible way to elucidate the question related to incomplete 
PNGase F digestion is to further digest the deglycosylated protein cores with trypsin and to 
subject them to MALDI-TOF analysis for investigating the occupancy of glycosylation sites. 
The presence of glycans still attached to the corresponding peptides would indicate 
incomplete PNGase F digestion. 
Another possible explanation of the above discussed results may be the existence of 
two forms of decorin protein cores, which we cannot totally exclude. Smaller protein cores 
may exist as a result of proteolytic degradation or alternative splicing. Both biglycan and 
decorin genes are composed of eight distinct exons, and the latter has two alternatively 
spliced leader exons (1a and 1b) that encode a 5' untranslated region [39]. A high degree of 
conservation suggests a regulatory function for these exons, but the function is not known. 
Isoforms of biglycan, having a smaller core protein, have been reported in articular cartilage 
[13] as well as in human lung fibroblasts [14]. Truncated forms of decorin, missing the 
carboxyl-terminal portion were identified in skin [40] and umbilical cord blood vessels [41]. 
Splice variants of decorin have been identified at the mRNA level, which translate into at 
least five distinct isoforms (accession numbers in the Swiss-Prot/TrEMBL database: P07585 
(isoform A); P07585-2 (isoform B); P07585-3 (isoform C); P07585-4 (isoform D); P07585-5 
(isoform E)). The length of the processed precursors (devoid of signal (amino acid 1-16) and 
propeptide (amino acid 17-30) domains) together with the expected molecular weights 
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corresponding to all five isoforms are presented in Table 3. The alignment of these isoforms is 
presented in Fig. 10. However, none of these isoforms matches the mass difference observed 
in our MALDI spectra. 
 
Table 3. Distinct isoforms of decorin. The length of the processed precursors (devoid of signal (amino 
acid 1-16) and propeptide (amino acid 17-30) domains) together with the expected average molecular 
weights are given for each individual isoform from the Swiss-Prot/TrEMBL database. 
 
Protein accession number 
 






P07585 329 aa 36326.65 Da 
P07585-2 220 aa 23932.84 Da 
P07585-3 182 aa 19857.19 Da 
P07585-4 142 aa 15822.64 Da 





Fig. 10. Alignment of decorin isoforms performed with the Clustal W XXL alignment tool available 
via Swiss-Prot/TrEMBL database. Unprocessed precursors (including signal and propeptide domains) 
are aligned. The dashed lines annotate missing amino acids in the corresponding isoforms, as 





Despite the uncertainties related to the presence of the peaks at 37,000 Da, it is worth 
underlining the similarity between the MALDI spectra corresponding to the preparations 
derived from the broad band decorin form, before and after PNGase F treatment. This 
suggests that these forms are not due to an artefact of the purification process or an accidental 
external contamination. MALDI spectra acquired from the intact protein cores evidenced also 
some subtle differences regarding the molecular weight of the low intensity peak (38,800 Da 
versus 40,200 Da) from the lower control lobe when compared with the forms derived from 
the emphysematous lobes. Further investigations need to be performed in order to establish 
the basis of these structural differences.  
We did not find any evidence to support the existence of two protein cores. Based on 
the similarity between the broad band decorin preparation we purified and the forms 
described so far in the literature, for which there has only been one form of the protein core 
reported, we favour the hypothesis that our preparations consist also of a single form of the 
protein core that is differentially substituted with N-linked glycans.  
Different molecules of the same protein could differ with respect to the number of 
sites occupied by N-glycans [16,18,42], hence each site may be fully occupied, partially 
occupied or totally unoccupied [18]. This variation in occupancy of glycosylation sites is 
referred to as macroheterogeneity or variable site occupancy and is a function of site 
availability, enzyme kinetics, and substrate concentration in the endoplasmic reticulum. 
Another variation associated with N-linked glycosylation is microheterogeneity, in which the 
structure of the oligosaccharide attached to each glycosylation site may vary between a 
complex type to a high-mannose type [42]. In proteins with multiple glycosylation sites, 
glycosylation on one site may hinder occupancy and/or processing of glycosylation at the 
other glycosylation sites(s) [19]. In particular, folding of the protein involving the formation 
of disulfide bridges hinder glycosylation [43]. 
A prerequisite for the occurrence of N-glycosylation is that asparagine (N) is in a 
consensus sequence (NXS/T), where X represents any amino acid except proline. Although 
this consensus sequence occurs frequently in proteins, it does not necessarily indicate the 
actual presence of an N-glycosydic linkage, most probably due to conformational factors [44]. 
In human decorin, the consensus sequence occurs at three different positions, located on the 
following three tryptic decorin peptides: 207–232 (2743.44 Da), 250–272 (2382.23 Da), and 
293–320 (3158.53 Da), respectively (see Fig. 6). PNGase F cleaves asparagine N-linked 
oligosaccharides at the β-aspartylglycosylamine bond, converting asparagine into aspartic 
acid and producing a +1 Da shift in molecular mass, which can be resolved by MALDI-TOF 
mass spectrometry [25,45]. MALDI-TOF-MS analysis of proteolytic peptides from 
glycoproteins, carried out with and without PNGase F deglycosylation represents an efficient 
approach to identify utilized N-glycosylation sites [25,45]. In order to establish which 
asparagines are occupied by N-glycans, we compared peptides derived from decorin after 
digestion with trypsin and after combined digestion with trypsin and PNGase F. The presence 
of asparagine in a tryptic decorin peptide digested with PNGase F indicates that the 
corresponding glycosylation site was not occupied by N-glycans prior to PNGase F treatment, 
while the presence of aspartic acid indicates that the site was glycosylated. The absence of a 
signal at the expected m/z values in the spectra from the samples treated with both trypsin and 
PNGase F would indicate that the glycan was still attached to the corresponding site, and that 
PNGase F digestion was incomplete. In the case of a partially occupied site, both peptides 
with no mass change (incorporating asparagine) and peptides with a mass increase of 1 Da 
(incorporating aspartic acid) are observed [46]. Based on this principle we examined all 
possible decorin glycosylation sites in the fourth batches of purified decorin. 
Since the two components of decorin (major and minor) were not very well separated 
by SDS-PAGE (see Fig. 2), they were not analyzed individually. It was thus not possible to 
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specify which glycosylation site was occupied in which of the two forms. However, the 
assumption emerging from the literature showing that PNGase F treatment resolved both 
decorin components to a single band, was that the upper decorin component had all three 
glycosylation sites fully occupied, while in the lower one only two out of the three sites were 
occupied. This means that two sites existed only as occupied in both lower and upper 
components, since the third site was non-occupied in the lower component and occupied in 
the upper one. Therefore, if we take into account this particular situation, after treatment with 
trypsin of the broad band preparations, one should be able to observe only the signal 
corresponding to the one peptide incorporating asparagine (derived from the non-occupied 
site in the lower component), while the peptides incorporating the other glycosylation sites 
would have the glycans still attached. After further treatment with PNGaseF, the two sites 
existing only as occupied in both decorin forms would display the signal corresponding to the 
peptides incorporating aspartic acid, while for the third site, the peptide derived from the 
higher molecular weight component would have incorporated aspartic acid and the one 
derived from the lower molecular weight component, asparagine. Therefore, even when 
analyzing the two bands together, in the described situation, it should be possible to determine 
which glycosylation site was non-occupied in the lower band. Unfortunately, our MALDI 
data were not consistent for all three decorin preparations containing the doublet of bands. 
Despite detecting one non-occupied site in the sample from the lower control lobe, in the 
samples from emphysematous tissue the corresponding signals were not detected. 
We obtained more detailed information from the LC-MS/MS as compared to MALDI 
data with respect to the number of non-occupied glycosylation sites. These differences may be 
due to the fact that only a small amount of DCN molecules possess non-occupied 
glycosylation sites, and these are revealed rather by LC-MS, which is a more sensitive 
technique as compare to MALDI. 
The combined results from MALDI-TOF and LC-MS/MS indicate that all three 
glycosylation sites were variably occupied (occupied and non-occupied) in decorin purified 
from the lower control lobe. Although we were not able to show the same heterogeneity in 
glycosylation site occupancy for decorin purified from the other three locations, this does not 
necessary mean that this heterogeneity does not exist. More experiments need to be performed 
in order to confirm our hypothesis that all glycosylation sites in human lung decorin are 
variably occupied by N-glycans. For biglycan it has been shown that only one N-linked 
glycans is attached to one protein core molecule [47]. This suggests that only one of the two 
glycosylation sites is occupied at any given moment, indicating that variable occupancy of 
glycosylation sites occurs for biglycan. These two glycosylation sites of biglycan are 
conserved in decorin (Asn262, and Asn303). This observation, taken together with the high 
structural similarity between decorin and biglycan, supports our findings with regard to 
variable glycosylation site occupancy in human lung decorin. 
Our experiments emphasize that occupancy of glycosylation sites in human lung 
decorin is a very complex process, which extends beyond the differential substitution with N-
glycans (with two and three sites fully occupied) of the same protein core. This is further 
complicated by the variable occupancy of the glycosylation sites. It is possible that the two 
decorin glycoforms, with two and three glycosylation sites fully occupied, are the most 
abundant forms, but other glycoforms, with variable degree of N-glycan substitution exist as 
well, even in a lower abundance. Therefore, investigating the occupancy of glycosylation sites 
using a quantitative method will be helpful in elucidating this complex mechanism. In this 
direction the recently developed methods [20,46], specially designed for the study of variable 
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The protein core of decorin, a small leucine-rich repeat proteoglycan, presents three 
consensus sequences for the attachment of N-linked glycans in its C-terminal region. We 
previously established a reduced presence of decorin in peribronchiolar tissue in emphysema. 
In order to investigate decorin glycosylation in relation to emphysema, we purified decorin 
protein core with the attached N-linked oligosaccharides from two different locations of a 
healthy human lung and from comparable locations of an emphysematous human lung. 
Following enzymatic digestion with PNGaseF, glycans were isolated after ethanol 
precipitation of the protein cores. The molecular masses of the sodiated adducts of glycans 
were obtained using Matrix-Assisted Laser Desorption Ionization-Time Of Flight-Mass 
Spectrometry (MALDI-TOF-MS). Structural information about representative members of 
the glycans was obtained by MALDI-TOF-MS with Post-Source Decay (PSD) fragmentation. 
The N-linked glycans attached to human lung decorin are of the complex type, being bi- or 
tri- antennary. We did not find structural differences between the N-glycans attached to 
decorin in the emphysematous and the control lung, nor between glycans from different areas 




5.1 Introduction  
 
Decorin is the archetypal and best characterized member of the small leucine-rich repeat 
(LRR) proteoglycan family. The structural hallmarks of this class of proteins are the internal 
tandem repeats (rich in leucine and other small hydrophobic residues) and two very well 
conserved cysteine clusters, flanking the LRR domains and forming disulfide bonds. Both N-
terminal and C-terminal cysteine capping motives are exclusive to eukaryotic proteins and 
play important roles in the stability of the LRR domains [1], which are involved in protein-
protein interactions [2,3]. Other members of the LRR proteoglycans include biglycan, 
fibromodulin and lumican, decorin sharing the highest degree of structural similarity with 
biglycan. Serine 4 of the mature decorin molecule is modified with a chondroitin/dermatan 
sulfate glycosaminoglycan (GAG) chain. Additionally, the protein core of decorin displays 
branched oligosaccharides attached at three N-glycosylation sites [4-6], which contain an 
asparagine (N) residue in the consensus sequence NXS/T. The attached oligosaccharides are 
all positioned towards the C-terminus to form a glycan-rich surface which is presumably not 
involved in protein-protein interactions. Although the function of decorin N-glycans is not 
fully elucidated, it has been established that they maintain the protein core in a non-
aggregated state [7], which ensures proper biological functionality. 
The alteration of glycoforms of different proteins in disease has been shown in several 
pathological conditions such as: inflammation [8], rheumatoid arthritis [9], cancer [10], 
inflammatory bowel disease [11], and diabetes mellitus [12]. Investigation of structural 
differences between glycans in the normal and diseased state is essential for elucidating their 
possible involvement in disease pathology. Although several recombinant glycoforms of 
decorin and biglycan have been characterized [13,14], there is little information available in 
the literature with respect to the structure and composition of the N-glycans attached to 
decorin. Scott and Dodd determined the elemental composition of the asparagine-linked 
glycans attached to decorin purified from bovine skin [5]. Shinkai et al [15] reported that 
biglycan purified from newborn-calf skin displays both neutral and acidic N-glycans of 
complex type attached to the protein core. Both studies were undertaken before the emergence 
of mass spectrometry (MS) as an important tool in structural characterization of 
glycoconjugates. Today, matrix-assisted laser desorption ionization time-of-flight (MALDI-
TOF) and electrospray ionization (ESI) mass spectrometry [16], are the most efficient 
strategies applied for structural investigation of protein-bound oligosaccharides. However, by 
using MALDI-TOF-MS alone it is difficult to discriminate unambiguously between 
oligosaccharide chains, due to the existence of several structural isomers with the same 
molecular mass but different branching patterns and linkage positions [17]. Important 
structural information can be obtained using MALDI post-source decay (PSD) fragmentation 
[18-20], which allows generation of structurally informative fragment ions from decay taking 
place in the field-free region after the ions have left the ion source [21].  
Several studies indicate a different distribution and function of decorin in 
emphysematous lungs as compared to controls. On this line it is worth mentioning that 
immunohistochemical investigations revealed significant reduction of decorin in the 
adventitia of small airways in lung tissue of patients with severe COPD as compared with 
control subjects [22]. Also lung fibroblasts from patients with severe emphysema stimulated 
by cytokines manifest dysregulation of decorin production when compared with matched 
control samples [23]. We recently also found that single nucleotide polymorphisms in the 
decorin protein core were not associated with COPD. The main purpose of the work described 
in this chapter was to establish whether alterations in N-glycans are induced during lung 
emphysema development and progression.  
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Decorin core protein with its attached N-linked glycans was purified from two 
different locations (upper and lower lobes) of an emphysematous lung and the same locations 
of a control lung (smoker without emphysema), as described in Chapter 3. SDS-PAGE 
analysis of the four purified decorin batches revealed a doublet of bands in three of them, and 
a single band in the forth one as has been shown in Chapter 4 indicating some 
microheterogeneity. In the present work we investigated whether the observed differences 
were due to variations in the number and/or composition of N-linked glycans attached to the 
decorin protein core. Following glycan isolation, the molecular masses of the sodiated glycan 
adducts were obtained using MALDI-MS. Additional structural information about 
representative glycans was obtained by partial sequence analysis using MALDI-PSD.  
 




Decorin core protein was purified from human lung tissue using the chromatographic method 
described previously [6]. In the present study we performed the profiling and partial structural 
characterization of the N-linked oligosaccharides attached to decorin protein core purified 
from two different areas (upper and lower lobes) of one control and one emphysematous 
human lung. Human lung tissue was obtained from the Department of Pathology of the 
University Medical Center Groningen based on protocols approved by the medical ethics 
committee. The classification as normal or emphysematous lung tissue was made based on 
histological examination of tissue performed by a pulmonary pathologist. The control lung 
presented only mild changes related to smoking, with limited airspace enlargement and some 
goblet cell hyperplasia in the airways. No major pathology was present.  
The enzymatic in-solution N-deglycosylation kit containing PNGase F from 
Chryseobacterium (Flavobacterium) meningosepticum was purchased from Sigma-Aldrich 
Inc. (St. Louis, MO, USA). All common laboratory reagents were obtained from Merck 
(Darmstadt, Germany).  
 
5.2.2 Release of oligosaccharides from decorin protein core by PNGase F digestion 
 
N-linked oligosaccharides attached to the intact decorin protein core were enzymatically 
released using PNGase F according to the protocol supplied by the manufacturer of the 
deglycosylation kit. Briefly, 60 µg of purified decorin protein core were reconstituted in 35 
µL of reaction buffer (200 mM ammonium bicarbonate solution). Five µL of denaturant 
solution containing 2% octyl-D-glucopyranoside and 100 mM 2-mercaptoethanol were added, 
the samples were boiled at 100°C for 10 minutes and cooled to room temperature (RT), 
followed by the addition of 5 µL of reaction buffer and 5 µL of PNGase F enzyme solution 
(500 units/ml). The resulting 50 µL samples were incubated at 37°C for 2 h using an 
Eppendorf Thermomixer. The reaction was stopped by boiling the samples at 100°C for 10 
minutes.  
 
5.2.3 Isolation of N-linked oligosaccharides  
 
Following PNGase F digestion, the protein cores from 50 µL decorin digest were precipitated 
by incubation with four volumes of 100% cold ethanol (-20◦C) for 30 minutes, followed by 
centrifugation at 20000 rpm (using an Eppendorf 5471R centrifuge) at 4◦C for 20 minutes. 
The supernatant was transferred into a new Eppendorf tube. The solvent was totally 
evaporated using a CentriVap Concentrator (Labconco, The Netherlands) and the N-linked 
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oligosaccharides were reconstituted in 20 µL of ultrapure water (approx 6 mM 
oligosaccharide mixture). This preparation was subjected to MALDI-TOF-MS analysis. 
 
5.2.4 Matrix-Assisted Laser Desorption Ionisation (MALDI)-Mass Spectrometry 
 
MALDI analysis was performed in the positive ionization mode using a Voyager DE Pro 
instrument (Applied Biosystems, Framingham, MA, USA). Oligosaccharides were analyzed 
using as matrix 20 mg/ml of 2,5-dihydroxybenzoic acid (DHB) in an aqueous solution of 50% 
acetonitrile, 0.1% TFA, doped with 10 mM NaCl. The possibility to use 2-(4-
hydroxyphenylazo) benzoic acid (HABA) as matrix was also evaluated, but this gave a 
weaker signal as compared with 2,5-DHB. As the fragment ions in general were rather weak, 
the matrix giving the strongest PSD signal, DHB, was used in this work. The oligosaccharide 
preparation was mixed with the matrix in the ratio 2:1 and 2 µL from the mixture was spotted 
on a stainless steel MALDI plate. Glycan spectra were acquired in reflector mode with 
delayed extraction.  
 
5.2.5 Analysis by Post Source Decay (PSD) MALDI-TOF-MS 
 
PSD spectra were recorded in positive ion mode using delayed extraction (delay time 200 
nsec). The accelerating voltage was adjusted to 20000V and the grid voltage to 78% of 
maximum. The laser intensity was 2700 W/cm2 and 200 laser shots/spectrum were acquired. 
Spectra were recorded in a variable number of segments, with the laser spot being continually 
moved over the target surface in order to compensate for sample depletion. 
Calibration of the PSD fragmentation spectra was performed using a few of the 
theoretical masses calculated for the ions present in the spectra of each individual glycan. For 
generating the theoretical masses of these ions we used the freely available version of the 





Decorin core protein was purified from two different areas (upper and lower lobes) of one 
control and one emphysematous human lung according to the method described in Chapter 3. 
In the present work we performed a comparative analysis of the N-glycan populations 
attached to decorin core proteins from all four batches of purified decorin. 
 
5.3.1 MALDI profiling of N-linked oligosaccharides 
 
Isolated glycan mixtures corresponding to each of the four decorin batches were subjected to 
MALDI-MS analysis. The glycan profiles, as presented in Fig. 1 a) and b) (control lung, 
upper and lower lobes, respectively) and Fig. 1 c) and d) (emphysematous lung, upper and 
lower lobes, respectively) are characterized by the presence of several clusters grouped 
around the following m/z values: 1300.4, 1461.9, 1664.8, 1810.6, 1978.0, 2124.0, and 2437.0. 
No major differences with respect to the molecular weights of glycans were found between 
the spectra, suggesting the same N-linked glycan composition on decorin in the upper and 
lower lobes from both control and emphysematous lungs.  
 






Fig. 1. Positive MALDI-MS profiles of N-linked glycans released from decorin protein core purified 
from the upper and lower lobes of a control (a, b) and an emphysematous (c, d) human lung tissue, 
respectively. Molecular masses of the ions correspond to the sodiated adducts. Glycans marked with 
an asterisk were further analyzed by MALDI-MS-PSD.  
 
5.3.2 PSD MALDI-TOF-MS analysis of N-linked oligosaccharides 
 
More structural information (determination of the antennary structure and monosaccharide 
composition) of individual glycans was gathered from the fragmentation spectra obtained by 
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Fig. 2. a) Schematic representation of the chitobiose core and the types of linkages between the 
constituting monosaccharides. The chitobiose core consists of two GlcNAc residues (open squares) 
and three mannose (Man) residues (closed circles). b) Formation of ions of type D, containing three 
mannose residues on the 6-antenna. This ion resulted from the loss of 3-linked antenna and the two 
reducing GlcNAc residues. 
 
Fragmentation pathways of glycans can be classified into two groups: a) glycosidic 
cleavages resulting from the breaking of a bond between two successive sugar residues, and 
b) cross-ring cleavages that involve the breaking of two bonds on the same sugar residue. 
When assigning the molecular ions we used the nomenclature proposed by Domon and 
Costello [25]. According to this nomenclature, the ions retaining the charge at the reducing 
terminus are numbered from this site and are designated X for cross-ring cleavages, and Y 
and Z for glycosidic bond cleavages. Those retaining the charge at the non-reducing terminus 
are designated A for cross-ring cleavages, and B and C for glycosidic bond cleavages, the 
numbering starting from the non-reducing end. The letter indicating the fragment type is 
followed by a subscript number indicating the residue. Subscript Greek letters are used to 
distinguish fragments from branched-chain glycans, with the letter α representing the largest 
branch. In the case of ring cleavages, superscript numbers indicate the ruptured bonds. 
Fragments resulting from cleavages, where only one glycosidic bond or one sugar ring is 
involved, are first generation ions and may undergo a second fragmentation to yield second 
generation ions. Ions resulting from more than one cleavage are designated with a slash 
between sites of cleavages (e.g. B3/Y3β). All N-linked glycans have a common core consisting 
of two GlcNAc residues and three mannose residues (see Fig. 2a), which is named a 
“chitobiose core”. The mannose residue linked to the GlcNAc residue on the chitobiose core 
will be termed “branching mannose”. The mannose residue linked α1-6 to the branching 
mannose will be part of the 6-linked antenna, since the one linked α1-3 will be part of the 3-
linked antenna (see Fig. 2 a). The internal cleavage ion resulting from the loss of 3-linked 
antenna and the two reducing GlcNAc residues will be termed “ion D” further in the text, as 
used by Harvey, who described also the mechanism for its formation [26]. The structure of 
ion D is schematically depicted in Fig. 2 b). The detection of this ion leads to the 
determination of the structural arrangement of the 6-linked antenna (see Fig. 2 a). 
In order to facilitate the ionization, we doped the matrix with NaCl. Therefore, the 
glycans were present in the spectra as sodium adducts. We will use the term “molecular ion” 
when referring to the sodium-cationized molecule. Z and C ions were not present in our 
spectra. 
The molecular ions for which we obtained fragmentation spectra were present in the 
glycan pools isolated from all four batches of purified decorin. The same fragmentation 
spectra were obtained for the ion with the same m/z in all four preparations.  
High-mannose glycans. The high-mannose glycan with the composition 
(Man)5(GlcNAc)2 and a parent ion with m/z 1257.3 produced the PSD spectrum shown in Fig. 
3.  











Fig. 3. a) Fragmentation spectrum obtained by MALDI-PSD of the molecular ion with m/z 1257.3 and 
b) schematic representation of the deduced antennary structure. HexNAc residues are represented by 




Fig. 4. Scheme of the high-mannose glycan (Man)5(GlcNAc)2. The fragmentation of the cross-ring 
cleavage ion 3,5A4 (m/z 908.6) is shown. 
 
The spectrum contained first generation B and Y ions (B3, m/z 834.6; Y2, m/z 447.8; 
Y3α, m/z 551.9) and cross-ring fragments. Second generation ions were also present (B3/Y3β, 
m/z 671.5; B4/Y4α, m/z 875.5) and were useful in determining the distribution of the mannose 
residues between the two antennae. The ion B3/Y3β contains four mannose residues and 
resulted from the loss of one mannose residue from the 3-linked antenna of the B3 ion. At the 
same time this ion reflects the presence of three mannose residues in the 6-linked antenna. 
The B3 ion resulted from the loss of both GlcNAc residues from the reducing-termini, as 
defined by the number of continuously linked mannose residues. Confirmation of this 
structure is provided by the presence of the 3,5A4 cross-ring cleavage ion (m/z 908.6) 
produced from the branching mannose. A schematic representation of the 3,5A4 cross-ring 
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Hybrid glycans. The PSD spectra of the hybrid glycans are more difficult to interpret 
due to coinciding masses of internal fragment ions formed by several different mechanisms. 
The spectra of the molecular ions corresponding to (Hex)4(HexNAc)3 (m/z 1298.5), 
(Hex)5(HexNAc)3 (m/z 1460.4), and (Hex)5(HexNAc)4 (m/z 1663.0) are depicted in Fig. 5, 6, 




Fig. 5. a) Fragmentation spectrum obtained by MALDI-PSD of the molecular ion with m/z 1298.5 and 




Fig. 6. a) Fragmentation spectrum obtained by MALDI-PSD of the molecular ion with m/z 1460.0 and 
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The parent ion at m/z 1298.5 produces the fragment ions B2α, B3α, B4, and Y4α, which 
are visible in the spectrum. D ions with m/z 916.1 (B1α/Y1) and m/z 711.8 (B3β/Y2) indicate 
the presence of HexNAc on the 6-linked antenna. Another possible structure may contain 
bisecting HexNAc, but the presence of acetylated hexose in this position is associated with 




Fig. 7. a) Fragmentation spectrum obtained by MALDI-PSD of the molecular ion with m/z 1663.5. 
Spectrum contains ions derived from two isomers. b) Schematic representation of the deduced 





Fig. 8. a) Fragmentation spectrum obtained by MALDI-PSD of the molecular ion with m/z 1663.5. 
Spectrum contains ions derived from two isomers. b) Schematic representation of the deduced 
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The spectrum of the molecular ion with m/z 1460.0 is dominated by the presence of B 
ions. Like in the previous case (m/z 1298.5), the presence of the D ion with m/z 712.6 
(B3β/Y2) indicates the existence of HexNAc on the 6-linked antenna. 
The fragmentation patterns of the (Hex)5(HexNAc)4 glycans are presented in Fig 7 and 
Fig 8. Spectra contain fragments derived from two isomeric forms, one belonging to the 
hybrid class (Fig 7 b)) and the other one to the complex class (Fig 8 b)). Because of the 
different compositions of the two isomeric antennae, the fragmentations and therefore the 
annotation of the B and Y ions are characteristic to each of the two structures. For a better 
understanding and interpretation of the data we present the same spectra in both Figs 7 a) and 
8 a), but with different annotations for the same m/z value corresponding to the two different 
isomers. The B and Y ion series are abundant and easily identified in the spectra, and the two 
isomers can be differentiated based on the observed D ions. The presence of the ion with m/z 
753.9 is associated with the structure depicted in Fig 8 b) as corresponding to the fragment 
B2α/Y2 resulting from B3 loosing the 6-linked antenna. The presence of the isomer 
represented in Fig 8 b) is also supported by the B2α ion with m/z 509.8, consistent with the 
presence of three mannose residues on the 6-antenna. The existence of the isomer represented 
in Fig 7 b) is supported by the ion with m/z 714.2, annotated as B3α/Y2 resulting from the loss 
of the 6-linked antenna from the B4 ion. The presence of the ion with m/z 1137.7 is consistent 




Fig. 9. a) Fragmentation spectrum obtained by MALDI-PSD of the molecular ion with m/z 1809.4. 
and b) schematic representation of the deduced antennary structure. Symbols are as in Fig. 3, and the 
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Complex glycans. Complex N-glycans contain fewer mannose residues and additional 
residues of other sugars (Fuc, Xyl, GlcNAc, Gal). The glycan with the molecular ion at m/z 
1663.0 has been already described in the previous section. Another complex glycan with the 
composition (Hex)5(HexNAc)4Fuc is present in the spectrum at m/z 1809.4. The mass 
difference between this ion and the one with m/z 1663.0 is 146.4, corresponding to a fucose 
residue, most probably attached to the reducing HexNAc. When comparing the PSD spectra 
of the ions with m/z 1809.4 (Fig. 9 a)) and m/z 1663.0, one observes fragments with the same 
molecular mass, suggesting that the attached fucose is rapidly lost and therefore the structure 
of the ion at m/z 1809.4 becomes the one depicted in Fig 7 b).  
From the total number of N-glycans attached to the decorin protein core, only the ones 
marked with an asterisk (see Fig. 1) have been successfully fragmented and characterized. 
The other glycans could not be fragmented possibly due to poor ionization. For the glycans 
with molecular ions at m/z 2124.15 and 2437.35, some fragmentation was observed, but we 
could not assign structures based on the fragments present in the spectra. When compared to 
literature data, the molecular masses of these two glycans do not match any N-linked glycan 
described so far. We do not exclude the hypothesis of novel structures, but in order to 
characterize them further additional experiments need to be performed. 
We investigated the possibility to fragment these glycans using other MS based 
techniques (MALDI-TOF-TOF-MS and atmospheric pressure MALDI-ion trap-MS), but 
could not obtain meaningful fragmentation patterns (probably related to a low glycan 
concentration in our samples).  
The N-glycans for which we proposed the above structures belong to the high-
mannose, hybrid or complex types. All these glycans are present in the data sets obtained 
from human lung tissue samples posted by the Analytical Glycotechnology Core on the site of 
the Consortium for Functional Glycomics, and are similar to the N-glycans attached to 






In order to assess whether alterations in N-glycans are present in emphysema lung tissue 
when compared to normal lung tissue, we facilitated their detailed structural analysis by 
enzymatical release from the protein cores and subsequent isolation. Post-Source-Decay is 
one way to obtain structural information of glycans [18-20] based on the decay of metastable 
ions in the field-free region of the mass spectrometer after ionization [20]. Delayed extraction 
of the generated ions is used in MALDI-TOF-MS instruments to increase mass resolution 
[21]. However, a complete product ion spectrum has to be acquired in several steps. This is 
due to the fact that the reflectron ion mirror is able to focus with sufficient resolution only 
ions resulting from metastable decay within a certain range of kinetic energy. Part of the 
product ion spectrum appears therefore as well-resolved signals, accompanied by a broad 
region of less resolved lower mass signals. In order to analyze the lower mass ions, the 
potential of the reflector has to be decreased in steps until all product ions have been focused 
into the detector with sufficient mass resolution. Therefore, each PSD spectrum was 
composed of several sections which were finally concatenated by the computer. 
In classical time-of–flight analysis of stable ions, the flight time (t) is proportional to 
the square root of mass over charge (m/z)1/2 for each ion. The mass-time relationship follows 





t = A +B(m/z)1/2 
 
The calibration constants can be derived by measuring the flight times of at least two 
different ions with known masses. Therefore, any time-of–flight spectrum of stable ions can 
be calibrated by a two-point calibration using at least two known masses from standard 
calibration substances. In PSD the situation is much more complicated for two-stage gridded 
as well as for gridless reflectrons, because there is no analytical function that can be used for 
an exact multi-point calibration [28]. Therefore, we calibrated the PSD spectra using the 
theoretical masses calculated for some known Y- and B-ions present in the spectrum of each 
individual glycan. 
Although the main target for mass spectrometric sequencing using MALDI-PSD is the 
primary structure analysis of peptides, this technique has been successfully applied for 
sequencing oligonucleotides [29], oligosaccharides [30-32], or branched peptides [33]. The 
level of quality, information content and reliability are the same for oligosaccharides as for 
peptides but interpretation strategies are more challenging for oligosaccharides and 
generalizable algorithms do not exist.  
In this study we employed the PSD technique for the characterization of N-linked 
oligosaccharides attached to human lung decorin. Relatively simple fragmentation patterns 
were observed and the spectra were dominated by the presence of B and Y ions. Second 
generation ions (B/Y), when present, offered more information about the branching of the 
antenna. Only few A ions resulting from ring cleavages were present. By measuring the 
overall molecular mass of an oligosaccharide, it is not possible to obtain information 
concerning the nature of isobaric monosaccharide residues such as hexoses (mannose, 
glucose, galactose) or N-acetylhexosamines (N-acetylglucosamine (GlcNAc), N-
acetylgalactosamine (GalNAc)). Although there is no formal proof for the nature of the 
HexNAc residues deduced from the mass measurements of the released glycans in this study, 
it would seem unlikely that HexNAc isomers other than GlcNAc would be present on glycan 
cores, as all N-linked glycans share the same pentasaccharide core, which is 
(GlcNAc)2(Man)3.  
In order to ascertain a glycan structure derived from a PSD spectrum, the structure has 
to be confirmed by comparing it with a matching PSD spectrum derived from a reference 
glycan. One of the problems associated with defining fragmentation modes in the PSD spectra 
of glycans is the provision of suitable reference glycans, as only a few are commercially 
available and, of these, most are symmetrically substituted [26]. The glycan structures we 
suggest here result from comparing our data with already elucidated N-linked structures from 
human tissues available at the Consortium for Functional Glycomics. 
Both decorin and biglycan have been addressed in earlier reports with the name 
proteodermatan sulfate (PDS). Studying biosynthesis and secretion of PDS produced by 
cultured human skin fibroblasts, Glossl and colleagues found that secreted PDS contains two 
or three complex-type or two complex-type and one high-mannose-type N-linked 
oligosaccharide chains and no O-linked oligosaccharides [4]. In the same study it was noted 
that “a large proportion of secreted PDS contains an oligosaccharide of high-mannose-type, 
which is not typical for secreted proteins”. These observations support our data. 
For all spectra presented and interpreted in the work described above, the possibility 
that some internal cleavage ions could have been formed by internal residue losses and 
rearrangements, rather than by simple combinations of B- and Y-type cleavages, may be 
excluded based on the study of Brull et al [34], which shows that sodiated monosaccharides 
(MNa+) do not undergo rearrangements of this type.   
 





The glycan populations isolated from the four batches of purified decorin core protein 
obtained from human lung are very similar in molecular weight and composition. We did not 
find differences with respect to the N-glycans attached to decorin in emphysematous tissue as 
compared to control tissue or between functionally different regions within the same lung 
(upper versus lower lobes). Our data indicate considerable heterogeneity with respect to the 
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Analysis of proteoglycans derived sulfated disaccharides by liquid 
chromatography/mass spectrometry  
 
 
A slightly adapted version of this chapter has been published as: Begona Barroso, Mihaela 
Didraga, and Rainer Bischoff. J Chrom A, 1080 ( 2005) 43. 
 
A method has been developed for the identification and quantitative determination of sulfated 
disaccharides derived from chondroitin sulfate (CS) and dermatan sulfate (DS) chains 
attached to proteoglycans (PGs). After digestion with Chondroitinase ABC, the pool of 
disaccharides can be directly separated by liquid chromatography on a porous graphitized 
carbon (PGC) column and identified by on-line electrospray mass spectrometry under 
negative ionization conditions. The relative intensities of the fragment ions obtained by 
MS/MS allow to distinguish the sulfate position. Calibration with standard disaccharides 
allows the quantification of the different isomers. The method showed good repeatability in 
terms of relative standard deviation (RSD < 2%) and linearity between 0.5 and 50 ng (total 
injected amount) for both 4- and 6-sulfated disaccharides. The limit of detection achieved in 
full scan mode was 0.1 ng. The methodology was applied to different types of biological 
samples obtained from patients suffering from chronic lung inflammation such as: lung tissue, 






Proteoglycans (PGs) are key components of the extracellular matrix consisting of a protein 
core with one or more long polysaccharide chains (glycosaminoglycans) covalently attached. 
These glycosaminoglycans (GAGs) are linear polymers of repeating disaccharide units (Fig. 
1) of uronic acid or galactose and hexosamine with varying length and composition. They 





Fig. 1. Schematic representation of a disaccharide typical for chondroitin sulfate. The sulfate group 
can be at position 4 or 6 of GalNAc. 
 
PGs have a polyanionic nature due mainly to the sulfate substituents on carbohydrate 
residues and to the carboxyl group of the hexuronic acid moieties. According to the type of 
monosaccharide constituents and the glycosidic bonds between them, GAGs can be divided 
into four main categories: chondroitin sulfate (CS) and dermatan sulfate (DS), heparin and 
heparan sulfate (HS), keratan sulfate (KS), and hyaluronan (HA). CS and DS contain 
galactosamine as the only hexosamine and are known as galactosaminoglycans. The rest 
contain glucosamine as the only hexosamine and are known as glucosaminoglycans [5]. 
Playing an important role as signalling molecules within the extracellular matrix 
(ECM), PGs influence the behaviour of malignant cells in both the tumour and the 
surrounding ECM. Anomalous structures of CS and DS chains have been found in cancer 
patients, in terms of increased concentration [6], chain length or position of glucuronic acid 
on the chain [7]. The neoplastic changes in the saccharide sequence of the CS/DS chain of 
DCN in human colon cancer may alter the interaction between DCN and the surrounding 
ECM macromolecules, consequently influencing tumour growth and invasion [7]. There are 
indications of an altered content and/or composition of decorin in patients with severe chronic 
obstructive pulmonary disease [6]. In our research we are interested in investigating the 
potential alterations of DCN in relation to smoking induced emphysema. The aim of this work 
was to develop an analytical method able to separate and identify the different types of 
sulfated disaccharides present in CS/DS chains derived from lung proteoglycans. 
Although the total glycosaminoglycan concentration can be assayed 
spectrophotometrically with dimethyl methylene blue [8,9], this methodology cannot provide 
any further structural information about the structure/composition of glycans. In order to 
investigate GAG structure, the general strategy consists in the treatment of the GAG chains 
with specific lyases, such as Chondroitinase ABC (from Proteus vulgaris), which acts by 
eliminative cleavage to produce disaccharides with an unsaturated C4–C5 bond on the uronic 
acid residue. Chondroitinase ABC degrades CS and DS into ∆-disaccharides, which can be 
sulfated in position 4 or 6. The degradation products formed are further separated by 
chromatographic or electrophoretic methods [10,11] and detected/quantified using different 
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The negative charge of the sulfate group facilitates the use of capillary electrophoresis 
(CE) providing high efficiency separations, mass sensitivity and rapid analysis time [13]. 
However, the limited loading capacity restrict the use of this technique to concentrated 
samples. 
Liquid chromatography has been also widely applied using size exclusion [14], ion 
pair [15] or amino-bonded stationary phases [16] due to the polar nature of the disaccharides. 
The most common detection method coupled to these techniques has been UV absorption at λ 
232 nm. However, due to its low sensitivity, several derivatization procedures have been 
developed using fluorescence detection. The most common derivatization agents are 2-
aminoacridone [17] and dansylhydrazine [18]. 
In recent years mass spectrometry (MS) has become a useful tool for the structural 
characterization of saccharides released from proteoglycans. Fast atom bombardment (FAB) 
MS has been utilized to identify unusual sulfated disaccharide units in digests of chondroitin 
sulfate E from various species [19]. MALDI-TOF with a DBH matrix has also been applied to 
digests of chrondroitin sulfate with different enzymes [20]. Also electrospray ionization (ESI) 
MS combined with flow injection analysis has been used quite widely for the study of 
glycosaminoglycan composition [21-23]. In this case extensive optimisation of the MS 
parameters is necessary to distinguish N-acetylgalactosamine (GalNAc) residues sulfated at 
the 4- versus the 6-position. 
In this work, we report the development of a new method for the quantitative direct 
analysis of disaccharides released from proteoglycans following Chondroitinase ABC 
digestion. The method combines a chromatographic separation using porous graphitized 
carbon (PGC) with mass spectrometric detection. PGC has exceptional chemical and physical 
stability and can be used throughout the entire pH range. PGC exhibits unexpected and 
largely unexplained retention properties for molecules containing polar groups. It has been 
successfully applied to the analysis of N and O-linked glycans released from glycoproteins 
[24]. Several reports have been published showing an increase in retention when the polarity 
of the analyte increases [25]. The dissacharides released from proteoglycans can be eluted 
with a gradient of acetonitrile containing 0.1% formic acid, and detected as negative ions 
without any derivatization. 
 
6.2 Materials and methods 
 
Human lung tissue, bronchoalveolar lavage fluid, induced sputum and urine from patients 
suffering chronic lung inflammation were obtained using protocols approved by the medical 
ethics committee and provided by the Pulmonary Research Unit of the Groningen Academic 
Hospital (Groningen, The Netherlands). 
Formic acid, ammonium acetate and acetonitrile were from Merck (Darmstadt, 
Germany). Chondroitinase ABC from P. vulgaris affinity purified, chondroitin sulfate A 
sodium salt from bovine trachea, chondroitin sulfated disaccharide ∆Di-4S and ∆Di-6S 
sodium salt, 1,9-dimethyl-methylene blue (DMB), phenylmethylsulphonyl fluoride (PMSF), 
and propylene glycol were purchased from Sigma–Aldrich Inc. (St. Louis, MO, USA). 
Ethylenediaminetetraacetic acid disodium salt (EDTA), tris (hydroxylmethyl) aminomethane 
(Tris) ultrapure, and glycine were from Duchefa (The Netherlands). 
 
6.2.1 Tissue extraction 
 
Lung tissue (20 g), obtained from patients who underwent lobectomy or lung transplantation, 
was homogenised with a blender and incubated with extraction buffer (100 w/v) for 20 h at 
4 °C, with continuous stirring. The extraction buffer was 20% propylene glycol, 50 mM 
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sodium acetate, 300 mM NaCl, containing 10 mM EDTA and 1mM PMSF as proteases 
inhibitor, pH 6.0. The resulting extract was centrifuged at 40,000 × g for 30 min at 4 °C using 
a Beckman Coulter centrifuge equipped with a JA-3050 rotor. The supernatants were filtered 
through OE 66 membrane filters (Schleicher & Schuell, Dassel, Germany), 0.2 µm pore size, 
using a vacuum filtration system. Lung extract (250 ml) was subjected to FPLC separation 
(Amersham Pharmacia Biotech) in two tandemly connected HiTrap-Q Sepharose (5 ml) 
columns equilibrated with the extraction buffer. The column was washed with the same buffer 
until the A280 decreased to baseline and further with five column volumes of 50 mM sodium 
acetate and 300 mM NaCl, pH 6.0. The bound fraction was eluted with 1.5 M NaCl, pH 6.0, 
subjected to buffer exchange to 10 mM Tris, pH 7.8, using an Amicon 8050 stirred 
ultrafiltration cell with a Biomax PBGC (10,000 NMWL) ultrafiltration membrane (Millipore 
Corporation, Bedford, USA), and further digested with Chondroitinase ABC. 
 
6.2.2 Biological fluids 
 
Bronchoalveolar lavage fluid (BALF) supernatant samples were obtained from chronic 
obstructive pulmonary disease (COPD) patients who underwent bronchoscopy. BAL was 
performed by instillation of saline solution. The lavage fluid was centrifuged and the 
supernatant stored at −80 °C until use. BALF samples were preconcentrated 25 times using a 
vacuum centrifuge. 100 µL preconcentrated samples were subjected to buffer exchange to 
10 mM Tris, pH 7.8, using Protein Desalting spin columns from Pierce, according to the 
manufacturer instructions. 
Sputum samples were diluted 1:1 in 10 mM Tris, pH 7.8. For the urine samples the pH 
was adjusted to 7.8 using 50 µL of 10 mM Tris buffer, pH 7.8 per ml urine. 
All samples (lung extract, BALF, sputum, and urine), after buffer exchange to 10 mM 
Tris or pH adjustment, were subjected to the DMB assay for GAG quantitation and further 
digested with Chondroitinase ABC, as described in the next two sections. 
 
6.2.3 DMB measurements 
 
Total chondroitin/dermatan sulfated GAGs were quantitated using the DMB assay as 
described by Farndale et al [26]. Briefly, 100 µL samples were mixed with 2.5 ml DMB 
colour reagent into a disposable spectrophotometric cuvette and absorbance (λ 525 nm) was 
read immediately, using an UV-160 UV–Vis recording spectrophotometer (Shimatzu, 
Benelux). Concentrations were determined from standard curves of chondroitin sulfate A. 
 
6.2.4 Chondroitinase ABC digestion 
 
GAG containing samples were incubated overnight with 2.8 mU Chondroitinase ABC per µg 
GAG, at 37 °C, 450 rpm using an Eppendorf thermomixer. The enzyme was used in excess to 




The HPLC part of the analytical system consisted of an Agilent Series 1100 LC system 
(Waldbronn, Germany) comprising a degasser, a binary pump, an autosampler and a 
thermostatted column compartment. Chromatographic separation of the disaccharides took 
place in a porous graphitized carbon column Hypercarb (Thermo Electron Corporation, 
Cheshire, UK), 0.32 mm I.D. × 100 mm length operated at 5 µL/min flow rate. 
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Mobile phase A consisted of 0.1% formic acid in ultrapure water. Mobile phase B was 
0.1% formic acid in acetonitrile. Separation was performed with an increasing gradient of B 
(5–90% in 60 min). The column temperature was kept constant at 28 °C. The analytes were 
detected by an Agilent SL ion-trap mass spectrometer equipped with an ESI source operated 
in negative mode. MS data were acquired over a scan range of 50–1200 amu and 5500 m/z 




Initial experiments were focused on the optimization of the chromatographic separation. After 
injection of the standard ∆Di-4S two chromatographic peaks were observed with the same 
spectrum, indicating that both peaks are isomers (Fig. 2A). The same was observed after 




Fig. 2. EIC (m/z 458.2) corresponding to injection of 5 ng of each of the standard disaccharides. 
2A = ∆Di-4S; 2B = ∆Di-6S. As observed two isomeric chromatographic peaks are obtained for each 
disaccharide. Gradient: 20–90% of B in 60 min. (B: acetonitrile containing 0.1% formic acid). 
 
Both 4- and 6-sulfated disaccharides were characterized by a single ion with m/z 458.2 
corresponding to [M − H]−. No sodiated or other adducts were observed. When this parent ion 
(m/z 458.2) was submitted to negative ion CID, similar mass spectra were observed for both 
disaccharides, but with quite different ratios between the daughter ions (Fig. 3) allowing to 
distinguish the position of the sulfate group. 
For ∆Di-4S the most abundant fragment ions are Y1 (m/z 300.1) and 0,2X1 (m/z 342.1), 
Z1 being absent, while for the ∆Di-6S the most abundant fragment ion is Z1 at m/z 282. Also a 
small ion corresponding to C1 at m/z 175 is seen (nomenclature according to Domon and 
Costello [27]). MS3 of Z1 (m/z 282) produced mainly one ion (m/z 97) corresponding to 
[SO4H]−. This is in agreement with the results obtained by Zaia et al. [14]. 
The influence of the pH on the chromatographic separation was also studied in the 
range 2–8, using mobile phases containing ammonium acetate at different pH values. Increase 
of the pH of the mobile phase resulted in decreased retention times for the 6-sulfated 
disaccharides and increased ones for the 4-sulfated isomers. However, peaks became broader 
and it was not possible to obtain a good separation of the isomers due to peak overlap. 

























Fig. 3. MS/MS spectra corresponding to each isomer of both disaccharides (sulfated in position 4 or 
6). As observed, the ratios of the different fragment ions depend on the position of the sulfate group. 
 
6.3.1 Calibration graphs 
 
In order to validate the method for quantitative analysis, calibration graphs were prepared by 
injecting 1 µL of different concentrations (0.5, 2, 8, 15, 20, 25, 35, 45, 50 ng/µL) of the 
standard 4- and 6-sulfated disaccharide solutions in Tris. The total area for each disaccharide 
was considered as the sum of the contribution of both isomeric peaks. 
The calibrations were linear up to 50 ng (in terms of total injected amount). The 
following equations were obtained: y = 2.1 × 105x + 1 × 103 (r2 = 0.997) for ∆Di-4S and 
y = 1.7 × 105x + 8 × 103 (r2 = 0.997) for ∆Di-6S. The limit of detection (calculated as the 
minimum injected amount which gave a response in the detector higher than three times the 
signal to noise ratio using the EIC (m/z 458.2)) was 0.1 ng for both disaccharides in full scan 
mode. 
Using MRM mode (458.2 > 300.1, 458.2 > 282.0), it was possible to detect 0.01 ng. 
The repeatability (calculated by repeating the calibration graph four times) gave a relative 
standard deviation (RSD) of less than 2%. Spiking of the standard disaccharides directly into 
the biological fluids showed that there was no interference from the matrix (e.g. ion 
suppression) with a RSD less than 3%. To check the reproducibility of the whole procedure, 
different concentrations of chondroitin sulfate A (0.5, 2 and 4 µg) were spiked into 300 µL of 
the different fluids (25 times preconcentrated BALF, induced sputum and urine) and the 
mixture digested with 2 mU of Chondroitinase ABC. After digestion, 5 µL were injected in 
the LC/MS system. The results showed that the amount of disaccharides obtained kept a good 
correlation with a digest of the corresponding amount of Chondroitin sulfate A (RSD less than 
5%), indicating that the enzyme is not affected by the matrix, and therefore, the method is 
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The methodology developed was applied to the quantitation of 4- and 6-sulfated disaccharides 
present in biological samples. 
 
6.3.3 Lung tissue extracts 
 
The first application was the monitoring of the digestion of proteoglycans isolated from lung 
tissue by anion exchange chromatography.  
In our research we are interested in the purification of small leucine-rich 
proteoglycans (e.g. decorin, byglycan) from lung tissue. One crucial step in this procedure is 
the digestion of the anion exchange fraction containing a mixture of proteoglycans with 
Chondroitinase ABC to release the core proteins which are recovered in the flow through after 
a new anion exchange run for further purification.  
For the tissue extract fraction, eluted with 1.5 M NaCl and subjected to buffer 
exchange to 10 mM Tris, pH 7.8, DMB measurements showed the presence of 46 µg 
GAG/ml. Due to the lack of information about the amount of CS and DS present in the tissue 
extract, it is difficult to estimate the amount of enzyme required for the digestion. Digests of 
lung extract were prepared with increasing concentrations of Chondroitinase ABC and the 
enzymatic reaction was followed by monitoring the amount of disaccharides released. Also 
different time points were selected during the digestion to find the optimal digestion time. In 
Fig. 4, one of these digests is presented showing clearly both disaccharides in the total ion 




Fig. 4. TIC chromatogram obtained after injection of a digest of lung tissue extract containing 





















6.3.4 Biological fluids 
 
The method was also applied to the quantitation of 4- and 6-sulfated disaccharides in 
biological fluids obtained from patients suffering chronic lung inflammatory diseases, such as 
chronic obstructive pulmonary disease. Two different BALF supernatant samples were 
preconcentrated (as described in the sample preparation section) and concentrations of GAGs 
measured by the DMB assay were 52 and 90 µg GAG/ml, respectively.  
After digestion with Chondroitinase ABC, the resulting digest was diluted five times 
with Tris and 5 µL injected in the LC/MS system. In Fig. 5A the total ion current 
chromatogram obtained for one of the samples is presented. When the extracted ion 
chromatogram (EIC) corresponding to m/z 458.2 is selected (Fig. 5B), both disaccharides can 




Fig. 5. LC/MS profiles corresponding to BALF from a patient with chronic obstructive pulmonary 
disease, digested with Chondroitinase ABC. The upper trace shows the total ion current chromatogram 
and the lower trace corresponds to the extracted ion chromatogram (m/z 458.4) showing the presence 
of 4- and 6-sulfated disaccharides. 
 
A similar procedure was followed with induced sputum. For the sputum sample, 
GAGs concentration was 75 µg/ml according to the DMB assay. In this case, after digestion, 
the sample was diluted 20 times with Tris before injection in the LC/MS system due to the 
high concentration of the disaccharides. Again the 4-sulfated form is present in higher 
abundance than the 6-sulfated (Fig. 6A and B). In Table 1 the calculated concentration of both 
disaccharides in some biological samples and the ratios ∆Di-4S/∆Di-6S are shown.  
When looking at the chromatogram for these biofluids, many other peaks can be 
distinguished. Tandem MS of these peaks revealed the presence of non-sulfated 
disaccharides. In Fig. 7, the EIC corresponding to the non-sulfated forms ∆Di-0S (m/z 378.3) 
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in induced sputum shows also several peaks (isomers). This fact indicates that our approach is 
also valid for the analysis of other saccharides after calibration with the appropriate standards.  
Application of the same methodology to two different urine samples did not show any 
disaccharide peaks, although the DMB assay indicated the presence of 1.2 and 5.2 µg/ml 
GAGs, respectively. If present, these disaccharides are in too low concentration to be 
detected. 
 
Table 1. Concentration of ∆Di-4S and ∆Di-6S in some biological samples  
 





BALF l 33.01 8.07 4.09 
BALF 2 24.13 8.62 2.80 
Sputum 105787.50 5185.66 20.4 
 
The developed method opens the possibility to compare the relative amounts of 4- and 
6-sulfated disaccharides in different biological samples as well as concentration variations 
which can be associated with disease progression. 
 
 
Fig. 6. LC/MS profile obtained after injection of a sample of induced sputum from a patient with 
chronic obstructive pulmonary disease (COPD) digested with Chondroitinase ABC. The upper trace 
shows the total ion current chromatogram and the lower trace corresponds to the extracted ion 
chromatogram (m/z 458.4) showing the presence of 4- and 6-sulfated disaccharides. 
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Fig. 7. TIC (upper trace) and EIC m/z 378.3 (lower trace) showing the presence of non-sulfated 




The methodology developed allows the separation and quantitation of disaccharides after 
Chondroitinase ABC digestion of natural proteoglycans as well as the elucidation of their fine 
structure (e.g. determination of the sulfate position) using tandem mass spectrometry. When 
compared with other methods, ours is simple and fast (after digestion the samples can be 
directly injected in the column without further clean up) and can be applied to different types 
of biological samples like tissue extracts, BALF, induced sputum and urine. Even with these 
complex matrices the elution window of the disaccharides is free of coeluting peaks. No 
derivatization strategies or isolation of the digestion products are required before LC/MS 
analysis. If necessary, the limit of detection (0.1 ng) can be improved using MRM to 0.01 ng. 
Glycosaminoglycans take part in several biological functions in the lung extracellular 
matrix through their specific structures. It has been reported that in certain diseases they 
undergo specific compositional and structural modifications [28]. In the future the method 
developed will be used to detect variations in the concentration and in the sulphation pattern 
of different galactosaminoglycans (chondroitin sulfate and dermatan sulfate) during the 
progression of COPD and other diseases involving chronic lung inflammation such as 
bronchiolitis obliterans. 
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Summary, general discussion, and future perspectives 
 
 
This chapter summarizes the overall results of the studies we performed and connect them 
with the goals of the thesis. A short outlook of the possible future research directions that can 
be followed for a more in depth study of decorin in relation to emphysema is also included.  
 
7.1 The requirement for decorin purification from human lung tissue 
 
In order to develop new and effective therapies for COPD it is necessary to understand the 
pathophysiological mechanisms underlying the disease and to establish the biochemical 
changes taking place at the molecular level. Decorin may play a role in emphysema 
development and progression since we previously showed less decorin and biglycan staining 
in lung tissue of emphysema patients, and less decorin production by fibroblasts of 
emphysema patients compared with healthy controls [1,2]. The implication of decorin in the 
pathophysiology of other ECM diseases strengthens our hypothesis about decorin as a 
candidate for revealing some of the pathways leading to emphysema. Two main purposes 
motivated us to purify decorin protein core from human lung tissue: the possibility of 
performing a structural comparison of native decorin purified from emphysematous versus 
control lungs, and the prospect to carry out in vitro studies using human lung decorin. 
Therefore, this thesis was mainly devoted to the development of analytical methods which 
would enable the purification of decorin and the characterization of its structural components: 
protein core, N-linked glycans, and GAG chain. The results are presented as a comparative 
study of decorin protein cores and the attached N-linked oligosaccharides purified from one 
control and one emphysematous human lung. Two similar locations (peripheral lower lobe 
and peripheral upper lobe) were chosen for each lung, and consequently four batches of 
decorin were purified from human lung tissue. A separate chapter was allocated to the 
investigation of GAG chain composition. 
 During the research performed in this thesis, some questions have emerged. While for 
some of them it was possible to provide the answers, others were more difficult to answer 
within the time frame allocated to the work herein described. Therefore, although we offered 
some possible explanations, more work is necessary in order to confirm our hypotheses. 
 
7.2 Summary and contributions made by this thesis 
 
Decorin purification method 
 
The exact composition and distribution of proteoglycans within lungs has not been fully 




reported [1-3]. With respect to the leucine-rich repeat (LRR) PGs it has been shown by 
immunoblotting that lumican is the most abundant, while biglycan, decorin and fibromodulin 
are present in low amounts in adult human lungs [2]. Because decorin is not an abundant 
protein within lung tissue, our purification strategy required first an enrichment step followed 
by a minimum number of isolation steps, in order to increase the overall purification yield. 
The strategy that we developed (which is presented in Chapter 3) consisted of two anion 
exchange and one reversed phase chromatography steps. Anion exchange chromatography 
(AEC) has been routinely used for isolating proteoglycans, as they bind strongly to the AE 
resins due to the negative charges of GAG chains, contributed by sulfate and carboxylate 
groups. Enzymatic treatment of the proteoglycan pool with chondroitinase ABC selectively 
removed only GAGs belonging to the CS/DS class. Consequently, rechromatography of the 
digest on the same AE column resulted in the enrichment of the protein cores from this 
particular class of proteoglycans in the flow through fraction. Reversed phase 
chromatography has not been exploited for the purification of proteoglycans, while affinity 
chromatography using lectins was preferred as the last purification step [4]. The use of 
reversed phase chromatography has the advantage to provide resolution between decorin and 
other copurified proteins. It offers in this way the possibility to profile the proteoglycans from 
the CS/DS class and to gain more insight into the proteoglycan composition of lung tissue. 
This option of “proteoglycan profiling” is a promising line to be further investigated in 
relation to emphysema development. The chromatogram obtained from the C4 column 
enabled us to establish that decorin was the most abundant CS/DS proteoglycan in human 
lung tissue, while lumican, a KS proteoglycan, appeared as the most abundant leucine-reach 
repeat proteoglycan in an adult human lung extract [5], when analyzed by Western blot. 
 
Investigation of N-glycosylation 
 
This chromatographic method has been applied for decorin purification from two similar 
locations (peripheral lower lobe and peripheral upper lobe) of one control and one 
emphysematous lung. Following the purification of the four batches of decorin, SDS-PAGE 
analysis revealed a broad band (composed of a major and a minor component) in three of the 
preparations (lower control lobe, upper and lower emphysematous lobes), and a sharper band 
(consisting of the major component only) in the upper control lobe. Taken together with 
earlier literature reports concerning decorin structure, our data suggest that the two decorin 
components present in our preparations consist of a single form of the protein core that is 
differentially substituted with N-linked glycans. We experienced some difficulties during 
digestion with PNGase F and we suspect that decorin protein core suffered proteolytic 
cleavage in addition to deglycosylation. Consequently, further experiments are required in 
order to confirm the existence of only one protein core form of decorin in our preparations. 
For understanding carbohydrate-protein interactions at a molecular level it is 
indispensable not only to identify the structures of the carbohydrate moieties, but also to 
determine to which of the Asn-X-Ser/Thr sequons they are attached, i.e. which of the 
potential N-glycosylation sites are in fact used. Therefore, we studied the occupancy of 
glycosylation sites (Chapter 4) and the structural composition of the attached N-glycans 
(Chapter 5), using mass spectrometry in combination with enzymatic treatments (with 
trypsin and PNGase F). These investigations did not reveal any notable differences in decorin 
isolated from emphysematous lung tissue as compared with the control lung, with respect to 
N-glycosylation. Unexpectedly, we found differences between decorin purified from the two 
locations of the control lung, in terms of the presence of different decorin glycoforms. This 
observation leads to two main questions: 1) is the lower molecular weight form of decorin 
protein core more susceptible to proteolytic degradation within lungs, and 2) is decorin 
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heterogeneity an ordinary event within human lung tissue unrelated to emphysema 
development? In order to answer these questions further research needs to be performed 
including the purification and structural comparison of decorin (inter- and intra-individuals) 
from a larger number of lung tissue samples. Although no major pathology has been found 
during histological examination of the control lung tissue, it is difficult to rule out some 
potential disease-related causes as this was a transplantation donor lung without available 
medical records. 
MALDI spectra acquired from the intact protein cores evidenced also some subtle 
differences regarding the molecular weight of the minor component (38,800 Da versus 40,200 
Da) from the lower control lobe when compared with the corresponding peak derived from 
the emphysematous lobes. This observation is directly related to decorin heterogeneity within 
lung tissue and further investigation is needed with the aim of establishing the basis of these 
structural differences.  
Occupancy of glycosylation sites in human lung decorin is a very complex process, 
which extends beyond the differential substitution of the protein core with N-glycans. Our 
study of glycosylation calls attention to the variable glycosylation site occupancy at all three 
decorin glycosylation sites. It is possible that the two decorin glycoforms, with two and three 
glycosylation sites fully occupied, are the most abundant forms, but other glycoforms, with 
variable degrees of N-glycan substitution exist as well, albeit at lower abundance. Therefore, 
investigating the occupancy of glycosylation sites using a quantitative method will be helpful 
in elucidating this complex situation.  
In Chapter 5 we performed the profiling and partial structural characterization of the 
glycans attached to decorin purified from control and emphysematous lung tissue, with the 
goal of comparing N-glycan structures between emphysema and control as well as between 
the two locations of the control lung. The method was based on the enzymatic removal of N-
glycans (using PNGase F) followed by selective ethanol precipitation of the protein cores and 
further structural analysis of glycans using MALDI-PSD-TOF mass spectrometry. The 
presence of the same glycans in all four preparations was observed, suggesting that no 
modifications of glycans were induced as consequence of emphysema. Also the same glycan 
populations were identified in the upper and lower control lobes, indicating that the observed 
differences between the corresponding decorin forms were not a result of different types of 
attached N-glycans.  
While a number of questions remain to be answered, this is, to our knowledge, the first 
study to report detailed structural information of the N-glycans attached to decorin isolated 
from human tissue. 
 
Analysis of GAG-derived sulfated disaccharides 
 
In Chapter 6 we present the development of a method for the identification and quantitative 
determination of sulfated disaccharides derived from chondroitin/dermatan sulfate chains 
attached to proteoglycans. Following digestion with Chondroitinase ABC, the pool of 
disaccharides can be directly separated by liquid chromatography on a porous graphitized 
carbon column and identified by on-line electrospray mass spectrometry under negative 
ionization conditions. The method is quantitative and discriminates between 4- and 6- sulfated 
disaccharides without any derivatization. We applied the method to different types of 
biological samples obtained from patients suffering from chronic lung inflammation such as: 
lung tissue, bronchoalveolar lavage fluid, induced sputum and urine. This method opens the 
possibility to compare the relative amounts of 4- and 6- sulfated disaccharides in biological 
samples as well as to determine concentration variations, which may be associated with 
disease progression. Therefore, the method could be used in the future for detecting variations 
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in the concentration and sulfation pattern of different CS/DS during the progression of COPD 
and in other diseases involving chronic lung inflammation, such as, for example, bronchiolitis 
obliterans. 
 
7. 3 Future research directions 
 
Some possible future directions to follow-up the path opened by the methods we developed 
have been already suggested while discussing the overall results of this thesis. In parallel with 
those, other autonomous investigation themes could be followed and the continuous 
methodological advances would inevitably open new perspectives. 
By investigating the structure of human lung decorin we experienced at some point the 
difficulties emerging from exploring a partially uncharted territory, with respect to the 
problem of heterogeneity of decorin glycoforms within human lungs and to the variable 
occupancy of glycosylation sites. Therefore, some of the questions emerging from our studies 
will remain open until further research in these directions would confirm or infirm our 
hypotheses.  
One question which necessitates further confirmation is the variable glycosylation site 
occupancy in human lung decorin. Given its complexity, it requires to be investigated 
systematically, choosing appropriate control samples. The recent strategy developed by 
Nettleship et al [8], specially designed for investigating variable N-glycosylation site 
occupancy in glycoproteins, may prove useful for confirming the partially occupied sites in 
decorin. The method is based on the same approach we used, taking advantage of the 1 Da 
mass difference resulting from the conversion of asparagine into aspartic acid by PNGase F. 
In their method, digestion with trypsin or other suitable proteases is also employed to generate 
peptides. Subsequently, the glycopeptides are bound to a sulfoalkylbetaine-based zwitterion 
chromatography-hydrophilic interaction chromatography (ZIC-HILIC) resin and the non-
glycosylated peptides are washed away. Following elution, glycopeptides are treated with 
PNGase F before LC-ESI-MS analysis. For each protein of interest five samples are prepared, 
according to the flow diagram presented in Fig. 1. The in silico peptide monoisotopic masses 
with asparagine at the predicted glycosylation site are compared with those obtained 
experimentally to identify the presence (an increased mass of 1 Da) or absence (no mass 
change) of a glycan attachment site. In the case of a partially occupied site, both peptides with 
no mass change and peptides with a mass increase of 1 Da are observed. 
An estimation of the relative abundance on different decorin glycoforms can be 
obtained using a quantitative method of N-glycosylation site occupancy such as the one 
developed by Hulsmeier et al [9]. Isotopically labeled standard peptides are used in order to 
directly quantify the level of N-glycosylation site occupancy on selected serum proteins, 
using multiple reaction monitoring LC-MS/MS. 
 
Table 1. Access to the main glycobiology consortia. 
 
Collaborative Glycomic Initiative 
(EuroCarbDB), Europe www.eurocarbdb.org 




Human Disease Glycomics/Proteome 
Initiative (HGPI), Japan www.hgpi.jp 
 






Fig. 1. Flow diagram showing the sample preparation steps used for the analysis of glycosylation site 
occupancy in ref [8]. Reproduced with permission from ref [8]. 
 
Glycan structural research is challenging at all levels: covalent structure, 3D structure, 
dynamics and interactions. In all these areas, computational tools and databases of existing 
structures are used to aid in the interpretation of experimental data [10]. There are significant 
ongoing efforts in glycobiology to create a global framework for glycan-related data 
exchange. Additionally, there is a stringent need to integrate various glycan-related 
information by developing database architectures that are able to link orthogonal data sets in 
order to facilitate data mining. The international collaborative networks in Europe, the US and 
Japan (see Table 1) have joined their efforts in investigating glycan structures.  
Identification of glycans‘ covalent structures relies mainly on LC-MS [11-13], 
coupled with exoglycosidase digestion [14]. Interpretation of glycans fragmentation spectra 
still lacks efficient automatic assignment and relies mainly on expert interpretation, although 
several computational approaches have been proposed lately [15-17].  
It has been shown that mechanical overload could also damage collagen fibers by 
disrupting the glycosaminoglycan chains rather than by decorin protein core detachment from 
collagen [18]. On the other hand, alterations in the concentration of chondroitin and heparin 
sulfate affect cell proliferation during wound repair [19,20]. All these observations suggest 
that the possibility of GAG chains (especially CS/DS) alterations related to emphysema needs 
to be investigated, and the method we developed and presented in Chapter 6 will be useful for 
this purpose. Complementary to that, the activity and expression levels of xylosyltransferases 
in lungs of emphysematous patients need to be measured and compared with those of normal 
individuals.  
The susceptibility of decorin to MMP-2, MMP-3 and MMP-7 [21] has been already 
proven using recombinant decorin prepared from the culture medium of Chinese hamster 
ovary cells. It has been suggested that, under pathophysiological conditions, the digestion by 
MMPs may induce tissue reactions mediated by TGF-beta1 released from DCN in the 
connective tissue. The availability of native lung decorin allows now performing in vitro 
digest with different lung proteases providing a more realistic fingerprint of the respective 
proteases at work. The following step will be to determine how far the results from in vitro 
degradation can be translated to the in vivo situation. One approach could be screening of 
different biological fluids from patients suffering from emphysema in search for the presence 
of the in vitro generated peptides. It has been reported that decorin binds to several host-
Chapter 7 
104 
defense proteins containing collagen-like domains such as C1q [22], scavenger receptor A 
[23], or surfactant-associated protein D [24]. These proteins may constitute a transporter for 
decorin peptides from the lung parenchyma (where proteolytic cleavage take place) into the 
airway mucosa, from where they can be recovered for e.g. in the lavage fluid.  
By generating knock-out mice a role has been proven for LRR proteoglycans in 
regulating the formation of collagen fibrillar networks in the cornea and other tissues. The 
null mutations of decorin, biglycan, fibromodulin and lumican have as consequence the 
malfunction of connective tissues associated with an abnormal extracellular matrix, 
manifested as: fragile skin, cloudy cornea, and thick collagen fibrils [25]. These observations 
point toward biglycan, fibromodulin and lumican as potential new targets to be investigated in 
relation to emphysema as well. 
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Dit proefschrift is grotendeels gewijd aan het ontwikkelen van methoden om het decorine 
eiwitkern te isoleren uit humaan longweefsel, en de karakterisatie van de structurele 
componenten van dit eiwit: het eiwit skelet, N-gelinkte suikergroepen en glycosaminoglycaan 
(GAG) ketens. De resultaten worden gepresenteerd in een vergelijking tussen humane 
decorine eiwitkernen en hieraan verbonden N-gelinkte oligosaccharides geïsoleerd uit een 
controle en een emfysemateuse long. Van beide longen is weefsel geïsoleerd van identieke 
locaties (perifere lagere longkwab en perifere bovenste longkwab) en hieruit zijn 4 
decorinepreparaten gezuiverd. De analyse van disaccharides die verkregen zijn uit GAG-
ketens van de chondroitine/dermatane klasse proteoglycanen wordt beschreven in een 
afzonderlijk hoofdstuk. 
Hoofdstuk 1 bevat een algemene introductie over het onderwerp van dit proefschrift 
en definieert de doelstellingen van dit onderzoek. In dit hoofdstuk wordt de pathogenese van 
emfyseem bij chronische obstructieve longziekten (COPD) beschreven en wordt de rol van 
decorine eiwitten in de extracellulaire matrix van de long, en de rol tijdens ziekte, benadrukt. 
Hoofdstuk 2 geeft een uitgebreid overzicht van proteoglycanen (PG), waaronder de 
diversiteit en complexe functie van PG in verschillende weefsels van het lichaam.PG zijn 
moleculen die bestaan uit een eiwit-kern, waaraan een of meerdere glycosaminoglycaan 
ketens (GAG) zijn bevestigd door middel van serine residuen. GAG zijn lineaire 
polysacchariden, die bestaan uit repeterende negatief geladen disacchariden. Decorine heeft 
maar een GAG keten van de chondroitine/dermataan sulfaat klasse, die bevestigd is aan serine 
4. Verder bevat de carboxy-terminus van decorine een aantal N-gelinkte glycanen. De huidige 
methoden voor zowel PG purificatie als hun structurele karakterisatie wordt bediscussieerd. 
Hoewel de aanwezigheid van leden van alle vier de PG families (chondroitine sulfaat, 
dermataan sulfaat, heparine en heparaan sulfaat) in de long beschreven is [1-3], is de precieze 
samenstelling en verdeling van PG in de longen nog onbekend. Voor de lucine-rijke repeat 
PG familie was door middel van immunoblot aangetoond dat lumican de meest voorkomende 
variant is, terwijl biglycan, decorine en fibromoduline in lagere hoeveelheden in de 
menselijke longen te vinden zijn [2]. Als gevolg van het feit dat decorine slechts in kleine 
hoeveelheden in de long voorkomt, moesten wij voor onze zuivering eerst een verrijkingsstap 
inbouwen, gevolgd door een zo gering mogelijk aantal isolatiestappen, om op deze manier de 
opbrengst zo veel mogelijk te verhogen. De methode die we hiervoor hebben ontwikkeld (en 
welke beschreven wordt in Hoofdstuk 3) bestond uit twee negatieve 
ionenwisselingchromatografiestappen en één omgekeerde-fase chromatografie stap. In het 
verleden is negatieve onenwisselingchromatografie al regelmatig gebruikt voor de isolatie van 
PG omdat deze sterk binden aan de negatieve ionenwisselingkunsthars. Dit is het gevolg van 
het feit dat de GAG ketens in de PG een negatieve lading hebben gekregen vanwege de 
aanwezigheid van sulfaat en carboxylaat groepen. Een enzymatische behandeling van het 
totaal aan PG middels chondroitinase ABC verwijderde selectief GAGs behorende tot de 
CS/DS familie. Als gevolg hiervan leidde het nogmaals chromatograferen van deze 
behandelde GAGs over eenzelfde negatieve ionenwisselingkolom tot een verrijking van deze 
CS/DS GAGs in de niet gebonden fractie. Affiniteits-chromatografie met behulp van Lectinen 
was de tot nu toe gebruikelijke laatste stap in de isolatie van PG [4], en omgekeerde-fase 
chromatografie was niet eerder gebruikt voor dit doel. Echter, omgekeerde-fase 
chromatografie heeft als voordeel dat er onderscheid kan worden gemaakt tussen decorine 
eiwitten en andere eiwitten welke tijdens de eerste stappen zijn mee gezuiverd. Dit maakt het 
mogelijk om een profiel te maken van de PG van de CS/DS familie en meer inzicht te 
verwerven in de PG samenstelling van de long. Opstellen van dit soort PG-profielen is een 
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veel belovende lijn van onderzoek die verder onderzocht dient te worden in relatie tot de 
ontwikkeling van emfyseem. Aan de hand van het chromatogram verkregen van de C4 kolom 
konden wij vaststellen dat decorine het meest voorkomende CS/DS PG in de menselijke long 
is, terwijl middels western blot lumican, een KS PG, het meest voorkomende lucine-rijke 
repeat PG in extract van volwassen menselijke long [5] bleek te zijn. 
De hiervoor beschreven methode van decorine zuivering middels chromatografie is 
gebruikt voor isolatie van dit PG uit twee locaties (perifere onderste longkwab en perifere 
bovenste longkwab) van een controle en een emfyseem long. Na het zuiveren van de 4 
decorine preparaten kon middels SDS-PAGE een brede band (bestaande uit een sterke en 
minder sterk aanwezige component) worden gevisualiseerd in drie van de preparaten 
(onderste controle longkwab, bovenste controle en emfyseem longkwab), en een scherpe 
belijnde band (bestaande uit alleen de sterk aanwezige component in de bovenste longkwab 
van controle longweefsel. Samen met reeds gepubliceerde data over de structuur van decorine 
maken onze bevindingen het aannemelijk dat de twee decorinevormen die wij vinden in onze 
preparaten bestaan uit eenzelfde eiwitkern welke echter verschilt in N-gelinkte glycanen. Het 
feit dat er problemen waren met digestie middels PNGase F doet ons vermoeden dat de 
decorine eiwitkern naast deglycosilering ook aan proteolitische splijting onderhevig is 
geweest. Als gevolg hiervan zijn verdere experimenten nodig om de aanwezigheid van slechts 
één decorine eiwitkern in onze preparaten te bevestigen. 
  Om carbohydraat-eiwit interacties op een moleculair niveau te kunnen begrijpen is het 
noodzakelijk om naast de identificatie van de carbohydraat groepen ook vast te stellen aan 
welke van de Asn-X-Ser/Thr sequenties deze groepen gebonden zijn. Met andere woorden, 
welke van de potentiële N-glycosilerings posities daadwerkelijk worden gebruikt. Om dit te 
bepalen hebben wij de bezetting van de glycosileringsposities (Hoofdstuk 4) en de 
samenstelling van de daaraan verbonden N-gelinkte glycanen (Hoofdstuk 5) bepaald met 
behulp van massa spectometrie in combinatie met enzymatische behandelingen (Tripsine en 
PNGase F). Deze onderzoekslijnen lieten geen verschil zien tussen N-glycosilering van 
decorine eiwitten geïsoleerd uit emfyseem of controle long. Echter, geheel onverwacht 
werden er wel verschillen in glycovormen gevonden tussen de decorine preparaten geïsoleerd 
uit de verschillende locaties van controle long. Deze observatie roept de volgende twee 
vragen op: 1) Is de decorine vorm met een lager moleculair gewicht gevoeliger voor 
proteolitische afbraak in de long, en 2) is het voorkomen van meerdere decorine glyco-
vormen in de long een normaal verschijnsel dat los staat van emfyseemontwikkeling? Om 
deze vragen te kunnen beantwoorden is er meer onderzoek nodig waarbij decorine eiwit wordt 
geïsoleerd uit longweefsel en vergeleken. In grotere groepen van controle en emfyseem 
longweefsel. Hoewel histologisch onderzoek van de controle long die gebruikt is in ons 
onderzoek geen tekenen van pathologie te zien gaf, is het gezien het feit dat van deze donor 
long geen medische gegevens beschikbaar waren moeilijk om eventuele ziekte gerelateerde 
veranderingen uit te sluiten. 
De MALDI spectra welke verkregen werden van de intacte eiwitkern lieten ook 
subtiele verschillen zien in het moleculaire gewicht van de minder sterk aanwezige band 
tussen preparaten uit de onderste controle longkwab in vergelijking met de emfyseem 
longkwabben (38.800 Da versus 40.200 Da). Deze observatie is direct gerelateerd aan de 
heterogeniteit van decorine in longweefsel en verder onderzoek zal moeten uitwijzen wat de 
structurele achtergrond van deze verschillen is. 
Bezetting van glycosileringsposities van long decorine vindt plaats via een zeer 
complex proces dat verder reikt dan verschillen in N-glycanen (met 2 of 3 posities bezet) 
gekoppeld aan de eiwitkern. Ons onderzoek naar de glycosilering van decorine maakt 
duidelijk dat bezetting van glycosileringsposities kan variëren op alle drie de posities 




en drie glycosileringsposities bezet zijn, de meest voorkomende vormen zijn. Afwijkende 
glycovormen met een variabele hoeveelheid N-glycanen kunnen echter ook bestaan, maar dan 
in lagere hoeveelheden. Dit maakt dat verder onderzoek naar bezetting van glycosilatie 
posities middels kwantitatieve methoden nodig zal zijn om deze complexe situatie te kunnen 
ontrafelen. 
In Hoofdstuk 5 beschrijven we de profielen en gedeeltelijke karakterisatie van de 
structuur van de glycanen welke verbonden zijn aan het decorine uit controle en emfyseem 
longweefsel, met als doel het vergelijken van N-glycaan structuren tussen controle en 
emfyseem long en tussen de verschillende controle long locaties. Onze methode was 
gebaseerd op enzymatische verwijdering van N-glycanen (middels PNGase F) gevolgd door 
een selectieve ethanol precipitatie van de eiwitkernen en verdere analyse van de glycanen met 
behulp van MALDI-PSD-TOF massa spectrometrie. In alle vier de preparaten werden 
dezelfde glycanen aangetroffen, wat suggereert dat er geen glycaanveranderingen werden 
geïnduceerd ten gevolge van het emfyseem. Tevens werden dezelfde populaties aan glycanen 
aangetroffen in de verschillende posities van de controle long, wat aangeeft dat de 
waargenomen verschillen in decorine eiwitten niet het gevolg zijn van de aanwezigheid van 
verschillende N-glycanen. 
Hoewel er nog een aantal vragen open staan is dit het eerste onderzoek dat een 
gedetailleerd overzicht geeft van de structuren van N-glycanen welke verbonden zijn aan 
decorine eiwitten uit menselijke weefsels. 
In Hoofdstuk 6 beschrijven wij de ontwikkeling van een methode voor de 
identificatie en kwantitatieve analyse van gesulfateerde disacchariden verkregen uit 
chodroitine/dermataan sulfaatketens verbonden aan PG. Na digestie met Chondroitinase ABC 
kunnen de verkregen disacchariden direct worden gescheiden middels vloeistof 
chromatografie in een poreuze grafiet kolom en worden geïdentificeerd met on-line 
electrospray massaspectrometrie onder negatieve ionisatie omstandigheden. Deze methode is 
kwantitatief en kan onderscheid maken tussen 4- en 6- gesulfateerde disacchariden zonder 
enige derivatie. Wij hebben deze techniek toegepast op verschillende biologische preparaten 
verkregen van patiënten leidend aan chronische longaandoeningen. Het betrof hier 
longweefsel, longspoeling, geïnduceerd sputum en urine. Middels deze methode is het 
mogelijk om de relatieve hoeveelheden van 4- en 6- gesulfateerde disacchariden te 
vergelijken in biologische preparaten, als mede het bepalen van variaties in concentraties die 
wellicht gekoppeld kunnen worden aan voortschrijding van de ziekte. In dit opzicht zou deze 
methode in de toekomst gebruikt kunnen worden om variaties waar te nemen in hoeveelheid 
en sulfateringspatroon van verschillende CS/DS gedurende de progressie van COPD, als ook 
in andere chronische longaandoening en zoals bijvoorbeeld bronchiolitis obliterans. 
 In het laatste hoofdstuk van dit proefschrift worden de resultaten van het onderzoek 
samengevat en bediscussieerd, zowel ten aanzien van de ontwikkeling van analytische 
methoden om decorine te bepalen, als de bestudering van de door chronische longontsteking 
geïnduceerde biochemische modificaties van PG. Tevens worden er aanbevelingen gedaan 
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Pe scurt despre aceastǎ lucrare 
 
 
Scopul cercetǎrii prezentate în aceastǎ lucrare a fost elaborarea unor noi metode de analizǎ 
care sǎ serveascǎ la purificarea proteoglicanului numit decorinǎ şi la caracterizarea structuralǎ 
a componentelor lui: miezul proteic şi carbohidraţii ataşaţi reziduurilor de asparaginǎ sau 
celor de serinǎ. Rezultatele sunt prezentate sub forma unui studiu comparativ între moleculele 
de decorinǎ purificate dintr-un plǎmîn uman sǎnǎtos şi din unul cu emfizem pulmonar. Pentru 
purificare au fost alese douǎ locaţii asemǎnǎtoare din fiecare plǎmîn (una în lobul periferal 
inferior si cealaltǎ în lobul periferal superior), ceea ce a condus la purificarea decorinei din 
patru locaţii pulmonare diferite.  
În Capitolul 1 este prezentatǎ o introducere generalǎ asupra tematicii abordate în 
aceastǎ lucrare şi este definit scopul lucrǎrii. Tot aici este descrisǎ patologia emfizemului 
pulmonar în contextul Bromhopneumopatiei Obstructive Pulmonare Cronice (BOPC) şi este 
prezentat rolul pe care îl are decorina în compoziţia matricii extracelulare din cadrul ţesutului 
pulmonar.  
Capitolul 2 conţine informaţii generale despre proteoglicani şi descrie diversitatea lor 
şi funcţiile complexe pe care aceştia le îndeplinesc în diferite ţesuturi ale organismului. 
Proteoglicanii sunt molecule compuse dintr-un miez proteic la care se ataşeazǎ, prin 
intermediul reziduurilor de serinǎ, unul sau mai multe lanţuri de glicozaminoglicani (GAG). 
Moleculele de GAG sunt structuri polizaharidice neramificate formate din unitǎţi dizaharidice 
repetitive. Încǎrcǎtura negativǎ mare a glicosaminoglicanilor se datoreazǎ radicalilor sulfat şi 
carboxil. Decorina conţine un singur lanţ GAG de tip chondroitin/dermatan sulfat ataşat prin 
intermediul reziduului de serinǎ din poziţia 4 şi alte lanţuri de glicani ramificaţi ataşate prin 
intermediul reziduurilor de asparaginǎ, care nu au fost caracterizate pînǎ în prezent. Metodele 
analitice disponibile la ora actualǎ pentru purificarea şi caracterizarea structuralǎ a 
proteoglicanilor sunt de asemenea discutate în acest capitol.  
Compoziţia exactǎ a proteoglicanilor ce constituie ţesutul conjunctiv pulmonar şi 
modul lor de distribuire în interiorul acestuia nu sunt înca pe deplin cunoscute, deşi prezenţa 
proteoglicanilor din toate cele patru clase existente (chondroitin sulfat şi dermatan sulfat, 
heparin si heparan sulfat, keratan sulfat şi hialuronan) a fost raportatǎ [1-3]. Referitor la 
proteoglicanii ce conţin în structura lor primarǎ secvenţe repetitive abundente în reziduuri de 
leucinǎ s-a stabilit prin tehnica de imunoblot cǎ lumicanul este cel mai abundent în timp ce 
biglicanul, decorina şi fibromodulina sunt prezenţi în cantitǎţi scǎzute în ţesutul pulmonar 
adult [2]. Datoritǎ faptului cǎ decorina nu este un proteoglican abundent în ţesutul pulmonar, 
este necesar ca procedura de purificare sǎ conţinǎ o primǎ etapǎ prin care sǎ se obţinǎ un 
extract pulmonar îmbogǎţit în decorinǎ. Numǎrul de paşi de izolare şi purificare aplicaţi în 
continuare trebuie redus la minim, pentru a evita pierderile şi a obţine o cantitate cît mai mare 
de produs final. În consecinţǎ, protocolul pe care noi l-am adoptat (descris în Capitolul 3) 
conţine numai douǎ etape de cromatografie de schimb ionic şi o singurǎ etapǎ de 
cromatografie cu lichide pe fazǎ inversǎ. Cromatografia de schimb ionic este de obicei 
folositǎ la izolarea proteoglicanilor deoarece radicalii negativi (sulfat şi carboxil) din lanţurile 
de glicosaminoglicani interacţioneazǎ puternic cu anionii imobilizaţi în sorbentul din coloana 
cromatograficǎ. Tratamentul enzimatic cu Condroitinaza ABC îndepǎrteazǎ selectiv 
glicosaminoglicanii de pe miezurile proteice ale proteoglicanilor de tip chondroitin şi 
dermatan sulfat. Ca urmare, atunci cînd amestecul de proteoglicani colectaţi dupǎ primul pas 
de cromatografie de schimb ionic este tratat cu Chondroitinaza ABC şi este reaplicat în 
aceeaşi coloanǎ cromatograficǎ, miezurile proteice ale proteoglicanilor de tip 
chondroitin/dermatan sulfat, deposedate de lanţurile de GAG, vor fi colectate în fracţia care 
nu a interacţionat cu sorbentul încǎrcat pozitiv din coloana cromatograficǎ. Cromatografia cu 
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fazǎ inversǎ nu a fost pînǎ acum utilizatǎ la purificarea proteoglicanilor, ca ultim pas al 
protocolului de purificare fiind perferatǎ cromatografia de afinitate bazatǎ pe lectine [4]. 
Folosirea cromatografiei cu fazǎ inversǎ ne-a permis sǎ separǎm cu o rezoluţie bunǎ decorina 
faţǎ de celelalte proteine cu care aceasta a fost copurificatǎ. Acest fapt oferǎ posibiltatea 
obţinerii de informaţii noi cu privire la proteoglicanii din compoziţia ţesutului pulmonar, în 
special a celor de tip chondroitin/dermatan sulfat. Aceasta este o linie de cercetare care poate 
fi dezvoltatǎ în continuare în relaţie cu emfizemul pulmonar. Folosind cromatografia cu fazǎ 
inversǎ ca ultim pas în procedeul aplicat de noi la purificarea decorinei am putut stabili cǎ 
decorina este cel mai abundent proteoglican de tip chondroitin/dermatan sulfat din ţesutul 
pulmonar, în timp ce lumicanul, un proteoglican de tip keratan sulfat, a fost identificat prin 
tehnica de Western blot drept cel mai abundent proteoglican din categoria celor cu secvenţe 
repetitive abundente în reziduuri de leucinǎ [5]. 
Metoda cromatograficǎ discutatǎ mai sus a fost aplicatǎ la purificarea decorinei din 
doua locaţii similare ale unui plǎmîn sǎnǎtos şi ale unuia cu emfizem pulmonar. În urma 
purificǎrii celor patru probe de decorinǎ, analiza de tip SDS-PAGE a arǎtat cǎ trei dintre 
probe prezintǎ o bandǎ proteicǎ largǎ (constituitǎ dintr-o componentǎ majoritarǎ şi una 
minorǎ) în timp ce a patra probǎ e compusǎ dintr-o bandǎ proteicǎ ingustǎ avînd în 
componenţǎ numai forma majoritarǎ observatǎ şi în celelalte trei preparate. Observaţiile 
noastre, împreunǎ cu studiile publicate anterior cu privire la structura decorinei, sugereazǎ cǎ 
cele douǎ componente rezultate în urma purificǎrii sunt compuse de fapt din aceeaşi formǎ a 
miezului proteic substituitǎ diferit cu glicani ataşaţi prin intermediul reziduurilor de 
asparaginǎ. În urma unor dificultǎţi experimentale la digestia cu PNGasǎ F (o enzimǎ ce 
indepǎrteazǎ glicanii ataşaţi reziduurilor de asparaginǎ) este posibil ca decorina sa fi suferit nu 
numai deglicozilarea doritǎ, ci şi alte procese de proteolizǎ nedorite, care ne-au impiedicat sǎ 
obţinem o concluzie clarǎ asupra formelor proteice substituite diferit cu glicani. De aceea, 
sunt necesare noi experimente care sǎ confirme ipoteza exprimatǎ mai sus.  
Pentru înţelegerea interacţiilor moleculare de tip carbohidrat-proteinǎ este necesar ca 
pe lîngǎ identificarea carbohidraţilor prezenţi sǎ se determine care dintre situsurile de 
glicozilare (secvenţele Asn-X-Ser/Thr) sunt în realitate ocupate de aceşti glicani. De aceea am 
studiat ocuparea acestor situsuri de glicozilare (Capitolul 4) şi am investigat compoziţia 
structuralǎ a glicanilor ataşaţi reziduurilor de asparaginǎ (Capitolul 5). Pentru aceasta am 
folosit spectrometria de masǎ în combinaţie cu tratamente enzimatice (cu tripsinǎ şi PNGasǎ 
F). În urma acestor investigaţii nu am gǎsit diferenţe semnificative între plǎmînul sǎnǎtos şi 
cel cu emfizem cu privire la compoziţia glicanilor. În mod neaşteptat am observat diferenţe 
între moleculele de decorinǎ purificate din cele douǎ locaţii ale plǎmînului sǎnǎtos. Aceste 
observaţii conduc la douǎ întrebǎri esenţiale: 1) forma de decorinǎ cu masa molecularǎ mai 
micǎ e mai susceptibilǎ la proteolizǎ? şi 2) heterogeneitatea decorinei este un proces normal 
în ţesutul pulmonar uman? Pentru a rǎspunde acestor întrebǎri e nevoie de noi experimente, 
inclusiv de compararea structuralǎ a decorinei purificatǎ dintr-un numǎr mai mare de plǎmîni. 
În ciuda faptului cǎ examinarea histologicǎ a ţesutului pulmonar sǎnǎtos nu a dezvǎluit semne 
patologice, este greu sǎ înlǎturǎm toate cauzele legate de alte posibile boli, deoarece ţesutul 
sǎnǎtos a provenit de la un donor cu un dosar medical incomplet. 
Miezurile proteice intacte din preparatele de decorinǎ au fost studiate prin 
spectrometrie de masǎ MALDI. Spectrele achiziţionate de la aceste probe au evidenţiat o 
masǎ molecularǎ diferitǎ pentru componenta minorǎ a decorinei (38,800 Da versus 40,200 
Da) obţinutǎ din lobul inferior al plǎmînului sǎnǎtos în comparaţie cu cea obţinutǎ din lobul 
corespunzǎtor al plǎmînului cu emfizem. Aceastǎ observaţie este direct corelatǎ cu problema 
heterogeneitǎţii decorinei în ţesutul pulmonar uman şi noi investigaţii sunt necesare pentru a 




Ocuparea situsurilor de glicozilare în decorina din plǎmînul uman este un proces 
foarte complex, care are şi alte aspecte în afarǎ de substituirea diferenţialǎ cu glicani (cu 
numai douǎ sau toate trei situsuurile de glicozilare total ocupate) a aceluiaş miez proteic. 
Studiul întreprins de noi asupra glicozilǎrii în decorinǎ atenţioneazǎ asupra ocupǎrii variabile 
a tuturor celor trei situsuri de glicozilare. Este posibil ca cele douǎ glicoforme ale decorinei, 
cu douǎ şi respectiv trei situsuri de glicozilare total ocupate sǎ fie formele cele mai abundente, 
însǎ existǎ şi alte glicoforme, cu un grad variabil de substituţie cu glicani, în cantitǎţi mult mai 
scǎzute. De aceea, pentru a elucida aceastǎ problemǎ complexǎ, este recomandat sǎ se 
investigheze ocuparea situsurilor de glicozilare folosind o metodǎ cantitativǎ. 
În Capitolul 5 am studiat compoziţia glicanilor ataşaţi moleculelor de decorinǎ 
purificate din plǎmînul sǎnǎtos şi din cel cu emfizem şi i-am caracterizat parţial din punct de 
vedere structural, cu scopul de a compara glicanii corespunzǎtori din cele patru locaţii 
pulmonare. Metoda de studiu aleasǎ se bazeazǎ într-o primǎ etapǎ pe înlǎturarea glicanilor 
intacţi de pe miezurile proteice, folosind digestia enzimaticǎ cu PNGazǎ F. Mai departe, 
miezurile proteice au fost precipitate cu etanol iar glicanii izolaţi şi analizaţi structural prin 
spectrometrie de masa MALDI-PSD. În toate cele patru preparate s-a observat prezenţa 
aceloraşi glicani, ceea ce sugereazǎ cǎ emfizemul pulmonar nu induce modificǎri structurale 
la nivelul glicanilor ataşaţi decorinei. De asemenea, faptul cǎ aceleaşi populaţii de glicani au 
fost observate în ambii lobi ai ţesutului sǎnǎtos exclude posibilatea ca diferenţele dintre 
gliformele de decorinǎ obseravate în aceste locaţii sǎ fie datorate unor tipuri diferite de 
glicani. Studiul nostru este primul care oferǎ informaţii structurale cu privire la glicanii ataşaţi 
decorinei naturale în plǎmînul uman.  
Capitolul 6 descrie metoda cromatograficǎ creatǎ de noi pentru identificarea şi 
determinarea cantitativǎ a dizaharidelor ce conţin radicali sulfat obţinute ca produşi de 
degradare din lanţurile de glicosaminoglicani de tip chondroitin/dermatan sulfat. Amestecul 
de dizaharide obţinut în urma digestiei cu Condrioitinaza ABC poate fi separat direct prin 
cromatagrafie de lichide folosind o coloanǎ cromatograficǎ cu carbon poros. Dizaharidele 
sunt apoi identificate datoritǎ cuplǎrii coloanei cromatografice la un spectrometru de masǎ cu 
sursǎ de ionizare de tip electrospray în mod de ionizare cu ioni negativi. Metoda e capabilǎ sǎ 
diferenţieze între dizaharidele cu grupǎri fosfat ataşate în poziţia 4- sau 6-, fǎrǎ a fi nevoie de 
derivatizare. Am aplicat aceastǎ metodǎ la investigarea unor probe biologice diferite (ţesut 
pulmonar, lavaj bronhoalveolar, sputǎ şi urinǎ) obţinute de la pacienţi care suferǎ de inflamaţii 
pulmonare cronice. Folosind metoda mai sus descrisǎ se pot mǎsura şi compara cantitǎţile 
relative de dizaharide sulfatate in poziţia 4- sau 6- în diferite probe biologice, precum şi 
variaţiile în concentraţii care pot fi asociate cu evoluţia în timp a bolii. Metoda poate fi 
folositǎ în viitor pentru detectarea variaţiilor de concentraţie şi a poziţiilor de sulfatare în 
diferite lanţuri de chondroitin/dermatan sulfat pe parcursul evoluţiei unor boli pulmonare 
precum BOPC sau alte boli asociate cu inflamaţie pulmonarǎ cronicǎ. 
Ultimul capitol sumarizeazǎ şi discutǎ rezulatatele si contribuţiile aduse de aceastǎ 
lucrare atît la dezvoltarea metodelor de investigare a structurii decorinei, cît şi la detreminarea 
modificǎrilor biochimice pe care inflamaţia pulmonarǎ cronicǎ le poate induce la nivel 
molecular. Sunt prezentate şi cîteva posibile linii de cercetare viitoare pentru un studiu mai 
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